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HSV Herpes simplex virus 
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type 2 
ICC Immunocytochemistry 
ICP MS Inductively Coupled Plasma Mass 
Spectrometry 
IHC  Immunohystochemistry 
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LOD Limit of detection 
LOX Lipooxygenase 
MTT 3-(4, 5-dimethylthiazol-2yl)-2,5-
diphenyl tetra bromide 
NSAIDs Non-steroidal anti inflammatory drugs 
PAGE Polyacrylamide gel electrophoresis 
Pb Phthalate buffer 
PBS Phosphate buffered saline 
PMSF Phenylmethyl sulphonyl fluoride 
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PRE Pomegranate rind extract 
RIPA Radio immune precipitation assay 
RK13 Rabbit kidney epithelial cell line 13 
SC Stratum corneum 
SDS Sodium dodecyl sulfate 
SDVM Scalpel dissected porcine vaginal 
mucosal membrane 
TBS Tris-buffered saline 
TDF Tannin devoid fraction 
TEMED N,N,N`,N-Tetramethylethylenediamine 
TFA Trifluoroacetic acid 
TPT Total pomegranate tannins 
US United states 
Vero Green monkey kidney epithelial cells 
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SUMMARY 
The health benefits of the fruit of Punica granatum (pomegranate) have been 
recognised for many centuries. This thesis tested the hypothesis that a potent novel 
antimicrobial system could be developed based upon the activity of pomegranate rind 
extract (PRE), particularly when combined with a potentiating agent, and focussed on 
studying activity against Herpes simplex virus, types 1 and 2 (HSV-1 and HSV-2). 
High potentiated virucidal action of PRE against HSV-1 was observed when ferrous 
sulphate (FeSO4) was added; however, this activity diminished rapidly and also gave 
rise to an unsightly black byproduct. Data was obtained suggesting this was linked to 
the rapid oxidation of ferrous to ferric (Fe (II) to Fe (III)); however, no such oxidation 
was indicated when zinc sulphate (ZnSO4) was added instead, prompting an exploration 
of the effects of PRE + ZnSO4 combination on HSV. The potentiation of PRE by 
ZnSO4 in virucidal mode was comparable to that observed with FeSO4 (at the 
concentration examined for both metal salts). More in-depth investigation of the 
potentiation of PRE and ZnSO4 achieved over a 9000 fold increase in viral destruction 
in comparison to either agent alone. This activity was not transient and did not produce 
a (black) byproduct. Other salts of Zn (II) generally performed similarly to ZnSO4, with 
the main exception of ZnO which was too insoluble in water to test. When the antiviral 
properties of PRE were examined, the results were again potent and comparable to 
Aciclovir, the established treatment for Herpes simplex infections. Furthermore, PRE 
demonstrated even greater potency against Aciclovir-resistant HSV-2. When applied to 
ex vivo skin, PRE produced a 66% reduction in the level of cyclooxygenase-2 (COX–2) 
- an important inflammatory mediator - with the presence of ZnSO4 having no effect. 
PRE and ZnSO4 were formulated as a stable hydrogel, which was able to effectively 
deliver the biologically active compounds through the epidermal, buccal and vaginal 
membranes to the epidermal/dermal interface - the major sites of HSV-1 and HSV-2 
vesicular clusters during a clinical infection. 
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1.1. Overview  
Funded by a Welsh Office of Research and Development (WORD) studentship, this 
thesis explored the potential for developing a new therapeutic antimicrobial system 
based on extracts of the fruit rind of Punica granatum, or pomegranate, referred to as 
PRE. In particular, the work built upon previous observations that potent antimicrobial 
activity occurred when PRE was combined with a potentiating or synergising agent. 
Although the health and antimicrobial benefits of the pomegranate have been known 
for many centuries, it had more recently been found that the addition of ferrous sulphate 
dramatically increased activity against bacteriophages. For reasons outlined, the focus 
of this work shifted to PRE and zinc sulphate, and this combination was probed in 
numerous multi-disciplinary scientific areas, particularly against Herpes simplex virus, 
but always with translation to a viable commercial topical product as a key goal, in line 
with the WORD award. 
This thesis will explore the virucidal, antiviral and anti-inflammatory properties of 
PRE, with the use of a number of virucidal potentiators, and will aim to develop a 
resultant topical therapeutic system for use in Herpes simplex viral type 1 and 2 
infections. This introduction includes the relevant background knowledge of PRE, 
viruses, particularly Herpes simplex virus, its clinical pictures and treatments currently 
available, and the structure of skin as it pertains to the topical delivery of therapeutic 
agents. 
1.2. Historical Summary of Punica Granatum L. 
The fruit of the Punica granatum (the pomegranate) has been known throughout 
recorded human history; it has not only been eaten as a fruit, but extracts rich in tannins 
have been used in tanning leather. The fruit was agriculturally grown in ancient Egypt; 
in Greek mythology the pomegranate is key to the story of Persephone and Hades and 
in many various mythological beliefs it is thought to be the fruit of the underworld. In 
Judaism its seeds represent the 613 commandments in the Torah, and Spanish 
conquistadors introduced it to the Americas where the fruit now grows in abundance. 
Punica granatum, a relatively small tree originating in the Orient, belongs to the 
Punicaceae family and at present is mainly grown in the USA, India and Far Eastern 
3 
 
countries. The main use of pomegranate is as table fruit, although large amounts are 
used in the beverage and liquor industries(Patel, et al. 2008). The pomegranate is 
classified as a family of one genus and two species, one species in the wild form with a 
smaller fruit (5-8cm diameter) in comparison to the cultivated form (6-12cm diameter), 
the other species being a dwarf form grown as an ornamental plant (Ward 2003). The 
pomegranate tree/fruit can be divided into distinct components; the seed, juice, rind, 
flowers, leaf, bark and root.  
In Greek, Arabic and Chinese history the pomegranate was representative of wealth, 
fertility and the afterlife. The pomegranate has also been used to treat a wide range of 
ailments throughout history. In De Materia Medica written by Dioscorides, in the first 
century A.D. the use of pomegranate flower, rind and seed for medicinal purposes has 
four main entries. The document describes the use of these extracts for the treatment of 
ulcers of the mouth and genitals, pains in the ears, bleeding gums and loose teeth. It 
was also used to kill latas tineas ventris (tape worm) (Gunther 1934). According to 
Unani Tibb medicine, with its roots in Greek, Egyptian, Arabic and Indian Medicine 
and mentioned in the Koran, pomegranates are used medicinally for diarrhoea, earache, 
bad vision, fevers, teeth and gum disorders and indigestion.  
In Cairo (circa 11
th
 century) it was discovered that pomegranates were used for the 
treatment of eye diseases, inflammatory conditions of the tongue and gums, fevers, 
heptic and septic fevers, cancer, erysipelas, soft and hard inflammatory swellings and 
elephantiasis (Lev 2007). 16
th
 century Cypriote monastery prescriptions detailed the 
topical use of pomegranate for the treatment of skin wounds and Herpes type infections 
(Lardos 2006). 
1.2.1. Phytochemical review of Punica granatum L 
Over 120 different phytochemicals have been identified in the juice, seed, peel and rind 
of the pomegranate (N. P. Seeram 2006). There has been a substantial amount of 
research conducted upon different components and chemical extracts of the 
pomegranate. Punica granatum rind extracts (PRE) have been shown to possess 
significant antioxidant activity in various in vitro models (Kotamballi 2002). PRE 
contains a large proportion of polyphenols e.g. ellagic acid, gallotannins, 
anthocyanidins such as delphinidin, cyanidin and pelargonidin, proanthocyananidins 
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and various flavonoids. Of specific interest are the hydrolysable tannins; punicalin, 
pedunicalin, punicalagin as well as gallic and ellagic acid esters of glucose (Mustafa, 
Yaşar and Gökhan 2009). Punicalagin is the most abundant, constituting 80-85% w/w 
of total pomegranate tannins. Other bioactivities have been described for PRE and 
punicalagin, including antiproliferation, apoptopic and antibacterial properties (Seeram, 
et al. 2005) (Negi and Jayaprakasha 2003). The antibacterial bioactivity of PRE has 
been attributed mainly to fractions extracted with acetone and MeOH. The antibacterial 
effect was observed against both gram-positive and gram-negative bacteria. 100 percent 
growth inhibition of B. cereus, B. subtilis, B. coagulens, S. aureus, E. coli and P. 
aeruginosa was shown at 300 ppm (Negi and Jayaprakasha 2003).  
The punicalagin is a large polyphenolic compound, the molecular formula is C48H28O30 
and it has a molecular mass of 1084.718 amu. The compound consists of 11 rings with 
ester bridging groups. Punicalagin exists in two anomers punicalagin α and β with a 
ratio of roughly 1:2 respectively. The structure of the molecule is shown in Figure 1-1. 
The hydrolysis of punicalagin to its breakdown products, ellagic acid and Punicalin, is 
shown in Figure 1-2. Punicalagin and its major degradation compounds are thought to 
be the main bioactive extracts present in PRE (Seeram, et al. 2005), analysis of the PRE 
research with respect to permeation and penetration will be quantified through the 
detection of the two punicalagin anomers. 
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Figure 1-1 Structure of the abundant hydrolysable tannin, Punicalagin.  
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Figure 1-2 Hydrolysis of Punicalagin yielding Punicalin and Ellagic acid. 
1.2.2. Radical Scavenging and Antioxidant Capacity of Punica granatum. 
An antioxidant is a substance that when present at low concentration, compared to that 
of an oxidisable substrate, significantly delays or prevents oxidation of that substrate 
(Gil, et al. 1996). Antioxidants may act in various ways, by scavenging free radicals or 
by decomposing peroxides and by chelating metal ions (Kulkarni, Aradhya and Divakar 
2004). Antioxidant properties extracted from plant species play an important part in 
human health care. The protective effects of antioxidants in biological systems are 
ascribed mainly to their capacity to scavenge free radicals, chelate metal catalysts, 
activate antioxidant enzymes and inhibit oxidization.  
The antioxidant activity of the pomegranate is largely attributed to the presence of the 
ellagitannin, punicalagin (Slusarczyk, et al. 2009). The ability of punicalagin to act as 
an antioxidant, with the potential to reduce free radicals involved in chain reactions that 
damage cells, has been well established with differing materials and methods (Turk, et 
al. 2008). Punicalagin anomers α and β are the main active phytochemicals for this type 
of cytoprotection, accounting for 92% of the antioxidant activity (Sestili, Chiara and 
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Vilberto 2007). It is also important to note that gallic acid and ellagic acid, which 
although are only in small quantity, are also potent antioxidants. Therefore when 
punicalagin breaks down, the total antioxidant capacity is not greatly decreased. 
1.2.3.  Antiviral and Virucidal Action 
The potential virucidal activity of the pomegranate rind extract is shown in the research 
on phage reduction assays (Stewart, et al. 1998), specifically the combination of 
pomegranate rind extract and Ferrous Sulphate (FeSO4) in an acid buffer (phthalate 
buffer at pH 4.5).  
The use of bacteriophages as suitable surrogates for mammalian viruses in both medical 
and environmental virology applications has been reported in a number of studies. A 
current review stated that there is a considerable body of evidence to suggest and 
support the use of bacteriophages as surrogates for mammalian viruses. ―The use of 
appropriately sized bacteriophages provides an innocuous, efficacious and expeditious 
method for economical testing and validation of viral clearance capabilities‖ (Aranha-
Creado and Brandwein 1999).  
This combination of PRE and FeSO4 was reported to be extremely potent, producing an 
eleven-log reduction in plaque forming ability of phage within two minutes of 
application of an aqueous mixture at room temperature (Stewart, et al. 1998).  The two 
bacteriophages Pseudomonas aeruginosa and Escherichia coli phage were used in 
Stewart‘s study. They displayed significant and detrimental damage to their head and 
tail regions as well as to their overall integrity, following treatment with pomegranate 
rind extract and Ferrous Sulphate solution combined. The use of an acidic buffer was 
believed to help protect the hydroxyl groups. Although this level of acidity would be 
expected to demonstrate a phagicidal effect, it is negligible when compared to that of 
the PRE and FeSO4. 
Research has been conducted to assess the antiviral effect of pomegranate juice by 
applied in vitro methods, and demonstrated that pomegranate juice extracts had 
antiviral effects against HIV; the mechanism of action appeared to inhibit the binding 
of the HIV-1 envelope glycoprotein gp 120, preventing the interaction of HIV-1 with 
the CD4 receptor, and thus reducing the infectivity of the virus (Neurath, et al. 2004). 
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Corao reported an inhibition in -glucosidase and Human Leukocyte Elastase activity 
by pomegranate rind extract (Corao 2001). This action impedes viral attachment and 
penetration via disruption of the glycosylation of viral glycoproteins and is also 
observed with an extract of Hamamelis virginiana bark, which displays significant 
antiviral activity against HSV type 1.  
1.3. General Virology 
Viruses are sub-microscopic particles unable to reproduce outside a host cell. Their size 
varies between 30-400 nm.  Each virion is composed of genetic material (RNA or 
DNA) within a capsid core of protein material and the shapes of viruses are very 
diverse. The replication process of viruses vary according to their specific make up but 
there are six basic stages of virus life cycles in the living cell: attachment, penetration, 
un-coating, replication, assembly and release – as shown in Figure 1-3.  
 
Figure 1-3 A Diagrammatic Representation of Viral Replication (Lamb and Krug 1996). 
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1.3.1. Attachment 
A prerequisite for this step is the collision between the virion and the cell. Viruses do 
not have the capacity for locomotion and so the collision event is a random process 
determined by diffusion (Sherris 1990) and Brownian motion. In some cases there is 
specific binding between the viral envelope and specific receptors on the host‘s cellular 
surface. This attachment can induce the viral protein receptor to change so that it fuses 
with the host cellular membrane. Once a virus has penetrated to the inside of the cell it 
is effectively hidden from the immune system. 
1.3.2. Penetration 
Following attachment the virus can enter the host cell in two main ways. Receptor 
mediated endocytosis which is when the virus binds to receptors on the surface and is 
surrounded and contained within a vacuole that fuses with cellular endosomes. The 
other main entry technique of viruses is fusion: where an enveloped virus can directly 
fuse with the cell membrane, which results in release of the viral capsid into the 
cytoplasm (rarely the whole virus particle can pass directly into the cytoplasm (Ojala, et 
al. 2000). 
1.3.3. Un-coating 
Un-coating refers to the process where the capsid core is degraded by viral and or host 
enzymes and the viral genome is exposed for transcription and replication. Removal of 
the capsid core from the virus can occur in two ways: upon entry or, for virions that 
replicate inside the nucleus, the genome must penetrate through the nuclear membrane 
or the virus un-coats in the cytoplasm. This process is enabled by interactions between 
the viral capsid and nuclear pore complexes, which results in the release of the viral 
genome into the nucleoplasm (Dimmock and Primrose 2007). 
1.3.4. Replication 
The process of replication is to synthesise viral mRNA (transcription) and protein 
synthesis. David Baltimore and Howard Temin discovered the reverse transcriptase in 
retrovirus and identified the key molecule for viral replication as mRNA (Flint 2000). 
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The Baltimore classification system identifies seven classes based upon the strategies 
used by virus mRNAs for replication. The initial stages of replication are very cell 
dependent, the late stages tend to be more virus led. Once uncoated the nucleic acids 
are revealed so that replication can take place.  
Class I: double stranded DNA (ds DNA) viruses e.g. Adenovirus, Herpes virus, and 
Poxvirus. These viruses are dependent upon the cell cycle, as they must enter the host 
nucleus to replicate and require host cell polymerization. In this class the designation of 
plus and minus is not meaningful since different mRNA species may come from either 
strand. 
Class II: e.g. parvoviruses, viruses which have a single stranded DNA genome of the 
same sense as mRNA. They replicate in the nucleus and form a double stranded DNA 
intermediate during replication. 
Class III: e.g. reoviruses. Consist of viruses with a double stranded RNA. This class 
replicates in the cytoplasm. 
Class IV: e.g. picornaviruses, togaviruses. Consists of viruses of a single stranded RNA 
genome of the same sense of mRNA (positive strand RNA viruses). Replication is 
mainly in the cytoplasm and does not rely upon the cell cycle in comparison to DNA 
viruses. 
Class V: e.g. orthomyxoviruses, rhabdoviruses. Consists of viruses that have a single 
stranded RNA genome that is complementary in base sequence to the mRNA (negative 
strand RNA viruses). Replication is mainly in the cytoplasm and does not rely upon the 
cell cycle as much as other viruses. 
Class VI: e.g. retrovirus. Consists of viruses that have a single stranded positive sense 
RNA genome and which have a DNA intermediate during replication. One of the 
defining features of this is the use of reverse transcriptase to convert the positive sense 
RNA into DNA. 
Class VII: e.g. hepadnaviruses. Consists of viruses with double stranded DNA that 
replicate through a single stranded RNA intermediate (Baltimore 1971). 
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1.3.5. Assembly and Release 
Virus assembly involves a process in which the chemically distinct macromolecules are 
transported, often through different pathways, to a point within the cell where they are 
assembled into a viral particle (Fields, Knipe and Howley 2007). The assembly process 
divides viruses into two distinct groups. This is based on the presence or absence of a 
lipid bi-layer envelope. For non-enveloped viruses the assembly takes place in the 
cytoplasm or nucleus. They exit from the cell by breaking through the cell membrane 
and causing lysis. Enveloped viruses must obtain a lipid bilayer in their assembly from 
one of the cells membranes. The nucleocapsids exit from the nucleus and pass out of 
the cell by a process known as budding where the virus acquires the lipoprotein 
envelope.  
1.3.6. Viruses Possibly Suitable for Topical Virucidal and Antiviral 
Treatment 
There are three main virus types responsible for the majority of viral skin infections 
poxviruses, papilloma viruses and herpes simplex virus. Pox viruses are a very large 
family of viruses that are always enveloped. They vary in shape and size but are up to 
250nm in diameter and 350nm in length. They are classified as a dsDNA virus and 
follow this route of replication. The papilloma viruses are a diverse group of non-
enveloped viruses. Over 100 different types of human papilloma viruses (HPV) have 
been identified. Each different virus is numbered as HPV 1, HPV 2 and so on. They 
replicate exclusively in the skin and mucosal surfaces of the genitalia, anus, airways 
and mouth. Some of these viruses have been linked to cancers that kill thousands of 
people each year, with the following being high risk - HPV 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, and 68 (Smith, et al. 2008). This is an interesting area for the 
possible use of transdermal and topically applied drugs. 
Examples of human pathogenic Herpes-viridae include Varicella-Zoster virus 
responsible for chicken pox and shingles, cytomegalovirus and Herpes simplex virus. 
Latency is a characteristic property of Herpes virus (Garner 2003). 
The mode of action of a drug used to combat a viral based infection can be placed into 
two main groups, anti viral and virucidal. Anti viral drugs work on the principle of 
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preventing one or more of the six basic stages of the virus life cycle in the living cell. 
Virucidal drugs effectively kill the virus by destroying a part or all of the viral 
structure, usually the viral capsid. 
1.3.7. Evaluating treatment efficacy 
From an efficacy standpoint, the most appropriate way to test the hypothesis of PRE 
with the combination of a metal salt either as a virucidal, or an antiviral, or both, would 
be via a controlled clinical investigation, involving an adequate number of human test 
subjects. Such evaluations are very costly, involve a great deal of coordination and 
necessitate the obtaining of full ethical approval (MHRA 2011). A crucial prerequisite 
is a series of in vitro tests performed to determine the potential of various treatments, 
prior to clinical evaluation. 
The activity of potential treatments against viruses can be determined in 2 modes, 
depending on the activity against the virus. 
1.3.7.1. Antiviral 
Antiviral activity occurs when a test agent acts to inhibit the replication of the virus, 
without actually destroying it. Most topical antivirals, including Aciclovir (a thymidine 
kinase inhibitor) competitively inhibit viral DNA polymerase (Whitley and Gnann 
1992). Although efficacious, this type of product cannot destroy the viral load near the 
point of application, which may be associated with viral latency, the re-emergence of 
cold sores and transfer. Furthermore continual use of stereosymetrical compounds can 
facilitate drug-resistance, for example the increasing prevalence of Aciclovir resistant 
HSV-1 and 2 strains due to continual/overuse of Aciclovir and similar derivatives 
(Erlich, et al. 1989) (Whitley and Gnann 1992) (Bacon, et al. 2003). To quantify the 
antiviral activity a plaque reduction assay was used to quantify the infectious HSV-1 
and HSV-ACR virions (Matrosovich, et al. 2006). 
1.3.7.2. Virucidal 
Virucidal activity may be described as one in which the viruses are destroyed by the 
presence of the test agent. Many compounds, given high enough concentration, are 
capable of destroying viruses. However these tend to be powerful biocides such as 
Dettol (chemical) and bleach (sodium hypochlorite). Such materials should not be 
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applied directly to skin in view of toxicity, inflammation and injury.  The virucidal 
activity can be tested via a plaque reduction assay due to the ability of HSV-1 to form 
plaques within the vero cell host, each plaque representative of one HSV-1 virion 
(Schuhmacher, Reichling and Schnitzler 2003). 
1.4. Herpes simplex virus 
The Herpes simplex virus is a member of the Herpes viridae family. The virus 
frequently infects humans, causing a range of diseases from mild uncomplicated 
mucocutaneous infection to life threatening illness. From this family the strains HSV-1 
and -2 are the most prevalent pathogens. HSV-1 is normally associated with orofacial 
infections and encephalitis, HSV-2 is normally associated with genital infections, and 
can transfer from mothers to neonates. After primary infection, HSV-1 and HSV-2 can 
cause latent infections, the virus resides in neurones of dorsal root ganglia and the 
autonomic nervous systems. However, it is now clear that HSV can also remain latent 
elsewhere, e.g. in the superior cervical and vagal ganglia. The suspicion that the virus 
might also remain latent in the cells of the skin or mucous membranes has never been 
proven in human infection (Topley and Wilson 1990). The virus resides in latently 
infected ganglia in a non-replicating state with a very low level of virus gene 
expression. Infective HSV grows rapidly in cell culture which has led to the speculative 
theory that the latent virus is not present as virions but as viral DNA integrated into 
cellular genomes. The viral latency lasts for the lifetime of the host. 
Recurrent oral facial infections of HSV-1 and -2 are generally referred to as cold sores, 
Herpes labialis and fever blisters. The lesions usually occur on the skin by the 
cutanneous branches of the maxillary and mandibular branches of the trigeminal nerve 
(Weatherall, Gledingham and Warrell 1996). Vesicles are most common on the lips or 
skin around the mouth and often recur in the same place. Recurrence only occurs in 
around 30% of people with only 10% being affected once a month. Recurrent herpetic 
eruptions are precipitated by overexposure to sunlight, febrile illnesses, physical or 
emotional stress, immunosuppression, or unknown stimuli. 
 
 
13 
 
1.4.1. Classification 
Herpes simplex virus 1 and 2 are two closely related viruses of the Herpes virus family. 
They are double stranded DNA viruses of the Herpes viridae family and are classified 
within a sub-family as alpha Herpes virinae of the simplex virus genus. 
1.4.2. Structure 
The structure of HSV-1 and HSV-2 are very similar, both encapsulated within an 
envelope as shown in Figure 1-4. They contain a large double stranded DNA molecule. 
The HSV virion is roughly 110-130 nm in diameter and consist of four main parts 
 an electron dense core containing viral DNA 
 an icosapentahedral capsid composed of 6 proteins 
 the tegument -an amorphous layer of at least 15-20 proteins, which is in  
contact with both the capsid and the envelope 
 the envelope containing at least 8 glycoproteins. 
  
1.4.3. Binding 
The entry of HSV-1 and -2 requires the binding of the virus to receptors on the cell 
surface for fusion of the envelope and the cell plasma membrane to occur. The 
Figure 1-4 TEM micrograph of a Herpes 
simplex virus (NASA 2009). 
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envelope glycoproteins that are known to be involved in the binding process are gB, 
gC, gD and gH-L(Heldwein and Krummenacher 2008). The proteins gB, gD and gH-L 
are indispensable as deletion of these proteins results in an entry defective phenotype 
(Browne, Bruun and Minson 2001) (Subramanian and Geraghty 2007). 
1.4.4. Nuclear Import, Replication and Transcription 
Upon entry to the host cell the HSV neucleocapsid is transported to the nuclear pores, 
where viral DNA is released onto the nucleus (Newcomb and Brown 2007). The 
immediate-early (α) phase of viral transcription occurs when the viral genome is 
accompanied by the α-TIF protein. The transcription of RNA occurs when DNA is 
transcribed to RNA, by DNA dependent RNA polymerase. 
The control of mRNA to: synthesize new virus particles causing cell death; synthesize 
new virus particles constantly shedding virus; and remain latent is dependent on the 
nuclear factors of the cell and proteins encoded by the virus. The formation of latent 
infection is due to the properties of the host cell preventing progression beyond the 
immediate early genes. DNA replication, the formation of capsids, and packing of viral 
DNA occur in the nucleus (Roizman 2007). 
1.4.5. Assembly and Budding 
The envelopment of alpha herpes viruses is a complex process. An outline of this 
process is shown in Figure 1-5 and a brief description is given below. The egress of the 
HSV-1 virion requires a budding process from the inner nuclear membrane that 
contains viral glycoproteins (Mettenleiter 2002). A mature capsid surrounded by the 
tegument protein UL31 directs the process of budding through the nuclear membrane 
into which the UL31 and UL34 phosphorylated membrane protein has been inserted 
(Wagner 2003). The primary envelope is then lost as the capsid buds through the outer 
nuclear membrane after which the tegument proteins (α-tif and vhs given in diagram) 
encapsulate the capsid (Enquist, et al. 1999). The mature capsids and tegument protein 
acquire the full envelope by budding into exocytotic vesicles (Gil, et al. 2002). The 
virion is now complete and can remain within the cell or be released as an infectious 
virion (Wagner 2003). 
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Figure 1-5 A diagrammatic representation of the Assembly and budding of HSV-1 within epithelial cells 
(Wagner 2003). 
1.4.6. Pathology and the Clinical Picture 
Irrespective of the viral type, HSV-1 or HSV-2 primarily affects skin and mucous 
membranes. The classic perspective on perioral and genital herpetic infections  describe 
peri-oral infection as caused by HSV-1 and anogenital infection as caused by HSV-2. 
However, these distinctions are imprecise as HSV-1 or HSV-2 can be associated with 
any of the syndromes and their symptoms listed in Table 1-1. 
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Herpetic infection Characterising Symptoms 
Primary Herpetic Gingivostomatitis Wisespread painful oral/perioral 
vesiculo-ulcerative lesions 
Reccurrent Orofacial Herpes Single painful lesions on skin of lip or 
face 
Genital Herpes Ulcerative lesions on the penis, vulvae 
and vagina 
Eczema Herpeticum Widespread infection of skin in 
someone with eczema 
Herpes Gladiatorum (Scrumpox) Painful vesicular rash of face, chest etc 
with fever and lymphadenopathy.  Due 
to direct abrasive contact. 
Herpetic Whitlow A pustular lesion close to the nail, 
usually finger 
Ocular Herpes Infection of the cornea and 
conjunctivae 
Neonatal Herpes Widespread vesicular rash contracted 
during birth. Very serious. 
Table 1-1 Symptoms of the different clinical diseases caused by HSV-1 and HSV-2. 
HSV-1 and -2 replication occurs at the epidermal/dermal interface with the 
establishment of vesicular clusters, culminating in the destruction of the overlying 
epidermal membrane and the formation of the clinical lesion. HSV -1 and -2 virus are 
therefore present in the vesicles, and transmission occurs via skin to surface (skin) 
contact. 
1.4.7. HSV-1 and -2 specific treatment 
Current treatment is with Aciclovir, a guanine analogue antiviral drug. ValAciclovir 
and famciclovir, derivatives of Aciclovir, are also used as they have better oral 
bioavailability (Balfou 1999). Table 1-2 is a representation for the prescription of 
antiviral therapy to combat various HSV infections.  
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Type of infection   Route and dose  Comments 
Genital HSV   
Initial episode   
Aciclovir  200 mg by mouth 5 
times/day for 7–10 days  
Preferred route in normal 
host 
 5 mg/kg intravenous every 8 
h for 5–7 days  
Severe cases only 
 400 mg by mouth 3 
times/day 
 
ValAciclovir  1 g by mouth twice daily for 
7–10 days 
 
Famciclovir  250 mg by mouth 3 times, 
i.e. 3 times/day for 5–10 
days 
 
Recurrent episode   
Aciclovir  400 mg by mouth twice daily 
for 5 days  
Limited clinical benefit 
ValAciclovir  500 mg by mouth twice 
daily for 5 days 
 
Famciclovir  125–250 mg by mouth twice 
daily for 5 days 
 
Suppression   
Aciclovir  400 mg by mouth twice daily  Titrate dose as required 
ValAciclovir  500 or 1000 mg by mouth 
once daily 
 
Famciclovir  250 mg by mouth twice daily  
Mucocutaneous HSV in 
immunocompromised 
patients 
  
Aciclovir  200–400 mg by mouth 5 
times/day for 10 days  
For minor lesions only 
 5 mg/kg intravenously every 
8 h for 7–14 days 
 
 400 mg by mouth 5 
times/day for 7–14 days 
 
ValAciclovir  500 mg twice daily by mouth  
Famciclovir  250 mg 3 times/day by 
mouth 
 
HSV encephalitis   
Aciclovir  10–15 mg/kg intravenously 
every 8 h for 14–21 days 
 
Neonatal HSV   
Aciclovir  20 mg/kg intravenously 
every 8 h for 14–21 days 
 
Table 1-2 Indication for therapy among patients with herpes simplex virus infections (Whitley and 
Roizman 2001). 
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The current topical therapeutic treatment of HSV-1 and 2 infections is much less 
effective than oral treatment; the topical therapy of penciclovir will accelerate healing 
by about one day (Whitley and Roizman 2001). Oral Aciclovir reduces the time to loss 
of crust by up to seven days, but does not alter duration of pain or time to complete 
healing (Clercq 2004). 
1.5. The Skin 
1.5.1. Function and Structure of Human Skin 
The skin is the main interface between the body and the external environment in which 
we live. It is the largest organ in the human body constituting almost 10% of the total 
body mass of an average person (Williams 2003). The skin is made up of multiple 
layers of epithelial tissues that cover the underlying muscles and organs.  
1.5.1.1. Skin Function 
The skin performs many functions and is an anatomical barrier to the environment 
protecting the host from pathogens and the external environment; it is a sensory organ 
with many nerve endings which react to heat, pressure and other stimuli. The skin is 
involved in the process of homeostasis (keeping different aspects of the body constant 
i.e. temperature). It controls evaporation from the body and a small amount of oxygen, 
nitrogen and carbon dioxide can diffuse into the epidermis. All these functions play a 
pivotal role when considering the creation of a topically applied drug. The skin 
comprises of three main layers: the epidermis, the dermis, and the hypodermis - as 
shown in Figure 1-6. 
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Figure 1-6 A Cross Sectional Diagram of Human Skin (London Health Sciences Centre 2003). 
1.5.1.2. The Epidermis  
The epidermis is never more than 0.1 cm thick in normal skin. The thickness varies 
depending on the age and specific area of the body. It is thickest on the palms and the 
soles of the feet, and thinnest on the eyelids. The epidermis contains no blood vessels 
and consists mainly of the cells keratinocytes, melanocytes Langerhans cells and 
Merkels cells. These are found in five main sub-layers of the epidermis called the 
Stratum Corneum (SC), Stratum Lucidum, Stratum Granulosum, Stratum Spinosom 
and Stratum Basale, shown in Figure 1-7. 
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Figure 1-7 A cross sectional diagram to show layers of the epidermis (London Health Sciences Centre 
2003). 
1.5.1.3. Stratum Corneum (SC)      
The skin‘s function as a barrier, specifically to permeation, is due to the characteristic 
architecture of the SC.  The SC is created by keratinocytes and an understanding of 
their life cycle enables us to understand the SC. 
The creation of new keratinocytes from stem cells is an exclusive feature of the stratum 
basale, the proliferation in this area forces the bulk of the cells to migrate upwards and 
to differentiate into the corneocytes. Cornification of the keratinocytes starts in the 
stratum spinosum but is more pronounced in the stratum granulosum (Houben 2007). 
The completely cornified cells now called corneocytes are embedded in an intercellular 
lipid (ICL) matrix in the SC (Weerheim and Ponec 2001). ICLs are considered to be an 
essential component of an adequate permeability barrier function. A ―sandwich‖ model 
has been proposed where a narrow fluid lipid phase is interspersed between two broad 
crystalline lattices. The terminal differentiation of keratinocytes results in cell death. 
This is not, however, exactly the same as normal cell death, apoptosis. Keratinocyte 
cornification is considered to be distinct from apoptosis, despite the fact that cell death 
is programmed from the moment the basal keratinocyte leaves the basal compartment, 
corneocytes are not phagocytised and the cytoskeleton is reorganized, also apoptotic 
caspases are not activated during cornification (Eckhart, et al. 2000). They do still play 
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an important role in the epidermal barrier function until they detach, desquamation is 
the final detachment of the corneocytes. 
It is obvious that the SC and the keratinocytes in all their forms are a very important 
part of the skin to understand when designing a topically applied drug. Other cell types 
found in the SC are melanocytes, which inject granules of pigment into the 
neighbouring cells. Melanin, the dark pigment produced, protects the skin by absorbing 
ultraviolet radiation, and visibly darkens skin exposed to sunlight.  
Langerhans cells are also found in the epidermis, they are dendritic cells and their main 
function is to process antigen and present it to other cells of the immune system.  
Merkel cells are cells found in the stratum basale and are associated with sensory nerve 
endings. The exact function of this cell is not fully understood. 
There are certain aspects of the skin that break the continuity of the SC and are 
pathways for drug delivery (hair follicles, sweat glands, sebaceous glands and apocrine 
glands). These routes supply a negligible amount of net flux.  
1.5.1.4. The Dermis 
The dermis comprises the largest fraction of the skin, about 90%, and is responsible for 
its structural strength. The dermis is connected to the epidermis via the basement 
membrane; the basement lamina consists of an electron-dense membrane called the 
lamina densa, which consists of different types of collagen. The dermis contains hair 
follicles, the previously stated glands and also provides an environment for nerve and 
vascular networks. The main cell types of the dermis are fibroblasts, macrophages, and 
mast cells. The blood vessels not only provide nourishment and waste disposal to this 
area but also to the stratum basale above.  
The dermis does not prove a hindering point for the permeation of most drugs. Only the 
most highly lipophilic drugs are likely to encounter resistance in this area after 
traversing the epidermis. The blood supply removes those molecules rapidly in vivo that 
have successfully penetrated the outer layer, however this blood uptake does provide a 
concentration gradient, which is considered the driving force behind effective 
transdermal absorbance. The concentration gradient is largely produced via the 
22 
 
lymphatic draining system which also facilitates immunological responses to foreign 
bodies. 
1.5.1.5. The Hypodermis 
Depending on the region of the body, the hypodermis, composed of fibroblasts, 
macrophages and adipocytes, is of varying thickness. The hypodermis provides 
insulation and energy storage in the form of fat, attachment of the skin to the 
underlying muscle, and supplies the skin with blood vessels and nerves.  
1.5.2. Topical Drug Delivery  
Pharmaceutical drug delivery is generally based upon the administration of oral or 
intravenous compounds. However for the treatment of skin diseases and afflictions both 
methods are often affected by issues such as first pass metabolism whereby the 
concentration of a drug is greatly reduced before it reaches the systemic circulation and 
therefore the target organ (the skin). The reduction is due to metabolism by the liver 
and it reduces the drug‘s bioavailability. The purpose of a vast range of research is to 
enhance drug targeting specificity, lower systemic drug toxicity, improving treatment 
absorption rates, and to prevent the biochemical degradation of active compounds. 
Delivery directly to or near the site intended especially for skin afflictions presents a 
possible mode of drug delivery which overcomes many of the previously stated goals. 
The delivery of drugs which uses the skin as a mode of transport can be categorized 
into three groups based upon the intended site of delivery, the topical transdermal, and 
transcutaneous routes.  
1.5.2.1. Topical  
Topical drug delivery is used to specifically target the local area of application with 
minimal absorption into systemic circulation. 
1.5.2.2. Transcutaneous  
The transcutaneous delivery system is intended to deliver drugs to tissues underlying 
the skin such as muscle or joints tissues. The drug must penetrate all layers of the skin 
but not be removed by the circulatory system. Topically applied non-steroidal anti-
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inflammatory drugs (NSAID`s) such as Ibugel Forte (ibuprofen) and Powergel 
(ketoprofen) utilise the transcutaneous mode of drug delivery. 
1.5.2.3. Transdermal 
A transdermal drug delivery system is intended to deliver the drug into the general 
circulation. The use of this system requires that a drug has to successfully penetrate the 
SC and epidermis. The drug must then be taken up by the circulatory or lymphatic 
system and transported to the intended site. Transdermal therapeutic systems have been 
designed to provide controlled and sustained drug delivery across the skin barrier. Two 
effective examples of drugs that utilize this are the nicotine replacement Exelon Patch 
(rivastigmine) and the hormonal replacement therapy Testoderm (Testosterone) 
1.5.2.4. Routes of Drug Permeation across the Skin 
Topically applied drugs have to permeate the skin to be effective. The stratum corneum 
is the primary barrier and the rate of permeation is governed by its affect. Three main 
routes of permeation have been identified - appendageal, intercellular and transcellular. 
It is important to note that these pathways are not mutually exclusive and depending 
upon the nature of the molecule permeation is often via a mixture of these pathways. 
1.5.2.4.1. Transappendageal (shunt route) 
The transappendageal route involves the transport of molecules across the stratum 
corneum via hair follicles and sweat ducts. Although these appendages have a relatively 
small surface area (approximately 0.1%) they contribute to a large percentage of the 
total permeation. The shunt pathway is the major contributor to the initial phase of skin 
permeation (Scheuplein and Blank 1971).  
1.5.2.4.2. Intercellular route 
The intercellular route is the mode in which non-polar molecules transverse the SC. It is 
often represented with a simple brick and mortar model, but the lipid matrix is a very 
tortuous pathway. This route provides the principal pathway by which most small 
uncharged molecules permeate the SC. 
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1.5.2.4.3. Transcellular Route 
The Transcellular route is often regarded as the pathway for polar molecules. Diffusion 
is predominately through hydrated keratinocytes, a quick process for polar molecules. 
Generally, this route is slowed due to the lipid bilayers either side of the keratinocyte. 
1.5.2.5. Factors Affecting the Absorption of Topically Applied Drugs 
Ficks Law of diffusion describes the permeability of intact stratum corneum ―the speed 
of movement of substances across a membrane is proportional to the concentration 
differences across that membrane‖. This appears to be a concise and succinct 
explanation to the permeability of the stratum corneum, however the law only applies 
to the uppermost layer of skin, which can accumulate a limited amount of drug with its 
saturated state being readily reached. The level of percutaneous absorbtion of a 
substance is affected by many contributing factors. 
-Thickness of skin -Site of absorption 
-Type of skin -Age 
-Hydration -Application variables 
-Partition coefficient -Co-permeation 
-Particle size  
1.6. Aims and Objective 
The thesis aimed to develop a therapeutic system for the treatment of Herpes simplex 
virus type 1 and 2 infections, which could be administred topically. 
The objectives are: 
 To investigate the virucidal, antiviral and inflammatory properties of PRE with 
the inclusion of a potentiating metal salt 
 To identify the optimal combination of PRE and potentiating agent 
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 To formulate any proposed biologically active combination so that the topical 
application of any combination will deliver the actives so that it is effective at 
the site specific regions of HSV-1 and -2 replication 
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Chapter 2 Materials and Methods 
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2.1. Materials 
All the materials used in this project are listed alphabetically in Table 2-1: 
24 well plates (24wp)  Fisher Scientific (Loughborough, UK) 
3-(N-mopholino) propanesulfonic 
acid (MOPS) 
Fisher Scientific (Loughborough, UK) 
50 mL sterile Blue cap  (Greiner Bio-One Ltd. (Stonehouse, UK) 
96 well plates (96 wp) Fisher Scientific (Loughborough, UK) 
Acetic acid Sigma-Aldrich Company Ltd. (Poole, UK) 
Aciclovir Gifted by Dr J J Bugert (Medical 
Microbiology, UHW, Cardiff) 
Acrylamide/bis-acrylamide 29:1 
(30%, v/v solution) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Ammonium persulphate (APS 
≥98%) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Anti-mouse primary antibody Amersham Biosciences Ltd (Amersham, 
UK) 
Aprotinin Sigma-Aldrich Company Ltd. (Poole, UK) 
Avicel  Sigma-Aldrich Company Ltd. (Poole, UK) 
Bio-Rad protein assay reagents Bio-Rad Laboratories Ltd. (Hertfordshire, 
UK) 
Bovine serum albumin (BSA) Sigma-Aldrich Company Ltd. (Poole, UK) 
Bromophenol blue (99% UV-VIS) Fisher Scientific (Loughborough, UK) 
Cab-o-sil M5 Sigma-Aldrich Company Ltd. (Poole, UK) 
Carbopol 942 P Fisher Scientific (Loughborough, UK) 
Carbopol 971 PNF Fisher Scientific (Loughborough, UK) 
Cell Scraper (sterile) (Corning®) Sigma-Aldrich Company Ltd. (Poole, UK) 
CellTiter 96® Aqueous solution Promega (Southampton, UK) 
Cetyl alcohol Fisher Scientific (Loughborough, UK) 
Chemiluminescent Supersignal® 
West HRP substrate (pico, dura and 
femto) 
Pierce and Warriner Ltd. (Cheshire, UK) 
Chloroform Fisher Scientific (Loughborough, UK) 
COX-2 primary antibody  Cell Signalling Technology, 
New England Biolabs (Hitchin, UK) 
Crystal violet Sigma-Aldrich Company Ltd. (Poole, UK) 
Cyclopore track etched membranes 
(CTEM) 
Fisher Scientific (Loughborough, UK) 
DAB liquid substrate chromagen 
system 
Dako (Ely, UK) 
De-ionised and phosphate buffered 
saline (DPBS, PBS) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Di-butylpthalatexylene (DPX)  Raymond A Lamb Ltd. (Eastbourne, UK) 
Dimethyl sulfoxide (DMSO) Fisher Scientific (Loughborough, UK) 
Di-thiothreitol (DTT), Sigma-Aldrich Company Ltd. (Poole, UK) 
Dulbecco's Modified Eagle Medium Fisher Scientific (Loughborough, UK) 
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(DMEM) (with L-Glutamine, 4500 
mg L-1 D-glucose, without sodium 
pyruvate). 
Ellagic acid Fisher Scientific (Loughborough, UK) 
Eppendorf tubes (1.8 mL) Sigma-Aldrich Company Ltd. (Poole, UK) 
Ethanol (HPLC grade) Fisher Scientific (Loughborough, UK) 
Ethylene diamine Sigma-Aldrich Company Ltd. (Poole, UK) 
Ethylene glycol-bis(2-amino-
ethylether)-N,N,N’,-tetraacetic acid 
(EGTA) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Ferrous sulphate (FeSO4) Fisher Scientific (Loughborough, UK) 
Foetal bovine berum (FBS)  Fisher Scientific (Loughborough, UK) 
Formaldehyde Fisher Scientific (Loughborough, UK) 
Gentamycin sulphate Fisher Scientific (Loughborough, UK) 
Glycerine Fisher Scientific (Loughborough, UK) 
Glycerol Sigma-Aldrich Company Ltd. (Poole, UK) 
Glycine Sigma-Aldrich Company Ltd. (Poole, UK) 
Hanks balanced buffered salt 
solution (HBBSS) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
HEPES (n-[2-hydroxyethyl] 
piperazine-N’-[2-ethanesulfonic 
acid]) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
High vacuum grease  Dow Corning (Barry, UK) 
Horseradish peroxidase (HRP)-
labelled anti-rabbit polymer 
EnVisionTM system 
Dako (Ely, UK) 
HRP-linked secondary antibody  Amersham Biosciences Ltd (Amersham, 
UK) 
HSV-1 17+ ECACC  (Salisbury, UK, ECACC No 
0104151) 
HSV-2-ACR  ECACC  (Salisbury, UK, ECACC No 513) 
HSV-2-HG32  ECACC  (Salisbury, UK, ECACC No 618) 
Hydrochloric acid (HCl) Sigma-Aldrich Company Ltd. (Poole, UK) 
Hydrogen Flouride Sigma-Aldrich Company Ltd. (Poole, UK) 
Hydrogen peroxide   Sigma-Aldrich Company Ltd. (Poole, UK) 
Hydroxymethylcellulose Sigma-Aldrich Company Ltd. (Poole, UK) 
Kodak MXB autoradiography film 
(blue sensitive)  
Genetic Research Instrumentation (GRI) 
(Rayne, UK) 
Lauric acid Fisher Scientific (Loughborough, UK) 
Leupeptin Sigma-Aldrich Company Ltd. (Poole, UK) 
Methanol (HPLC grade) Fisher Scientific (Loughborough, UK) 
Methocel 856N Fisher Scientific (Loughborough, UK) 
Methyl green Sigma-Aldrich Company Ltd. (Poole, UK) 
Methylparaben Fisher Scientific (Loughborough, UK) 
Micro stirrer bars (2x5 mm)  Fisher Scientific (Loughborough, UK) 
Microscope slides  Surgipath (Cambridgeshire, UK) 
Milk (MarvelTM original dried 
skimmed milk) 
Sainsburys (Cardiff) 
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Millex®HA syringe-driven filter 
unit  
Millipore (Watford, UK) 
Monoclonal Anti-β-Actin antibody 
(clone AC-74, ascites fluid, A 5316) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
N,N,N’,N’-tetramethylene-diamine 
(TEMED) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Nitrocellulose transfer membrane 
(Protran® BA85) 0.45µm pore size  
Schleicher and Schuell (Dassel, Germany) 
Pasteur pipettes  Sigma-Aldrich Company Ltd. (Poole, UK) 
PBS + 0.02% Tween  Sigma-Aldrich Company Ltd. (Poole, UK) 
Phenylmethyl sulphonyl fluoride 
(PMSF) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Phosphoric acid Fisher Scientific (Loughborough, UK) 
Pluronic F 127 Sigma-Aldrich Company Ltd. (Poole, UK) 
Pluronic F-127 Sigma-Aldrich Company Ltd. (Poole, UK) 
Polyetheylene glycol sorbitan bees 
wax 
Fisher Scientific (Loughborough, UK) 
Polyethylene glycol 400 (PEG 400) Sigma-Aldrich Company Ltd. (Poole, UK) 
Polyethyleneglycol (100) stearate Fisher Scientific (Loughborough, UK) 
Polyoxyethylene-sorbitan 
monolaurate (Tween 20) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Pomegranate  Sainsburys (Cardiff) 
Ponceau S solution (0.1%, w/v in 
5% acetic acid) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Potassium hydrogen phthalate Fisher Scientific (Loughborough, UK) 
Potassium hydroxide Fisher Scientific (Loughborough, UK) 
Propylparaben Fisher Scientific (Loughborough, UK) 
Punicalagin Phytolab (Vestenbergsgreuth, Germany) 
Radioimmunoprecipitation assay 
(RIPA) buffer 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Rainbow Marker (12-225 kDA) GE Healthcare Life Sciences (Buckingham, 
UK) 
RK13 cells ECACC, (Salisbury, UK, ECACC No 
88062427 ) 
SDS-PAGE lower buffer (tris 1.5M 
pH 8.8)  
Bio-Rad Laboratories Ltd. (Hertfordshire, 
UK) 
SDS-page upper buffer (tris 0.5M 
pH 6.8),  
Bio-Rad Laboratories Ltd. (Hertfordshire, 
UK) 
Sellotape Sainsbury’s (Cardiff) 
Sephadex LH-20 Sigma-Aldrich Company Ltd. (Poole, UK) 
Sodium azide  Sigma-Aldrich Company Ltd. (Poole, UK) 
Sodium bicarbonate Sigma-Aldrich Company Ltd. (Poole, UK) 
Sodium chloride (NaCl)  Sigma-Aldrich Company Ltd. (Poole, UK) 
Sodium citrate Sigma-Aldrich Company Ltd. (Poole, UK) 
Sodium dodecyl sulphate (SDS)  Sigma-Aldrich Company Ltd. (Poole, UK) 
Sodium hydroxide,  Sigma-Aldrich Company Ltd. (Poole, UK) 
Spectrophotometer micro-cuvettes Bio-Rad Laboratories Ltd. (Hertfordshire, 
UK) 
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Stearic acid Fisher Scientific (Loughborough, UK) 
Stearyl alcohol Fisher Scientific (Loughborough, UK) 
Sterile pipettes 10 mL and 25 mL  Greiner Bio-One Ltd. (Stonehouse, UK) 
Super glue Sainsburys (Cardiff) 
Syringe (5 mL, Sterile) Sigma-Aldrich Company Ltd. (Poole, UK) 
Syringe needles Sherwood-Davies and Geck (Gosport, UK)  
T 75, T 25 and T150 TPP tissue 
culture flasks 
(Greiner Bio-One Ltd. (Stonehouse, UK) 
Tetraacetic acid (EDTA), Sigma-Aldrich Company Ltd. (Poole, UK) 
Triflouroacetic acid (TFA) Sigma-Aldrich Company Ltd. (Poole, UK). 
Tris(hydroxymethyl) 
aminomethane (TRIS) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Trizma® base  Sigma-Aldrich Company Ltd. (Poole, UK) 
TrypLETM Express trypsin solution Invitrogen ( Paisley,UK) 
Uranyl acetate Sigma-Aldrich Company Ltd. (Poole, UK) 
Vero cells (green monkey kidney 
epithelial cells) 
ECACC, (UK , ECACC No 85020205)  
Wax pen Dako (Ely, UK) 
Western blocking reagent Roche Diagnostics, Gmbh (Mannheim, 
Germany) 
Whatman filter paper Fisher Scientific (Loughborough, UK) 
White paraffin wax pellets Sigma-Aldrich Company Ltd. (Poole, UK) 
X-ray film developer and film 
fixative solutions  
X-O-graph Imaging System (Tetbury, UK) 
Xylene Fisher Scientific (Loughborough, UK) 
Zinc citrate  Fisher Scientific (Loughborough, UK) 
Zinc gluconate Fisher Scientific (Loughborough, UK) 
Zinc iodide  Fisher Scientific (Loughborough, UK) 
Zinc nitrate  Fisher Scientific (Loughborough, UK) 
Zinc oxide  Fisher Scientific (Loughborough, UK) 
Zinc stearate  Fisher Scientific (Loughborough, UK) 
Zinc sulphate (ZnSO4) Fisher Scientific (Loughborough, UK) 
β-actin primary antibody Sigma-Aldrich Company Ltd. (Poole, UK) 
Table 2-1 Alphabetised list of the chemicals and materials and their sources used in this thesis. 
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2.2. Methods 
2.2.1. Preparation of Solutions 
2.2.1.1. Pomegranate Rind Extract (PRE) 
The primary extraction method of pomegranate rind (PRE) was derived from a 
published method which favoured the extraction of polyphenols (Stewart, et al. 1998). 
Six fresh pomegranates were peeled; the rinds cut into thin strips approximately 2 cm in 
length, blended in DI H2O (25% w/v) and boiled for approximately 10 minutes. The 
crude solution was then transferred into centrifuge tubes and centrifuged at 10,400g at 
4C for 30 min using a Beckman Coulter Avanti J25 Ultracentrifuge and vacuum 
filtered through a Whatman 0.45m nylon membrane filter. The solution was then 
freeze dried, occluded from light and stored at -20C until required. The punicalagin 
concentration of each extract was analysed, and consisted of 20% w/w of PRE.  
2.2.1.2. Phthalate Buffer 
Solutions of potassium hydrogen phthalate (0.1 M) and sodium hydroxide (0.1 M) were 
prepared in DI H2O. Potassium hydrogen phthalate solution (250 mL) was added to 
Sodium Hydroxide solution (87 mL) in a 1litre bottle. The volume was adjusted to 1 L 
with DI H2O and sonicated (5 min). The pH of the final solution was adjusted to pH 4.5 
with Phosphoric acid 
2.2.1.3. Reconstitution of Freeze-Dried PRE 
Freeze dried PRE (2 mg) was added to phthalate buffer (10 mL, pH 4.5). The solution 
was sonicated for 10 min at 50-60 Hz. Once fully dissolved the solution was 
subsequently filtered through a 0.45 m Millex®-FG syringe driven filter unit and 
frozen at -20°C until further use. 
2.2.1.4. FeSO4 
Ferrous sulphate heptahydrate (0.0533g) was added to phthalate buffer (10 mL, pH 
4.5). The solution was sonicated for 10 min at 50-60 Hz. Once fully dissolved the 
solution was filtered through a 0.45 m Millex®-FG syringe driven filter unit. 
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2.2.1.5. ZnSO4 
Zinc sulphate heptahydrate (2.875g) was added to phthalate buffer (10 mL, pH 4.5) 
(1M solution). The solution was sonicated for 10 min at 50-60 Hz. Once fully dissolved 
the solution was subsequently filtered through a 0.45 m Millex®-FG syringe driven 
filter unit. The preparation of other zinc salts followed that for ZnSO4 above; however 
the stock solutions were made to the concentrations stated in Table 2-2. 
Salt Stock solution 
Concentration (M) 
Zinc oxide 0.00004 
Zinc nitrate 0.002 
Zinc citrate 0.002 
Zinc Iodide 0.002 
Zinc Stearate 0.002 
Zinc Gluconate 0.002 
Table 2-2 Concentration of zinc salt stock solutions. Note: solution of ZnO lower due to low solubility. 
2.2.1.6. Punicalagin 
Punicalagin (10 mg) was added to phthalate buffer (10 mL, pH 4.5) and sonicated for 
10min at 50-60 Hz. Once fully dissolved accurate dilutions were made from this 
solution using phthalate buffer (pH 4.5).   
2.2.1.7. Ellagic acid 
Ellagic acid (50 µg) was added to phthalate buffer (10 mL, pH 4.5) and sonicated for 
10min at 50-60 Hz. Once fully dissolved accurate dilutions were made from this 
solution using phthalate buffer (pH 4.5). 
2.2.1.8. HEPES-Buffered Hanks' Balanced Salt (HBHBS) 
The solution was made up of Hanks‘ balanced salt buffer (9.7 g), HEPES (6 mg), and 
sodium bicarbonate (0.35 g) in 1L DI H2O 
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2.2.1.9. Running Buffer I (10 x stock solution) 
Tris base (30.35 g) was added to glycine (144 g) and 10 mL SDS and made up to 1 L 
with DI H2O. 
2.2.1.10. Running Buffer II  
Tris base (36.42 g) was added to glycine (180 g) and 10 mL SDS and made up to 1 L 
with DI H2O. 
2.2.1.11. Transfer Buffer 
Immediately before use 40 mL of running buffer II was added to 200 mL EtOH and 
760 mL DI H2O. The solution was mechanically mixed for 15 min before use. 
2.2.1.12. TBS-Tween (10 x stock solution) 
A stock solution of tris buffered saline tween-20 solution was prepared by the addition 
of 10 mL Tween-20, 24.2 g Trizam base and 80 g NaCl made up to 1 L with DI H2O. 
The solution was mechanically stirred until complete dissolution was obtained, then 
stored at 2 - 4 °C. 
2.2.1.13. Citrate Buffer 
The citrate buffer used for the recovery of antigen within skin samples after the fixation 
process was made by dissolving 2.94 g of sodium citrate in DI H2O and sonicated for 
10 min at 50-60 Hz. The solution was adjusted to pH 6 by the dropwise addition of 
hydrochloric acid. 
2.2.1.14. LaemmLi Buffer 
A double-strength LaemmLi buffer was made by the addition of 1.2 mL of 1 M Tris-
HCl pH 6.8, 4 mL of 10% w/v SDS, 2 mL glycerol and 0.01% w/v bromophenol blue 
in DI H2O to make up a total volume of 10 mL. 
2.2.2. Porcine Membrane Preparations 
The porcine ears, vagina and cheeks were collected from a local abattoir as soon as 
possible after they were excised, then transported to the lab immersed in iced HEPES- 
buffered Hanks balanced salt solution (HBHBS), generally arriving in the laboratory 
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within 1h. Only freshly excised skin was used throughout this thesis, application of test 
materials began at a maximum of three hours after excision.  
2.2.2.1. Full Thickness Ear Skin 
The ears were gently washed under cool running water and full thickness skin removed 
from the dorsal cartilage by blunt dissection, using a scalpel. The skin was further 
sectioned into 2 x 2 cm squares and used straight away. 
2.2.2.2. Heat-Separated Epidermis (HSE) 
The skin samples were prepared as previously reported (Kligman and Christophers 
1963). After they were cut into 2 x 2 cm squares (section 2.2.2.1) they were immersed 
in DI H2O at a temperature of 55 C for a period of 1 min. The epidermis was then 
manually separated from the dermis using gloves by slowly peeling one away from the 
other. Each separated epidermis was visually assessed for holes and defects etc, and any 
damaged epidermis was discarded. 
2.2.2.3. Buccal Mucosal Membrane 
The porcine cheeks were washed under DI H2O, the full thickness membrane was 
excised from the inner cheek region via blunt dissection and placed in DI H2O at 80 °C 
for 60 s. The epithelial mucosal membrane was then peeled away carefully using 
forceps. Each peace was cut into 2 x 2 cm
2
 sections and visually assessed under a 
microscope, then used immediately.  
2.2.2.4. Vaginal Mucosal Membrane 
Excess fat and muscle was cut away from the porcine inner vaginal wall via scalpel 
dissection. The vaginal cavity was opened by cutting one vaginal wall from the vaginal 
opening to the cervix. The vaginal mucosal membrane was then trimmed down 
carefully by hand using a scalpel until only the top epithelial mucosal membrane 
remained, this was sectioned into 2 x 2 cm
2
 pieces and used immediately. 
2.2.3. Franz Diffusion Cell (FDC) 
For membrane permeation and penetration studies, all-glass FDCs were used 
(Sartorelli, et al. 2008) with nominal diffusional area of 1 cm diameter (0.88 cm
2
) and 
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nominal receptor phase volume of 3 mL. These were custom fabricated by retired glass-
blower, Mr DW Jones, Loughborough, UK. The membrane was mounted on the lightly 
pre-greased flanges of the receptor compartment of a Franz cell shown in Figure 2-1. 
The donor chamber was placed on top of the membrane and clamped in position. A 
micro-stirrer bar was added to the receptor compartment, filled with temperature 
equilibrated (37
o
C) solution and the sampling arm capped. The cells were placed on a 
multiple stirrer plate in a thermostatically controlled water bath set at 37 °C for 15 min 
to allow the temperature to reach equilibrium. The receptor fluid used was DI H2O to 
provide a sink for the water-soluble compounds of interest in this work. The donor cells 
and sampling arm were occluded. 
 
 
2.2.3.1. Penetration Through Epidermal Membrane  
This technique is used to assess the cumulative drug permeation over time. Using heat 
separated (porcine) epidermis as a model for the permeation of drugs through human 
epidermis is qualitatively and quantitatively similar to dermatomed skin and 
circumvents complications from the presence of the dermis. Depending on the 
penetration study the use of heat separated epidermis, heat separated buccal membrane 
or vaginal mucosal membrane (following the methodology of Section 2.2.2.) which had 
been sectioned into 2 cm
2
 sections were placed onto the pre-greased flanges of the 
Figure 2-1 A typical Franz diffusion cell (FDC) assembly as used throughout the 
work in this thesis. 
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Franz type diffusion cell (Section 2.2.3.), the receptor phase filled with DI H2O, placed 
in an incubator at 37°C for 15 min before the application of test materials. 
2.2.3.1.1.  Finite Dose Application 
The application of a 40 µL, representative of a finite dose of test material, is done via 
pipette onto the centre of the membrane. The sample chamber was occluded after 
application. The entire receptor phase was removed using Pasteur pipettes at pre 
defined time points 3, 6, 12, 18 and 24 h and replaced with fresh receptor phase stored 
at 37C. The removed receptor phase was transferred into Eppendorf tubes and frozen 
at -20C for analysis at a later time. 
2.2.3.1.2. Infinite Dose Application 
Sterile syringes, 5 mL, were used for the application of 300 mg of hydrogel/emulsion 
formulation, representative of maximal delivery. A separate sterile 5 mL syringe was 
used for each gel and these were filled with the formulation (hydrogel or emulsion) 
slowly. The syringe was then weighed prior to and after application to ensure the exact 
weight of applied formulation. A sterile glass rod (0.7 cm diameter, with a rounded 
bottom) was placed into the donor chamber and twisted slowly 10 times with a small 
but constant level of pressure. The glass rod was weighed prior to and after application, 
the amount of hydrogel dosed to each FDC was then determined by difference. For 
every hydrogel, a dedicated sterile syringe was used.  Sampling was as above. 
2.2.3.2. Spontaneous Release  
Spontaneous release of the active ingredients from a formulation matrix was 
determined by the use of a minimal resistance membrane, Cyclopore Track Etched 
Membrane (CTEM), mounted in FDCs. Section 2.2.3.  The CTEM was soaked in 
receptor phase (DI H2O) prior to fixing between the pre-greased flanges and being 
clamped. A micro stirrer bar was added via the sampling arm. The complete cells were 
placed onto the magnetic stirrer base set up in a water bath set at 37 ºC. A replication of 
n=4 cells were used per application. After 15 min, the donor phases were dosed with 1 
mL of formulation. Receptor phase samples were taken at 0.5 h to replicate a maximal 
application end point, and 24 h as a maximal release end point. The receptor phase was 
completely removed using a sterile pipette and 0.5 mL aliquots stored at -20 °C until 
analysis. The receptor chamber was refilled using another sterile pipette.  Thawed 
37 
 
samples were analysed for punicalagin and zinc content by HPLC and ICPMS 
respectively, as outlined in Sections 2.2.4.1. and 2.2.4.2. 
2.2.3.3. Stability 
The stability analysis of the hydrogel formulation was determined in terms of the 
concentration of the spontaneous release of both the ZnSO4 and punicalagin from the 
Methocel 856N matrix after a designated period of storage. Due to the breakdown of 
PRE constituents after long term exposure to light all proposed formulations would 
remain occluded from light at all times prior to use or evaluation. Therefore 
formulations were stored at ambient temperature within sealed containers, which were 
occluded from light and air. Samples of the formulations were taken at 0, 3, 6 and 12 
months and subjugated to analysis via spontaneous release (Section 2.2.3.2). These 
storage conditions of the test materials adhere to the basic guidelines for preliminary 
analysis into the stability of a product (Food and Drug Administration 2009). 
2.2.3.4. Tape Stripping of Full Thickness Skin 
At 24 h the skin was removed from the Franz cell and placed on a clean, dry surface. 
Excess formulation was removed from the skin surface using a cotton bud. The 
pressure applied and number of strokes was kept uniform between samples. Twenty 
strips are taken from the skin by applying the tape with constant pressure, and removal 
at a constant velocity. The first two strips were discarded as they usually contain excess 
formulation. The 20 strips were then grouped 2 per vial containing 4mL ethanol and 
rocked on an electronic rocker for no less than 24 h. The remaining skin sample was 
placed in ethanol and agitated over night using a laboratory rocker. The solution was 
evaporated to dryness then 1mL aliquots of DI H2O was added to each vial and 
centrifuged at 15000 g for 15 min. The supernatant was then transferred to auto sampler 
vials and analysed by reverse phase HPLC (Escobar-Chávez, et al. 2008) (Weerheim 
and Ponec 2001). 
2.2.3.5. Reverse Tape Stripping  
Reverse tape stripping was conducted after a 24 hr epidermal membrane penetration 
study was completed. The same methodology followed that in Section 2.2.3.4; 
however, instead of starting from the top layer of the membrane which is in contact 
with the donor phase, the bottom side was the starting point (which is in contact with 
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the receptor fluid). This allows the analysis of the amount of analyte that has localised 
within the basal layer, i.e. adjacent to site of HSV replication. 
The epidermal membrane was removed from the FDC using sterile plastic tweezers and 
dabbed clean of formulation very carefully and trimmed to the area of application. 
Superglue was applied to a ceramic tile, the membrane was placed on the superglue, 
donor application side down. Regular adhesive tape strips were placed on to the 
membrane and a small amount of pressure applied. The tape was then carefully 
removed using tweezers and is placed in a vial containing 2 mL of methanol and rocked 
over night (0 °C and occluded from light). This was repeated twice for each porcine 
membrane. The tape was removed from the vials and he methanol was evaporate under 
vacuum at less than 0 °C and occluded from light. The vials were filled with 2 mL of 
DI H2O and rocked until all solid was re-dissolved. The samples were then stored at -20 
°C and occluded from light until the point of analysis. 
2.2.4. Analytical Methods 
2.2.4.1. HPLC Analysis of PRE and Punicalagin 
The analysis was performed using an Agilent series 1100 HPLC system at 258 nm 
fitted with a Phenomex Gemini NX C18 110A 250 X 2.6 mm column. Gradient elution 
was used, involving A: MeOH with 0.1% trifluoroacetic acid (TFA) and B: DI H2O 
with 0.1% TFA. The gradient timetable and percentage composition of mobile phase is 
shown in Table 2-3. 
Time (min) A. % MeOH + 0.1% TFA B. % H2O + 0.1% TFA 
0 5 95 
15 20 80 
30 60 40 
40 60 40 
Table 2-3 Gradient timetable for the HPLC analysis of PRE 
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2.2.4.1.1. Punicalagin Standard 
The punicalagin standard was analysed over a range of concentrations so that a 
calibration curve could accurately be produced (Figure 2-2) to incorporate all sample 
data throughout the project. Punicalagin was dissolved in DI H2O, analysed following 
the HPLC method outlined above, and is found to exist as two natural anomers: 
punicalagin α and β as stated in Chapter 1 and within the chromatogram in Figure 2-3. 
A calibration curve representative of peak area vs total punicalagin concentration of 
each anomer is shown in Figure 2-2. 
 
Figure 2-2 HPLC calibration curve for punicalagin anomers α and β (n=3 ± s.d.) 
 
Figure 2-3 A sample HPLC chromatogram of punicalagin anomers α and β. 
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It was determined that the punicalagin anomers in the standard were at all times in the 
ratio of punicalagin α : β is approximately 1 :  2, which is similar to that described for 
other PRE extracts (Satomi, et al. 1993) (Nigrisa, et al. 2011). The consistent ratio of 
punicalagin anomers within PRE, as stated previously (Seeram 2006) and shown by 
Figure 2-4, allows for the analysis of punicalagin to be drawn from the peak area values 
of just one anomer. Due to the increased concentration of punicalagin β this anomer 
was used for quantification of total punicalagin concentration.  
 
Figure 2-5 shows that the concentration of punicalagin within the freeze dried 
pomegranate rind extract is one fifth the total mass extracted.  
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Figure 2-5 Concentration of punicalagin within freeze dried PRE (n=3 ± SD). 
Figure 2-4 The ratio of the area of absorbance via HPLC analysis between the anomers of punicalagin: 
α and β. (n=3 ± s.d.). 
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2.2.4.2. Inductively Coupled Plasma Mass Spectrometry (ICPMS) 
The levels of zinc were determined by ICPMS analysis in the laboratories of Dr. I 
MacDonald, School of Earth Sciences, Cardiff University. Analysis was performed 
using a Thermo Elemental X Series 2 ICP-MS system equipped with a Plasma Screen.  
Analysis was performed in triplicate on each solution using 
66
Zn as the analytical mass.  
Calibration was carried out using synthetic standard solutions prepared from single 
element stock standards. Periodic checks for accuracy were performed by analysis of a 
solution of the international rock standard JB1a as an unknown. This standard was 
prepared by digesting a sample in HF/HNO3 and then HNO3 procedures described 
previously (Parkinson and Pearce 1998). 
2.2.4.3. Isothermal Titration Calorimetry (ITC) 
Binding interactions were probed by ITC in the laboratories of Professor Niek Buurma, 
School of Chemistry, Cardiff University. Figure 2-6 is an illustration of an ITC 
instrument. When the reference cell and titrate cells have equilibrated, the titrant 
(FeSO4) is injected into the ITC cell containing the titrate (PRE). The enthalpy change 
due to the introduction of the titrant is measured, the cell re-equilibrates leading to a 
slower drift back to the baseline. This peak is then integrated which gives the enthalpy 
change of that experiment. The subsequent enthalpy changes of each injection are 
added until there is no further heat change, which allows the measurement of ∆H. The 
series of several injections can lead to the calculation of free energy, enthalpy, entropy, 
Kd, and stoichiometry of binding. The ITC instrument used was the Microcal VP-ITC 
(Amersham, UK). 
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Figure 2-6 Representation of Isothermal Titrated Calorimetry (ITC) with PRE as the titrate and FeSO4 as 
the titrant. 
Each cell was washed and emptied twice with a solution of 50% 3-(N-morpholino) 
propanesulfonic acid (MOPS) buffer and 50% DI H2O. A preliminary titration was run 
with DI H2O and the buffer solution being titrated in to note any underlying heat 
effects. This involved injecting an aliquot of 15 µL into the cell over a period of 15 sec 
with 420 sec between each injection (n=18) to note any heat changes. Each cell was 
washed and emptied twice with a solution of 50% MOPS buffer and 50 % DI H2O 
before the addition of PRE 0.6 mg mL
-1
 which equilibrated to 25˚C. An aliquot of 15 
µL of the FeSO4 (2.5 mM) solution was injected into the cell over a period of 15 
seconds with 420 sec between each injection (n = 36). The first in the series of 18 
injections is always discarded due to heat irregularities that occur with the first 
injection. To account for varying pH in calculating the binding constant a further 
experiment was run using an acetate buffer pH 4.5, all other factors remained the same. 
All solutions were degassed before analysis. 
2.2.4.4. Protein Analysis and Western Blotting  
The process of western blotting is to detect proteins extracted from the lysis of cells or 
tissue homogenate. The separation of proteins, in order to probe for specific proteins of 
interest (i.e. COX-2), was done via gel electrophoresis. The analysis of the 
inflammatory marker protein, COX-2, has been established by the use of Western 
blotting techniques (Abdalla, Sanderson and Fitzgerald 2005)(Laouini, et al. 2005), and 
used as a standard model in our laboratory (Zulfakar, Abdelouahab and Heard 2010) 
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2.2.4.4.1. Preparation of Skin Lysates 
Porcine full thickness skin sections were prepared and set up in Franz diffusion cells 
following the methods outlined in sections 2.2.2.1 and 2.2.3, with a receptor phase 
comprised of Hanks buffer. After a 6 h application time the FDC assemblies were 
dismantled, the membranes recovered and test materials carefully removed then gently 
cleaned with PBS. The area of application was excised by scalpel dissection and 
homogenised using a Silverson homogeniser (Chesham, UK) in 1 mL RIPA lysis buffer 
(1 mM EDTA, 150 mM NaCl, 0.1% SDS, 1 mM PMSF, 1% sodium deoxycholate, 50 
mM Tris-HCl (pH 7.4), 1% Triton x-100, 5 μg mL-1 aprotinin and 5 μg mL-1 leupeptin), 
the protease inhibitors were added immediately prior to homogenising. The 
homogeniser was cleaned after each skin section with PBS. The lysates were incubated 
for 15 min on ice then pelleted by centrifugation at 1400 g for 2 x 15 min at 4°C. The 
supernatant was stored at -20°C. 
2.2.4.4.2. Protein Assay 
The total protein concentration of each supernatant sample was determined via 
spectrophotometric analysis by the use of BIO-RAD protein assay kit, following the 
instructions given with the kit (BIO-RAD laboratories Hercules, California). A 
calibration curve was produced between 0 and 50 µg mL
-1
 BSA in DI H2O. The sample 
supernatant (5 µL) was diluted to 1/200 in DI H2O (1000 µL). 200 µL of the BIO-RAD 
reagent was added to 800 µL of the diluted sample. Samples were left for a 15 min 
development time before optical density was read at 595 nm using a Cecil CE2041 
series 2000 spectrophotometer (Cecil Instruments, Cambridge, UK). The volume 
needed for 30 µg of protein for each sample was calculated from the calibration curve. 
2.2.4.4.3. Protein Denaturation 
Skin lysates containing 30 µg of soluble proteins were aliquoted diluted in a 1:1 ratio 
with 2 x LaemmLi buffer containing 0.1 M DTT within Eppendorf tubes. The mixtures 
were mixed gently on Eppendorf Mixer 5432 (Eppendorf®-Netheler-Hinz GmbH, 
Germany) for 5 min. The lids of the tubes were pierced with a syringe needle before 
heating at 100 °C for 5 min, to denaturise the tertiary form of the proteins, after which 
they were left to cool for 5 min. The samples were mixed as before on an eppendorf 
mixer at room temperature and centrifuged (14,000 g at 4C for 1 min, Heraeus 
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Multifuge 3 S-R). The denatured samples were then stored at -20°C or used straight 
away for Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
2.2.4.4.4. Sodium Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
The SDS-PAGE protein separation was carried out using the Xcell SureLock 1-d 
electrophoresis system (Invitrogen, Paisley UK) shown in Figure 2-7. The separating 
gel (3.3 mL 30 % acrylamide, 2.5 mL 1.5 M tris HCl (pH8.8),  4 mL DI H2O, 0.1 mL 
10 % SDS, 0.1 mL 10% APS and 10 µL TEMED) was pipetted into disposable plastic 
cassettes, DI H2O was carefully pipetted on top and the gel was allowed to set for 30 
min. Once set the H2O was poured of the top of the gel and the stacking gel solution 
(1.7 mL 30% acrylamide, 2.5 mL 1.5 M tris HCl (pH6.8), 5.8 mL DI H2O, 0.1 mL 10% 
SDS, 0.1 mL 10% APS and 10 µL TEMED) was pipetted on top of the separating gel, 
with a well-casting comb and left to set for 20 min. Once set the comb was removed, 
the wells were washed with DI H2O and the cassette was locked into position within the 
Xcell SureLock case. The wells were carefully filled with 1 x running buffer (100 m L 
running buffer I was added to 1 L DI H2O) via pipette after which the tank was slowly 
filled with 1 x running buffer I. The samples were applied via pipette to the bottom of 
each well, in one well 5 µL of the rainbow marker was applied. The proteins were 
separated via electrophoresis at 125 V for between 1.5 - 2 h. The cassette was removed 
once adequate separation had taken place and carefully broken apart for the removal of 
the gel. 
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Figure 2-7 Components of XCell SureLock™: (A) electrophoresis module consists of a running tank, 
buffer core, and lid; (B) gel tension wedge; (C) Xcell™ Blot Module; (D) buffer dam; (E) plastic 
cassette; and (F) comb. 
2.2.4.4.5. Blotting (Transfer of Proteins) 
Prior to blotting, filter paper and sponge pads were soaked in transfer buffer. 
Nitrocellulose blotting membrane (0.45 µm pore size) was wetted with methanol and 
shaken in DI H2O. The sponge pads filter paper gel and blotting membrane were 
assembled as shown by Figure 2-8 and placed in the Xcell blotting module. The module 
was filled with transfer buffer and placed inside the Xcell Sure Lock case which was 
subsequently filled with DI H2O. The transfer was run at 25 V for 1.5 h.
 
Figure 2-8 Assembly of the sponges, filter papers, nitrocellulose blotting membrane and gel for Western 
blotting of proteins. 
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2.2.4.4.6. Immunohistochemistry for Western Blot (IHC) 
The completion of protein transfer to the nitrocellulose membrane was assessed by 
removing the membrane from the blotting module assembly with tweezers and placing 
it in a solution of Ponceau S (0.1% w/v Ponceau S in 5% acetic acid) briefly followed 
by washing with 1 x TBS-Tween and visual assessment of the protein bands was 
carried out, washing resumed until the blot was cleared. 
2.2.4.4.7. Membrane Blocking 
To prevent the non specific binding of protein the blot was blocked using 5% milk in 1 
x TBS tween for 1 h at room temperature with constant rocking. After blocking, the 
milk solution was discarded and the blot was rinsed with TBS-Tween (3 x 10 min, 10 
mL per blot). 
2.2.4.4.8. Primary and Secondary Antibody Conjugation 
The blot was incubated in the diluted primary antibody (COX-2, 1/1,000 dilution, 5 mL 
per blot) at 4°C overnight with constant rocking. After the overnight incubation the blot 
was washed with TBS-Tween (3 x 10 min, 10 mL each blot). The blot was incubated 
with the secondary HRP-linked antibody at a 1/10,000 dilution in TBS-Tween with 1% 
w/v Marvel milk (a total volume of 5 mL per blot), for 1 h under constant rocking, at 
room temperature. The membrane was washed in PBS-Tween (3 x 10 min, 10 mL each 
blot) prior to chemiluminescence signal detection. 
2.2.4.4.9. Detection of Protein 
The chemiluminescence detection of the protein was carried out by the transfer of the 
blot into a light-proof x-ray cassette with the protein side facing up. The blot was 
evenly covered with 300 µL of freshly prepared SuperSignal West Dura Substrate 
working solution. It was incubated in the reagent for 2 min at room temperature. A 
clear plastic wrap was carefully placed on the cassette to cover the blot, to prevent air 
pocket formation, and the excess reagent was drained with a soft tissue. The exposure 
of the blot to autoradiography film varied between experiments until a plot specific 
exposure time was achieved. The film was developed using X-ray developer (X-O-
graph Compact X2, X-O-graph Imaging System, Tetbury, UK). The resulting dark 
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bands corresponded to the protein of interest. Membranes were subsequently washed in 
TBS-Tween (3 x 10 min, each) and stored in the fridge for up to 14 days. 
The bands were scanned and analysed using Scion Image software for Macintosh, 
version alpha 4.0.3.2 (National Institute of Health Image, U.S.). β-actin served as a 
loading control. Histograms represent the ratio of the protein of interest against β-actin 
and the control is 100%. 
2.2.4.4.10. Loading Control 
β-actin, a 42kDa ubiquitous protein, was used as the loading control to account for any 
pre experimental variations within the excised skin. The blot was probed with 1/50,000 
β-actin primary mouse antibody for 45 min followed by conjugation with Anti-rabbit 
IgG, secondary HRP-linked antibody for 1 h. Both incubations were done at room 
temperature with constant rocking. After each incubation the blots were subjected to 3 
x 10 min washes in TBS-Tween. 
2.2.4.5. Immunohistochemistry (IHC)  
IHC is a standard technique used to qualitatively assess the localization and relative 
levels of proteins within a tissue (Lia, et al. 2005). The specific binding of an antigen to 
a fluorescently linked antibody, with subsequent staining, allows for the visual 
assessment of a protein specific colouration of a tissue sample. 
2.2.4.5.1. Application to, and Fixation of, Full Thickness Porcine Skin 
Full thickness porcine skin were set up within a Franz diffusion cell as stated in 
sections 2.2.2.1 and 2.2.3. The application of 1 mL of test solution to the skin was done 
via pipette, the receptor solution was HBSS. The porcine skin was removed from the 
FDC at 0, 3, and 6 h. The application and diffusional area was sectioned into 1 x 0.1 
cm
2
 strips, placed in disposable cassettes and fixed in 4 % formaldehyde over night. 
2.2.4.5.2. Dehydration and Wax Embedment of Tissues 
The cassettes were passaged through increasing concentrations of EtOH and then 
chloroform, following Table 2-4, to dehydrate the skin sections.  
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Solution Time 
70 % Ethanol 2 x 30 min 
90 % Ethanol 2 x 30 min 
100 % Ethanol 2 x 30 min 
Chloroform 1 x 1 h, followed by 2 x 30 
min 
Table 2-4 Protocol for the dehydration of excised porcine skin sections. 
The wax used for embedding the skin samples was de-gassed following the vacuum 
protocol outlined in Table 2-5.  
Wax bath Vacuum timings 
1 Vacuum off 15 min 
Vacuum on 10 min 
Vacuum off 5 min 
2 Vacuum off 10 min 
Vacuum on 15 min 
Vacuum off 5 min 
3 Vacuum off 10 min 
Vacuum on 15 min 
Vacuum off 25 min 
Table 2-5 Protocol for de-gassing embedding wax. 
The skin samples were then embedded within the degassed wax by placing the skin 
sections in moulds so that the skin layers were perpendicular to the mould surface. 
Molten degassed wax was then carefully poured into the moulds, the cassette lid was 
placed on top and left to solidify over night. The wax blocks were then removed from 
the mould so that they could be sectioned. 
2.2.4.5.3. Microtoming 
The wax blocks were mounted on a Shandon Finesse microtome and 5 µm sections 
were taken. Each section was flattened by floating on 40 °C DI H2O and mounted on 
Surgipath microscope slides. 
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2.2.4.5.4. Dewaxing and Rehydration 
The dewaxing and rehydration of the skin sections, required prior to staining, was done 
by heating the slides within an oven at 60 °C then passaging of the slides through 
solutions following Table 2-6. 
Solution Time 
Chloroform 2 x 7 min 
Ethanol 100 % 2 x 3 min 
Ethanol 90 % 2 x 3 min 
Ethanol 70 % 2 x 3 min 
Table 2-6 Dewaxing and rehydration protocol for microtomed, wax 
embedded, skin sections on microscope slides. 
2.2.4.5.5. Peroxidase Blocking 
The use of a HRP conjugated antibody may result in high non-specific background 
staining. It is therefore important to block the staining caused by the endogenous 
peroxides. A 3% hydrogen peroxide solution was applied to the skin sections for 5 min, 
excess hydrogen peroxide was removed by passaging the slides through PBS (2 x 3 
min). 
2.2.4.5.6. Antigen Recovery 
To recover any antigen which is masked by the fixation process the samples were 
microwaved in 1 L citrate buffer for 15 min, followed by cooling In situ for 35 min. 
The slides were washed with running tap water for 15 min and then rinsed with PBS. 
Each skin section was outlined with a wax pen and were then blocked by the incubation 
of the slides in PBS-Tween, for 20 min, within a humidity chamber. 
2.2.4.5.7. Primary Antibody 
The primary antibody COX-2, at a 1 in 50 dilution (PBS), was added via pipette onto 
each section and left over night at room temperature. The slides were then washed by 
PBS and then PBS-Tween. 
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2.2.4.5.8. Detection, Staining and Counter Staining 
The Dako Envision+ system horse radish peroxidise labelled polymer anti rabbit (HRP) 
was used as the detection system. The HRP linked secondary antibody was applied to 
the skin sections and left at room temperature for 2 h. The sections were rinsed in PBS 
and PBS-Tween. The application of the Dako Chromogen system enables the binding 
of  three 3 Diaminobenzidine to the HRP, if binding occurs then a brown colour is 
observed. One drop of stock solution was added to 1 mL DI H2O and was applied to the 
skin sections for a period of 10 min, after which the slides were rinsed in DI H2O. Each 
sample was then counterstained by the application of 0.5% methyl green for 2 min, 
followed by rinsing in DI H2O. After drying the slides were covered with DPX and a 
cover slip. The skin sections were imaged under a microscope (Optihop, Nikon 
Corporation, Tokyo, Japan) equipped with a camera (Axiovision LE, Carl Zeiss Ltd., 
Welwyn Garden City, UK). 
2.2.4.6. Rheology 
Hydrogel formulations were subjected to rheological examination in order to obtain the 
shear strain, shear rate and viscosity parameters, using a Bohlin CS10 Rheometer 
(Malvern, UK). Viscoelastic measurements were taken shortly after the formulation of 
the hydrogel. For this specific analysis the rheometer was fitted with a cone and plate 
assembly. A mass of 300 mg of gel was placed on the plate and the cone was lowered 
onto the matrix so that the gap between cone and plate was 0.5 mm, this gap and the 
temperature (32.5 ± 0.1 °C) was maintained throughout the experiment. The cone was 
spun with at incremental speed and the force required for the maintenance and increase 
in revolutions was measured. The mechanical analysis of these factors on the increase 
and decrease of the shear stress from 30 Pa to 300 Pa back to 30 Pa enabled the 
calculation of shear rate, strain and viscosity (Barbucci, et al. 2008). The technique was 
repeated twice for each sample and the averages plotted graphically. The interpretations 
of the graphs were done in respect to the illustrations of flow curves for typical 
Newtonian, plastic, pseudoplastic and dilatant flow (Barry 1983). 
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2.2.5. Cell Culture Techniques 
2.2.5.1. Cell Culturing 
As already mentioned, viruses are unable to replicate without a host. Therefore cultures 
of cells were used to act as host cells and allow the replication of the virus. All cell 
culture experiments were performed in an Envair class II unidirectional laminar-down 
flow microbiology safety cabinet (Haslingden, UK). These were kept at 37°C and 
5%CO2. The cell types used within this thesis are green monkey kidney epithelial Vero 
cells, and rabbit kidney 13 (RK13) cell line, which was initiated from the kidney of a 5-
week-old rabbit (Oryctolagus cuniculus) (Nikon 2011). 
2.2.5.2. Sterile Technique 
Sterile manipulation was used in cell culture as any bacterial contamination can cause 
bacterial over growth resulting in competition for nutrients in the media, and possible 
cell death, and it will also alter the behaviour of the cells to any test conditions. 
Antibiotics can be used to prevent any growth; however good aseptic technique is often 
the best practice to adopt. In all of the work antibiotics were not used as one cannot 
always fully distinguish the role in which they are playing in the tests and the effect of 
their interaction with any drug added. In this study, a class II cabinet was used for all 
cell culture manipulation. 
2.2.5.3. Isolation of Cells 
The cells are isolated from soft tissue, such as monkey kidney epithelial tissue, by 
enzymatic degradation. The enzyme used is trypsin, which is a protein digestive 
enzyme that releases the cells from the extra cellular matrix to produce a suspension of 
cells, however this enzyme will kill the cells if left on for an extended period of time. 
The cells are left to settle in a bottle containing a nutrient rich media as described 
below. 
2.2.5.4. Cell Media 
Cells need to be grown in an environment that mimics physiological conditions, 
therefore the cells were grown in a nutrient rich medium and incubated at 37
o
C, 5% 
CO2 in an incubator. The type of nutrient rich medium used was Dulbecco Modified 
Eagles Medium (DMEM) which contains +glucose, +glutamine and -pyruvate. For 
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cells to grow effectively Foetal Bovine Serum (FBS) was also added at a concentration 
of 10%. The environment of the cells was kept at a neutral pH, DMEM is a bicarbonate 
buffer but the pH of added drugs and other media was taken into careful consideration. 
Media changes were required to avoid a build up of metabolic by-products and dead 
cells, and to replace nutrients. 
2.2.5.5. Passaging of Cells 
Passaging or splitting of the cells was done on a regular basis when the cells become 
90-100% confluent as shown by Figure 2- 9. If this is done regularly the health of the 
cells is maintained. If not done regularly the cells will no longer grow in a monolayer 
upon the bottom of the container and they may morphologically change. A high density 
can cause death of cells due to depletion of nutrients or arrest of replication due to 
contact inhibition. Although the number of times a particular cell line is able to be 
passaged is around 50 times, after this many passages the cells will degrade and 
morphologically change and no longer act normally.  
 
Figure 2-9 An inverted phase contrast microscope image of Vero cells. 
To passage Vero cells from a T75 following sterile technique the cell media was 
removed and discarded, 2 mL of trypsin was added to the T75 and washed over the 
cells 5 times, then removed and discarded. 1 mL of trypsin was added to the cells and 
spread over the bottom of the container the container which was then incubated for 5-7 
min at 37°C, 5% CO2 until all cells were freely moving in the liquid. This was 
microscopically assessed before any further action. The Trypsin containing cells was 
then removed and either discarded, used or stored in an Eppendorf tube for further use. 
53 
 
The T25 was then refilled with 10 mL DMEM With 10% FBS and replaced in the 
Incubator. 
2.2.5.6. Plating Vero Cells in a 24wp 
The Vero cell trypsin solution obtained following the passaging of a confluent T75  
(section 2.2.5.5.) was added to 50 mL of DMEM containing 10% FBS. This was 
thoroughly mixed and pipetted in 1 mL portions to each well. The 24WP was incubated 
overnight and microscopically analysed for confluency before use. 
2.2.5.7. Cell Titer 96® AQueous Assay 
A cytotoxic assay allows the evaluation of  the effect a drug or foreign body has upon 
cells. The assay was done in a 96 WP with a known concentration of cells in each well, 
which allowed for the quantification of viable cells. To do this after a pre-defined 
incubation period Cell Titer 96
®
 was added. Cell Titer 96
®
 AQueous assay is a 
colorimetric test for determining the living cells. It consists of a tetrazolium compound 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt] (MTS) and an electron transfer reagent phenazine 
methosulphate (PMS). Cells which are still metabolically active convert MTS into a 
water soluble Formazan product through dehydrogenase enzymes, these enzymes 
generate the reducing agents NADH and NADPH which are thought to play an 
important role in converting MTS into Formazan. Formazan is a coloured compound so 
therefore the absorbance measured at 490nm is directly proportional to the amount of 
viable cells (Berridge and Tan 1993).  
A concentration of 2.5 x 10
3
 cells per well for each plate was used, by the trypsinisation 
of 80% Vero cells within a T75 container and reconstituted in fresh media. Cells were 
seeded onto 96-well plates and incubated for 24 h at 37°C, 5% CO2. The medium was 
removed by aspiration, washed 3 times with DPBS then immediately replaced with the 
dilutions of test materials. Cells were incubated for 6, 24, 48 and 72 h. Cell Titer 96
®
 
AQueous solution was used to detect cell viability. It was added to each well and the 
plates were incubated for 1 h at 37
°
C, 5% CO2. The optical density was then determined 
at 492 nm. The reading from the blank sample was subtracted from each sample 
reading and the means of density for the control cells were arbitrarily assigned a value 
of 100%. 
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2.2.5.8. HSV-1 -2 and ACR Growth Kinetic 
The growth conditions required for the propagation 
of high titre HSV-1 and HSV-2 ACR (Aciclovir 
resistant) was investigated by assessing the optimum 
container size and host cell. 
2.2.5.8.1. Viral Growth:  
For the viral stock Growth kinetic an MOI 
(multiplicity of infection) of 0.01 was used (Balfou 
1999) (Clercq 2004).  Each confluent T25 of Vero 
cells and RK-13 cells contained approximately 3 x 
10
6 
cells so the viral titre must equal 3 x 10
4
.  
In confluent T25s the medium was removed and 
discarded, the cells were washed 3 times with 10 mL 
PBS.  300 µL of virus (moi 0.01) was added to each 
T25, the virus was pipetted into one area at the top 
of the T25 and spread from left to right to form a 
solution front, the T25 was slowly tipped so that the 
virus solution front flows over all the cells. This 
process takes 2-3 min and is illustrated in Figure 2-
10. 
After infection, cell medium was replaced with 
DMEM and 2.5% FBS. The T25s were then 
incubated at 35 °C and 5% CO2 for as many days as 
desired before collection. 
2.2.5.8.2. Collection of Virus 
After incubation, the supernatant was mixed and 
removed from the T25 via a pipette then frozen in 1 
mL aliquots at -70 °C. The cells were removed from 
each bottle using a sterile cell scraper in an oscillatory fashion, slightly rocking the 
bottle so that all the cells were floating in the medium. This motion was repeated until 
Figure 2-10 A diagrammatic 
representation of the viral infection in 
confluent T25 flasks 
Figure 2-11 Cell removal from a 
T25 flask using a cell scraper. 
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no cells were visible on the bottom of the tissue culture flask, as shown in Figure 2-
11.The suspension was then washed over the base of the culture flask, 1 mL of this was 
frozen at -70°C. 
2.2.5.8.3. Viral titre analysis 
The analysis of the supernatant titre was carried out on Vero cells in 24 well plates 
(24WP) following the same method as that used for virucidal titre analysis below. 
2.2.5.9. Plaque reduction assay 
A plaque reduction assay uses titration of a known concentration of a virus to infect a 
cell culture monolayer in a number of different wells of the same size. This was 
performed in a 24WP. Each virion resulted in a localized area of infection known as a 
plaque. From this the number of plaque forming units (pfu) was quantified 
representative of the number of virions present. A crystal violet stain distinguished 
between healthy or damaged and destroyed cells. The number of plaques was then 
counted. Figure 2-12 shows an example of an individual experiment in a 24WP.  
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Figure 2-12 An example experimental 24 well plate of the number of plaque forming units (pfu) 
observed after the  3 day incubation of  HSV-1 on confluent vero cells. The HSV-1 was introduced to 
PRE 0.01 mg mL
-1
 for 30 min prior to incubation, the control HSV-1 was not. 
The annotations to the top plate are: ‗Inf‘ refers to infection, followed by the date (09) 
day and month (26-6), the circled number represents the numbered infection on this 
day, eg 7, then a brief description of the drug used i.e. PRE 0.01 mg mL
-1
 + pb 
(phthalate buffer pH4.5), the virus strain used was HSV-1. The untreated control HSV-
1 dilutions are the lower row of 6 wells. DH refers to the initials of the experimenter 
and the host cells are Vero cells with the passage number (P33) and the date of that 
passage (23-06-09). 
2.2.5.10. Antiviral Plaque Assay 
Antiviral activity was analysed by the application of drug and then virus (after an 
incubation period) to confluent Vero cells in a 24WP (section 2.2.5.6.). For each 
confluent 24WP one drug was analysed in 5 different concentrations i.e. 100 µM, 50 
µM, 10 µM, 5 µM and 1 µM and a control. Each dilution was replicated in 4 wells. 
Using suction, media was removed from the first row of four cells and application of 
400 µL of drug was applied.  This was repeated until all medium was removed and 
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replaced. Once the last well was filled the time was noted, and the plates incubated for 
30 min to allow for any cellular absorption or reaction. 
After the 30 min incubation period, 100 µL of virus (ca 150 pfu mL
-1
) was added to 
each well. Each plate was rocked / swirled to ensure an even spread of the virus. The 
plate was then incubated at 37°C for 45 min with rocking/swirling every 5 min, to 
ensure potential viral entry into the cells. After the incubation period, 300 µL of 1.2 % 
Avicel overlay was applied to each well and the plate was incubated for three days. The 
plates were then stained using crystal violet. A plaque assay was used to assess the 
antiviral activity of a compound by quantifying infectious viruses (Matrosovich, et al. 
2006). 
2.2.5.10.1. IC50 Calculation 
Antiviral results are normally presented as an IC50 value, IC50 is an abbreviation for the 
half maximal inhibitory concentration. This is a measure of the effectiveness of a 
compound in inhibiting biological or biochemical function. In this case the inhibitory 
effect was in respect to HSV-1 infection. When an IC50 value was not present due to 
incomplete results or when testing a vehicle (i.e. phthalate buffer) an IC50 was either 
taken from the curve or the greatest antiviral response was stated. 
The IC50 was calculated from the equation given by the application of a special logistic 
function producing a sigmoid curve. This was always done in respect to the log of the 
drug concentration, and as a percentage of the control. Graph Pad Prism 5 (GraphPad 
Software Inc, California, USA) was used to analyse the data.  
2.2.5.11. Avicel Overlay Medium  
An overlay medium is added to all plaque assays in order to stop the virus becoming 
detached from the infected cells and thus spreading over the cell monolayer. If the 
overlay is not applied then plaques would become too large and merge, the virus could 
also replicate within the cells and produce secondary plaques giving a false result. 
Avicel microcrystalline cellulose that had been partially hydrolysed with acid and 
reduced to a fine powder was the overlay medium used for this study. Avicel is a 
relatively new medium that is a colloidal form of water insoluble cellulose 
microparticles blended with sodium carboxymethylcellulose to facilitate dispersion. 
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The Avicel particles are readily dispersed in water to form suspensions and thixotropic 
gels and it also has a relatively low viscosity. 
2.2.5.12. Recovery of Penetrants in FDC Receptor Phases  
The methodology for the penetration of test compounds through HSE for maximal 
delivery was given in sections 2.2.2.1. and 2.2.3, however the receptor phase was only 
removed once after 24 h and was freeze dried. This was reconstituted in 100 µL of DI 
H2O and passed through a 0.45 µm pore size Whatman syringe filter for sterilisation. 
The solution was retained and stored in a sterile Eppendorf tube, after which it was 
used as the test material for virucidal analysis following that stated in section 2.2.5.9. 
2.2.6. Fractionation of PRE by Column Chromatography 
Fractionation of PRE was achieved in a 2-step process, generally following the method 
of Seeram et al (2005). 
2.2.6.1. Amberlite XAD-16 
All H2O was degassed and deionised prior to use. All MeOH was degassed prior to use. 
The column was slurry packed using 75g of Amberlite XAD-16 resin in H2O with 2cm 
sand protecting layers above and below the resin, using a glass wool plug. The resin 
was washed with 300 mL MeOH then 100 mL H2O and left for 12 h to equilibrate. PRE 
was adsorbed onto the column, the optimal loading volume 40 ± 5 mL per 75g of 
preconditioned XAD-16 resin per column. The column was eluted with 300 mL of H2O 
until the tannin devoid pale yellow eluent (fraction1) shown in Figure 2-13 was fully 
removed. The remaining tannins were eluted with 100 mL MeOH to yield a dark red 
solution (fraction 2). The time taken to produce one cycle <30 min. 
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Figure 2-13 XAD-16 Column with adsorbed PRE. Using H20 to fraction the yellow tannin devoid 
solution being collected, leaving the red total pomegranate tannins (TPT) on the column. 
2.2.6.2. Sephadex LH-20 Column 
The fractionation of TPT was done following an established method for purifying 
punicalagin from total pomegranate tannins (TPT) (Seeram et al., 2005). The precise 
solvents used were solvent A (H2O 80 : 20 MeOH) and solvent B (H2O 20 : 80 MeOH). 
Each solvent was filtered through a Whatman 0.45μm filter before use to protect the 
column from large insoluble particles, bacteria and reduce the risk of gas bubbles 
forming. The solvents were introduced to the column via two automatic syringe drivers. 
Non-return valves were fitted at the point of solvent mixture. 
A 35 cm
3 
column (0.75 cm radius) was slurry packed with 8.8g of Sephadex LH-20 in 
40 mL MeOH with a glass wool filter. The slurry was left to expand for 3 h prior to 
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packing. The gradient elution timetable with the two solvent systems running in unison 
(combined total of 18 cm
3
 h
-1
) followed that stated in Table 2-7 with collection of each 
fraction after 1 h (fractions 1-8) with the last fraction collected over 3 h (fraction 9). 
Solvent A (mL h-1) Solvent B (mL h-1) H2O % MeOH% 
18 
 
0.00 80 20 
16.5 1.44 75.2 24.8 
15.12 2.88 70.4 29.6 
13.50 4.50 65.0 35.0 
11.88 6.12 59.6 40.4 
10.44 7.56 54.8 45.2 
9.00 9.00 50.0 50.0 
7.38 10.62 44.6 55.4 
5.94 12.06 39.8 60.2 
4.50 13.50 35.0 65.0 
2.88 15.12 29.6 70.4 
1.44 16.56 24.8 75.2 
0.00 18.00 20 80 
Table 2-7 Gradient elution timetable for the fractionation of TPT with solvent A and solvent B through a 
Sephadex LH-20 column 
2.2.6.2.1. Removal of Solvents from the Fractions 
After column chromatography all fractions were occluded from light and cooled to -
20°C. MeOH was removed under vacuum at less than 0°C and occluded from light, 
using two liquid nitrogen cold traps. After which the samples were frozen at -20°C so 
that the remaining H2O could be removed by freeze drying. The residue of each fraction 
was weighed, occluded from light and stored at -20°C until further use. 
2.2.7. Hydrogel Formulation 
The ‗hot/cold‘ technique involved heating 1/5th to 1/3rd of the desired overall volume 
to approximately 80°C and then dispersing the required amount of thickening agent to 
the heated liquid. The solution was mixed continuously until all particles were 
thoroughly wetted (DOW Chemical Company 2002). To complete the solubilisation 
process the remainder of the liquid required to make the total volume was added to the 
heated solution.  This liquid was cooled or iced to ensure the thickening agent becomes 
solubilised in water, and therefore result in the powder hydrating and the hydrogel 
becoming more viscous. Agitation of the hydrogel continued for 30 minutes after the 
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addition of the cooled water to guarantee a uniform and evenly dispersed hydrogel.  All 
formulations were refrigerated for a minimum of four hours after agitation so that a 
uniform hydrogel was formed (Tonic-Ribarska, et al. 2005). 
In the formulation process of Methocel 856N with PRE it was observed that black dots 
appeared within the hydrogels, Figure 2-14 shows examples of this phenomenon. After 
the application of a strong magnetic field to the Hydrogel the coloured dots migrated 
towards the source of the magnetic field leaving a dark streak behind. Due to the 
migration of the dots and the aforementioned blackening of PRE upon the addition of 
FeSO4 it was hypothesised that the dots were due to iron flakes attached to the magnetic 
stirrer bars, used for continuous agitation, which were removed from the magnet as the 
gel thickened. Therefore it was decided to use a glass rod for all agitation and stirring, 
after which no black dots appeared. Therefore to prevent Fe contamination the 
formulation process used no magnetic stirrers. 
  
Figure 2-14 Comparison of hydrogels containing 2.5% Methocel 856N, 0.1 mg mL
-1
 PRE and 0.1M 
ZnSO4 after formulation with (left) and without (right) the use of a magnetic stirrer, (formulation using a 
magnet displaying "black dots" due to contamination with iron particulates). 
2.2.7.1. Aesthetic tests 
Generally, 3 tests were carried out to determine formulation aesthetics: 
 Appearance was determined visually under normal light. The gels were 
examined for obvious properties including hue, clarity and homogeneity. 
Additionally, approximately 50 μL of formulation was applied to porcine 
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epidermis and a clean round bottomed glass rod used to apply pressure and was 
twisted 20 times. A visual inspection of the dermis was then conducted to assess 
the appearance on skin.  
 Formulations were also probed by the author, for any discernible odour. 
 Tactile properties were determined by rubbing a small amount (approx 50 L) 
of formulation between thumb and index finger, where obvious greasiness, 
grittiness and sensitivity were noted. 
2.2.8. Statistical Analysis 
Data are expressed as means ± s.d. unless otherwise stated. One way analysis of 
variance (ANOVA) with either Tukey‘s post test (to identify statistical significances 
between groups) or Dunnett post test (to compare groups against the control) and p < 
0.05 and p < 0.01 were defined as significant and very significant respectively. the 
analysis was carried out using InStat for Macintosh, version 3.0 (GraphPad Software 
Inc, San Diego, CA). 
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Chapter 3 HSV Growth Kinetic and the 
Virucidal Activity of PRE and Ferrous 
Sulfate against Herpes Simplex Virus 
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3.1. Introduction 
As described in Chapter 1 the combination of PRE + FeSO4 has been shown to exhibit 
potent synergistic (potentiated) phagicidal activity. Within the patent (Jassim, Stewart 
and Denyer 1995) it was further stated that synergistic HSV-1 virucidal activity had 
been observed, although no data was provided. It was hypothesised that the synergistic 
phagicidal action observed with respect to a range of bacteriophage [Staphylococcus 
NCIMB 9563, Salmonella Felix O-1, Pseudomonas NCIMB 10884 and Pseudomonas 
NCIMB 10116 (Stewart, et al. 1998)] was due to modulation of the bacteriophage 
envelope and that this action may also be observed with other microorganisms with 
similar envelopes, for example enveloped viruses such as Herpes simplex virus. This is 
due to the similarities between the bacteriophage protein envelope and the protein 
envelope encapsulating the HSV-1 virion. The phagicidal activity of PRE and FeSO4 
was shown to be transient in nature and inactive after a 3 minute reaction time between 
PRE and FeSO4. The reaction of PRE and FeSO4 also created a black precipitate 
(Stewart, et al. 1998). 
Possible modes of action for the phagicidal activity have been attributed to the reaction 
of compounds within PRE and Fe
2+
 resulting in both the destruction of the 
bacteriophage envelope and the creation of a black precipitate (Stewart, et al. 1998). An 
alternative hypothesis was that the phagicidal action of one or more compounds within 
the PRE mixture and the Fe
2+
 ion acted synergistically whilst the ion is in free solution.  
After the ion had undergone reaction it had bound with the phagicidal compounds 
within PRE thus inactivating the mixture. Another theorised mode of action is the 
creation of free radicals, the addition of the ferrous ion enabling a cascade effect of 
electrons, the transient nature of the observed bioactive state occurring within this 
window of free radical production before the known ability of punicalagin to act as an 
antioxidant, with the potential to reduce free radicals involved in chain reactions that 
damage cells. This protective effect of punicalagin has been well established with 
differing materials and methods (Slusarczyk, et al. 2009) (Turk, et al. 2008) (Seeram, et 
al. 2005). 
The objective of this Chapter was to determine whether the previously reported activity 
of PRE and FeSO4 against bacteriophage and Herpes simplex virus type one (HSV-1) 
could be replicated. In particular, similarities to the previously reported work, in terms 
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of the kinetics of antimicrobial activity, were probed and the implications of the black 
by-product considered. 
3.1.1. Objective and Aims 
To establish the optimum growth parameters for HSV-1 and HSV-2 ACR and evaluate 
the virucidal activity of PRE and FeSO4 against Herpes simplex virus and consider its 
practical complications. 
-Optimise the growth conditions for HSV-1 and HSV-ACR 
-Analyse the cytotoxic effect of all formulations 
-Probe the kinetics of virucidal activity of PRE + FeSO4 against HSV-1 and HSV-ACR 
-Consider the implications of any black by-product 
3.2. Materials and Methods 
3.2.1. Materials 
The materials used within this Chapter are given in Chapter 2 section 2.1. 
3.2.2. Methods 
The methodology for general cellular microbiology and the formulation of solutions 
extracts and buffers follows that described in Chapter 2 section 2.2.1. unless otherwise 
stated. 
3.2.2.1. Growth Kinetics of HSV-1, HSV-2 and HSV-ACR  
In order that high stocks of HSV-1 and -2 ACR (Aciclovir resistant HSV-2) can be 
grown, it was important to investigate the specific growth kinetics of each virus type. 
Titres up to or greater than 1 x 10
7
 are needed in order to carry out both antiviral and 
virucidal studies. For the purpose of viral growth kinetics Vero cells (Brant, Coakley 
and Grau 1992) and the rabbit kidney 13 (RK13) cell line, which was initiated from the 
kidney of a 5-week-old rabbit (Oryctolagus cuniculus) (Nikon 2011), were evaluated as 
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host cell lines (Epstein, Yvonne and Jacquemont 1990)  (Rigby and Johnson 1972). The 
methodology for this is stated in Chapter 2 section 2.2.5.8. 
3.2.2.2. Viral Titre Determination  
The titre of the supernatant was established on Vero cells in 24 well plates following 
the same methodology as that used for virucidal titre determination (section 2.2.5.8.3.). 
3.2.2.3. Virucidal Assessment 
To establish the virucidal activity of PRE and FeSO4 against HSV-1 the virucidal 
plaque reduction assay was used and followed the procedure detailed in section 2.2.5.9. 
HSV-1 was retrieved from storage in a freezer at -80°C. The materials tested were PRE, 
FeSO4 and phthalate buffer alone and in combination. The virucidal analysis of the 
combination of PRE, FeSO4 and phthalate buffer was indicated by introducing HSV-1 
to the combination immediately upon mixture. To assess the time dependant nature of 
activity, samples of mixture were held occluded from light and at room temperature for 
3, 12 and 24 h after which they were introduced to the virus beginning the virucidal 
plaque reduction assay.  
3.2.2.4. Cell Titre 96 Aqueous Cell Proliferation Assay 
The metabolic viability of green monkey epithelial kidney cells (Vero cells) treated 
with PRE, FeSO4 and phthalate buffer (pH4.5) was assessed using the cell titre 96 
aqueous one solution assay as described in section 2.2.5.7. 96-well plates were 
prepared, the medium was removed by aspiration and 10-fold dilutions of PRE (1mg 
mL
-1
), FeSO4 (1M) and phthalate buffer (pH 4.5) in DMEM were added onto sub-
confluent Vero cells in 4 replicates for each concentration. 12 sub-confluent wells 
containing 100 µL DMEM were used as a control and 12 wells containing only DMEM 
in the absence of cells was used as a blank. After an incubation time of 6, 24, 48 and 72 
h the growth medium was removed via aspiration and the cells were washed three times 
with DPBS. Following this 20 μL of cell titre 96 one solution (containing MTS and 
PES) and 100 μL of DMEM was added to each well. After an incubation of 1 h (37°C, 
5% CO2) optical density measurements at 490nm were taken and the results plotted 
graphically. 
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3.2.2.5. Statistical Analysis  
The statistical analysis of data followed that stated in Chapter 2 section 2.2.8. 
3.3. Results 
3.3.1. Optimizing Viral Growth Conditions for HSV-1 and HSV-ACR 
Figure 3-1 displays the viral titre retrieved after the incubation of HSV-1 in two types 
of container (T25 and T150) using vero cells as the host. It can be seen that throughout 
all time points analysed the greatest viral titre retrieved was following incubation 
within the T25 container. A generally linear growth pattern was observed with time of 
incubation and viral titre from the T150 container; this trend was not so apparent within 
the T25 flask, which increased over 48 h, followed by a slight decrease at 72 h with a 
linear response to time after this point.  
An incubation time of 5 days as expected resulted in the largest titre of HSV-1 retrieved 
from the T150 at 3.0 x 10
6
 ± 1.9 x 10
6
 and T25 4.3 x 10
7
 ± 1.8 x 10
6
. However the 
smaller container (T25) produced a higher titre at each time point, this was an 
unexpected result due to the use of the same multiplicity of infection (MOI).  
Figure 3-1 The log viral titre of HSV-1 after infection of confluent Vero cells within T25 and T150 
containers over 5 days (MOI 0.01) (n=4, ± S.D.) 
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Figure 3-2 shows that the growth kinetics of HSV-1 with an MOI of 0.01 in Vero cells 
and RK-13 cells is similar within both types of host cell. A slight decrease is observed 
at 72 h however the titre reaches a maximum after a 5-day incubation period within the 
host RK-13 and Vero cells resulting in a maximum titre of 3.7 x 10
7
 and 4.3 x 10
7
 
respectively. 
 
Figure 3-2 The log viral titre for the growth of HSV-1 after infection of confluent T25 with Vero and 
RK-13 host cells over 5 days (MOI 0.01) (n =3, ± s.d.) 
The growth kinetics in Figure 3-3 of HSV-2 ACR with Vero and RK13 as the host cells 
within a T25 container shows a similar trend with respect to the time of incubation. 
However the titre obtained using a Vero cell host was greater with maximum levels of 
1.74 x 10
8
 ± 1.5 x 10
6
 and
 
1.79 x 10
8
 ± 1.2 x 10
6
 after 2 and 4 day incubation periods 
respectively. After 4 days of incubation full lysis of the cells was observed this resulted 
in a decrease in viable HSV-2 ACR.  
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Figure 3-3 The log viral titre for the growth of HSV-2 ACR after infection of confluent T25 containers 
with Vero and RK-13 as the host cells over 5 days (MOI 0.01) (n=3, ± s.d). 
The viral growth of HSV-2 ACR, with Vero and RK 13 as host cells within the T150 
container is displayed in Figure 3-4, this shows that viral growth is maximised after 24 
h in Vero and RK-13 cells with titres of 4.2 x 10
7 
± 8.4 X 10
5
 and 2.6 x 10
7
 ± 7.2 x 10
5
 
respectively. There was a general decrease in titre within both cell lines with respect to 
time. The viral titre retrieved was not significantly different between the host cells 
except after an incubation of 4 days, in which a greater titre was retrieved from the 
Vero cell host.  
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Figure 3-4 The log viral titre for the growth of HSV-ACR after infection of confluent T150 with Vero 
and RK-13 host cells over 5 days (MOI 0.01) 
The optimal growth conditions for HSV-1 and HSV-2 ACR was observed using Vero 
cells as the host cell and within the T25 container after an incubation of 5 and 2 days 
respectively. 
3.3.2. Cytotoxicity of PRE, Ferrous Sulphate and Phthalate Buffer  
Figure 3-5 shows the cell proliferation of Vero cells after application of the test 
materials over a 72 h period. It was observed that after this period of exposure Phthalate 
buffer and FeSO4 (1M) caused no significant decrease P>0.05 in cell viability. 
Application of PRE (1 mg ml
-1
) led to a decrease of cell viability by 14% ± 0.14 and 
47% ± 0.183 after 48 and 72 h respectively; it was therefore necessary to examine the 
effect of PRE at lower concentrations, to determine whether the in-vitro application of 
PRE to Vero cells would affect the cells during virucidal or antiviral testing via plaque 
assays. The highest applied concentration used within this project was PRE 0.1 mg mL
-
1
. Figure 3.5 shows that after 48 h incubation no significant decrease in viable Vero 
cells was observed at this concentration. Therefore the concentrations employed in all 
testing during this project do not affect cell viability and the compounds used are 
proven to have a low cytotoxicity. 
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Figure 3-5 Proliferation of Vero cells at 6, 24, 48 and 72 h after the application of PRE (1 mg mL
-1
), PRE 
(0.1 mg mL
-1
), FeSO4 and Phthalate buffer. 
3.3.3. Virucidal Activity of PRE and FeSO4 
Figure 3-6 shows the virucidal activity of PRE against HSV-1 in the absence and 
presence of FeSO4. PRE alone exhibited a 0.49 ± 0.02 log reduction, whereas FeSO4 
gave a log reduction of 0.24 ± 0.38; and the reduction caused by the control phthalate 
buffer was negligible. However, when all components were used in combination a log 
reduction of 3.27 ± 0.74 was achieved. As this value was much greater than the 
resultant addition of the log reduction of the components, this result was evidence of a 
synergistic or potentiated effect of the addition of FeSO4 to PRE. 
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Figure 3-6 The virucidal log reduction of PRE, FeSO4 and phthalate buffer following their immediate 
combination (n=4 ±SD). 
 
Figure 3-7 The virucidal log reduction of HSV-1 after addition of PRE + FeSO4. The combination was 
added after the PRE/FeSO4 mixture was allowed to react at room temperature and occluded from light 
for a period of 0, 3, 12 and 24 h (n=3 ±SD). 
It is apparent from Figure 3-7 that the formulation loses its synergism and almost all of 
the virucidal activity after a three hour reaction time between PRE and FeSO4. The log 
reduction of HSV-1 drops from 3.27 ± 0.74 to 0.26 ± 0.21 and remains at this level for 
all other reaction times, a level similar to that of FeSO4 alone. 
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3.3.4. The Black By-Product 
It was apparent that very soon after PRE came into contact with FeSO4 a black by-
product appeared in the test solutions, confirming earlier observations. Figure 3-8 
illustrates the colour change observed on the addition of FeSO4 (0.05 mg mL
-1
) to PRE 
(0.05 mg mL
-1
) 3 min after addition a strong black by-product has formed. Neither 
FeSO4 nor PRE in solution alone have a discernable colour. 
 
Figure 3-8 The colour change associated with the addition of  FeSO4 to PRE after three minutes at room 
temperature. From left to right PRE 0.05 mg mL
-1
 and PRE 0.05 mg mL
-1
 +FeSO4 1 M. All are dissolved 
in phthalate buffer pH 4.5 and DI H2O. 
 
Figure 3.9 shows the sequential addition of FeSO4 to PRE. Immediately on addition the 
black colour and precipitate begins to form. After a 3 min reaction time at room 
temperature the whole solution is filled with an opaque black solution. 
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Figure 3-9 The sequential addition of FeSO4 1 M to PRE 5 mg mL
-1
. From left to right before addition, 
upon addition of FeSO4 and 3 minutes after addition. 
Figure 3.10 shows the solution when applied to the lower arm. This clearly shows 
unsightly colouration. 
 
Figure 3-10 The black stain left on human forearm skin after a 20 second application of the fully reacted 
solution of PRE 0.05 mg mL
-1
 + FeSO4 1 M (The forearm belongs to the author Mr D. Houston). 
3.4 Discussion 
A definition of potentiation is that activity exceeds the additive effects of combining 
two substances. In this work, the log reduction for PRE and FeSO4 individually were 
0.49 and 0.24 respectively, with an additive activity value of 0.73, whereas the 
combination resulted in a potentiated log reduction far in excess of this, namely 3.27, 
thereby confirming potentiation. However, this potentiation was only apparent soon 
after mixing, and diminished rapidly thereafter – a feature also observed previously in 
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experiments involving bacteriophage. After 3 h, the activity had reduced to non-
potentiated levels, as shown in Figure 3-7. 
It is clear that there are two major problems with any potential commercial product 
based upon a combination of PRE and FeSO4. Firstly, the diminishing virucidal activity 
observed when the two components are combined gives rise to major stability problems 
in a proposed formulation. A patented single compartment formulation strategy had 
been developed (Heard, Bowen and Denyer 2008), where the potentiating agent 
(FeSO4) was entrapped within liposomes overcame this to a certain extent, although 
stability issues remained a problem. A 2-compartment solution might be viable, 
although this would not resolve the second problematic issue. 
The second problem is the generation of the very insoluble black by-product.  As 
outlined in Chapter 1, PRE is rich in ellagitannins. Apart from issues relating 
microbicidal activity, the addition of FeSO4 to Tannin/ tannic acid rich solutions 
producing a black precipitate is well known, and the process for and use of 
pomegranate ‗gall ink‘ has been used since the early sixth century (Carvalho 2008). 
These were widely used up until the early 20
th 
century: JS Bach used this to notate his 
music; Rembrandt used it for his sketches; while Thomas Jefferson used this type of ink 
to write the Declaration of Independence (Kolara, et al. 2006). ―The ink was used due 
to the difficulties in removing the stain, however the ink‘s corrosive properties, 
identified already at a Conference at St. Gallen in 1898, inflict severe damage to 
numerous artefacts‖(Bundar, et al. 2006). 
3.5 Conclusion 
The potentiated activity of PRE and FeSO4, as observed in earlier work has been 
confirmed against HSV-1 and the combination of PRE and FeSO4 has also proven to be 
non-cytotoxic. However, also consistent with previous work are the phenomena of a 
short window of virucidal activity and the generation of a black by-product. 
Overall, it is unlikely that patients would accept a product that would 1. Have such a 
narrow window of efficacy and 2. Leave behind such an obvious post-application stain 
to the skin, as shown in Figure 3-7. However, the high potentiated virucidal activity 
would appear to have potential as an anti-HSV therapeutic, if these problems can be 
resolved. 
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Chapter 4 Probing Aqueous-Based 
Interactions Between PRE And Ferrous 
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4.1. Introduction 
Chapter 3 confirmed three major features concerning the combination of PRE and 
FeSO4, namely:  
1. Potent synergistic virucidal activity  
2. The short-lived transient nature of this activity 
3. The development of a black by-product that accompanied the decrease in 
activity  
The studies in Chapter 3 sought to probe the basis of this activity, in particular the 
transient nature and colour change. Furthermore, as the development of a commercial 
product would be compromised by features ‗2‘ and ‗3‘ the potential for alternative 
potentiating agents was explored.  
4.1.1 Redox Reactions and PRE Potentiation 
Redox reactions describe all chemical reactions in which there is a change in oxidation 
number/state. As previously stated it was hypothesised that the virucidal nature of PRE 
and FeSO4 was due to the interaction of compounds within PRE and the Fe (II) ion, and 
that the transient nature of the activity was due to the conversion of free Fe (II) ions to 
bound Fe (III) ions, following a similar reaction to that of tannic acid and Fe (II). Such 
redox processes are very likely to be behind the depletion of both antimicrobial activity 
and associated colour change. Iron is a transition metal with an atomic mass of 26. 
Other transition metals have previously demonstrated activity against microorganisms 
(Nagar 1990) (Singh and Katiyar 2008).  
PRE has been used with the addition of copper sulphate and has shown moderate 
synergistic bactericidal properties (Naughton 2007) (Gould, et al. 2009); however Cu
2+
 
as well as Fe
2+
 and Pb
2+ 
readily form complexes with tannins within the PRE mixture 
(Stewart, Jassim and Denyer 1998) (El-Ashtoukhya, Amina and Abdelwahabb 2008) 
(McCarrell, et al. 2008) (Gould, et al. 2009). Changing the oxidation state and the 
formation of highly coloured solutions is a characteristic of transition metals. However, 
as the change from Fe (II) to Fe (III) is associated with diminishing antimicrobial 
activity, then it can be hypothesised that similar behaviour would arise in redox 
reactions involving these other transition metals. Furthermore, from a patient 
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perspective, colouration and colour change is likely to remain unacceptable in a 
commercial product. The salts of alternative transition metals with similar d orbital e-, 
yet able to remain in the 2+ state without colour change upon addition to PRE were 
considered and zinc identified as a suitable candidate.
 
4.1.1. Rationale for Examining Zn
2+
 as an Alternative Potentiating Agent 
Initially, the electronic configuration of zinc was considered. Most transition metals 
readily form two or more ions due to the free space within the 3d-orbital. The electron 
orbital filling for iron is 1s
2
, 2s
2
, 3s
2
, 3p
6
, 3d
6
, 4s
2
, Fe 2+ ([Ar] 3d
6
), enabling the 
transfer of electrons to and from the unfilled 3d orbital requiring relatively low energy, 
a characteristic of most transition metals.  However, due to the specific sub d orbital 
filling of zinc it only forms one ion Zn
2+
 as it has a completely full 3d sub-orbital losing 
the 4s
2
 electrons first, giving the following configuration: 1s
2
 2s
2
 3s
2
 3p
6
 3d
10
. With this 
configuration the Zn
2+
 ion is in a thermodynamically stable and favourable state as 
Zn
2+
. This is available in many water soluble salt forms which are typically white 
(uncoloured).  
In the current chapter the solution chemistry of zinc sulphate (ZnSO4) was compared 
with that of ferrous sulphate (FeSO4). Zinc sulphate, having the same sulphate 
counterion, would thus provide a direct comparison with ferrous sulphate. Furthermore, 
ZnSO4 has high water solubility, low toxicity (Poires, et al. 1967) (Hoogenraad, Van 
Hattum and Van den Hamer 1987) and, as stated, no discernible colouration. 
4.1.2. Methods for Probing Interactions 
Evidence for solution interactions following the combination of metal ion with PRE can 
be either spectroscopic (where shifts of specific absorbances may be determined) or 
calorimetric (where enthalpy changes are determined).  
4.1.3. Aims 
The aim is to seek evidence for the transient nature of PRE and ferrous sulphate activity 
in comparison to zinc sulphate. Three different approaches were taken: 
1. Comparative Ultra violet-visual spectroscopy (UV) 
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2. Comparative High Pressure Liquid Chromatography (HPLC) 
3. Comparative Isothermal Titration Calorimetry (ITC) 
4.2. Material and Methods 
4.2.1. Materials 
The materials used in this chapter are given in Chapter 2.1 
4.2.2. Methods 
The preparation of the extracts, buffers and solutions are stated in Chapter 2 section 
2.2.1. unless otherwise stated. 
4.2.2.1. Ultra Violet (UV) Visual Spectroscopy 
UV spectroscopy analyses the absorbance of UV light waves by a compound (Watson 
2005). The addition of compound into a solution of another can affect the UV 
absorbance spectrum, a change (shift) of the UV spectrum is indicative of electron 
transfer and suggests the formation of an intermolecular interaction, or the formation of 
a new complex - this is a common and sensitive method for the indication of metal 
chelation (Andjelkovic, et al. 2006). Alternatively, interactions can result in 
solvatochromic effects, a hypsochromic blue shift or bathochromic red shift can be 
observed depending on solvent polarity. 
For the UV spectroscopy determinations, all solutions were prepared using a phthalate 
buffer at pH 7.4. PRE was used at a concentration of 0.05 mg mL
-1
, and to establish the 
effect of FeSO4 addition to PRE the concentration range of 1, 2, 3, 4, 5, and 6 x 10
-4
 M 
was used.  This follows on from previous work where it was stated that the reaction 
between PRE and FeSO4 was completed within this range (Kulkarni, et al. 2007). The 
range of ZnSO4 concentration analysed was 1.6, 3.1, 6.3, 12.5, 25, and 50 x10
-4 
M. PRE 
and each salt was analysed individually, and in combination after a 1h reaction period 
at room temperature and under occlusion from light. Due to the spectral shift analysed 
on the addition of FeSO4 at low concentrations and the absence of any change on the 
addition of ZnSO4  it was deemed pertinent to analyse the addition of ZnSO4 over a 
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greater concentration range. Samples were centrifuged for 10 min at 10000 g prior to 
the supernatant being sampled and analysed. 
Each sample was analysed in a silica cuvette (L 0.1cm) placed into a Cary 50 UV 
Spectrophotometer. UV scans were run at 960 nm min
-1 
between 300-600 nm using the 
phthalate buffer as the baseline UV absorbance. 
4.2.2.2. High Pressure Liquid Chromatography (HPLC)  
HPLC is routinely and widely used to quantitatively analyse compounds using 
absorption spectrophotometry; the method can be used to specifically identify 
compounds i.e. punicalagin within a complex solution such as PRE. Chromatographic 
information can be used to determine the amount of compounds within PRE and upon 
addition of metal ions any changes to compound levels or the formation of new 
compounds. However, a limiting factor for HPLC is that during analyses the analytes 
are dissolved within a variety of solvents; this can lead to the breakdown or dissolution 
of unstable products.  
Quantitative determinations were carried out on a HP series II 1090 liquid 
chromatograph, fitted with a Phenomex Gemini NX 5 C18 110A 250 X 2.60 mm 
column. Gradient elution was used, involving, A, MeOH with 0.1% Triflouroacetic 
acid (TFA) and, B, DI H2O with 0.1% TFA. The gradient timetable and percentage 
composition of mobile phase is shown in Chapter 2 section 2.2.4.1. Analysis was 
carried out using an UV detector at 258 nm, injection volume 20µL and a flow rate of 1 
mL min
-1
. Samples were prepared according to section Chapter 2 section 2.2.4.1. The 
concentration range of PRE used varied between 0.05, 0.1 and 1 mg mL
-1
. 
4.2.2.3. Isothermal Titration Calorimetry (ITC) 
ITC is used to measure interactions between ligands and substrates, and is ideal for the 
analysis of the addition of one material (FeSO4) to another (PRE) and elucidating any 
interactions which may take place within a system place based on any observed change 
in enthalpy (Grolier and Rio 2009). The sample preparation and machine methodology 
followed that described in Chapter 2 section 2.2.4.3. 2.4 mL of PRE 0.6 mg mL
-1
 was 
used as the titrate within the titrate cell and FeSO4 2.5 mM in a 50% MOPS and 50% 
DI buffer was used as the titrant. To account for varying pH in calculating the binding 
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constant a further experiment was run using an acetate buffer pH 4.5; all other 
conditions remained the same. 
4.3. Results 
4.3.1. UV Spectroscopy  
The UV spectra for punicalagin produced a max at 379 nm (Figure 4-1) for each 
concentration of FeSO4. When the absorbances were measured at 379 nm significant 
dose dependent increases were found (p<0.0001), which when plotted against the 
concentration of FeSO4, produced a linear relationship (Figure 4-2)  
 
Figure 4-1 Punicalagin 0.03 mg mL
-1
 plus FeSO4 (0-6 x10
-1
mM) in pH 4.5.  Punicalagin alone (red) with 
increasing concentration of FeSO4. 
 
Figure 4-2 Plot to show change in absorbance at 379 nm for punicalagin 0.03 mg mL
-1
 
with increasing concentrations of FeSO4 (0.1 – 0.6 mM) (n=3, ± SD). 
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According to (Andjelkovic, et al. 2006) the binding constant can be determined from 
the gradient and the y intercept of a double reciprocal plot of concentration vs 
absorbance for FeSO4 for the linear portion: This is shown in Figure 4-3. 
 
Figure 4-3 A double reciprocal plot of FeSO4 on addition to punicalagin mg mL
-1
 verses absorbance 
(linear portion only). 
Therefore, by substituting in the numbers from Figure 4-3 ka for FeSO4 and punicalagin 
can be calculated as: 
 
  
         
        
 
   
      
      
 
              
In contrast to FeSO4, on addition of ZnSO4 to punicalagin no significant changes in 
absorbance were apparent. The average absorption at 379 nm for PRE and on the 
addition of ZnSO4, was found to be statistically the same (p > 0.05) at 0.250 ± 0.006 
(Figure 4-4). Figure 4-5 re-affirms this and shows there was no correlation between 
increased concentration and absorption at this wavelength.  
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Figure 4-4 The UV-vis absorbance spectra of punicalagin 0.03 mg mL
-1
 with the addition of ZnSO4 (0-5 
mM). 
 
Figure 4-5 The absorbance of punicalagin 0.03 mg mL-1 following the addition of increasing 
concentrations of ZnSO4 (0.16-5 mM) at 379 nm (n=3 ± S.D). 
It should be noted that no absorbance increase was observed with either ZnSO4 or 
FeSO4 alone at 379 nm. Therefore any increase at ≈ 379 nm or deviation from the 
punicalagin spectra can be entirely attributed to the chelation of FeSO4 with 
punicalagin.  
It was then pertinent to investigate the UV absorbance spectra following the addition of 
the two metal sulphates PRE to examine whether similar UV spectra would be observed 
to that seen with punicalagin. 
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Figure 4-6 The UV-vis spectra for PRE 0.2 mg mL
-1
 and the addition of FeSO4 (0-0.6 mM). PRE alone 
(red), and the addition of FeSO4 0.1 mM (blue), 0.2 mM (purple), 0.3 mM (brown), 0.4 mM (green) and 
0.5 mM (navy) overlapping with 0.6 mM (black).  
From Figure 4-6 it is clear that FeSO4 does indeed change the spectra from PRE alone 
(as shown in red) shifting the λmax.  At higher concentrations there is no clear λmax for 
PRE and a plateau is observed. However, PRE at 0.2 mg mL
-1
 gave a λmax of 371 nm, 
which was shifted to 379 nm on the addition of FeSO4. This is compelling evidence of 
electron transfer probably resulting from a redox reaction (Neudeck, Petr and Dunsch 
1999). 
The plot of absorbance at λmax against FeSO4 concentration (Figure 4-7) confirms the 
dose response relationship as shown with punicalagin. However, it is clear that the 
standard deviation is larger. This could be due to variations within the PRE formulation 
and specific concentrations of polyphenols present; it could also be due to a variation in 
the binding of FeSO4 to different molecules within the PRE mixture. The difference in 
the gradient between the Figure 4-7 and Figure 4-1 (the plot of absorbances of the 
addition of FeSO4 to punicalagin against the concentration of FeSO4) eludes to the 
binding of FeSO4 to more than one compound within PRE. 
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Figure 4-7 The relationship between increasing FeSO4 concentration and absorbance at λmax. 
Similarly, then compared with punicalagin, a binding constant Ka can be determined by 
plotting a double reciprocal plot of concentration against absorbance. (Figure 4-8) 
 
Figure 4-8 Double reciprocal plot of FeSO4 concentration against absorbance. 
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This further shows the complexation of Fe with punicalagin and/or other components 
within PRE. The k value of 1.02 x 10
4 
M
-1
 given for the interaction between FeSO4 and 
punicalagin is half of the value for the addition of FeSO4 to PRE suggesting that the 
binding of the Fe
2+
 is stronger when added to the pure extract of punicalagin as opposed 
to the mixture of PRE. This is likely due to the Fe
2+
 ion binding with more than one 
polyphenol within the PRE mixture. The large mixture of polyphenols and the resulting 
competition for chelation could also account for the decrease in binding strength by 
creating a scenario in which two or three binding events occur.   
 
 
Figure 4-9 The UV-vis absorption spectra for 0.05 mg mL
-1
 PRE with the addition of ZnSO4 (0-5 x 10
-3
 
M). PRE (red) the repeat absorptions of the additions of ZnSO4 (0-5 x 10
-3
 M) are given (range of 
colours). 
Figure 4-9 shows the Uv-vis absorbance spectra for PRE alone and the addition of 
ZnSO4 (0-5 x 10
-3
 M). It is clear that there was no change in the λmax (371 nm), which is 
demonstrative of no correlation in increased absorbance or any change in λmax with the 
addition of ZnSO4. As the data shows no effect on absorption when ZnSO4 is added to 
PRE there is no complexation occurring.  
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4.3.2. HPLC 
HPLC analysis was used to study the interaction of punicalagin with the transition 
metals. Figure 4-10 shows the HPLC trace at 258 nm for punicalagin (0.03 mg mL
-1
) 
with punicalagin α eluting at 12.21 min with an AUC 782.4 ± 6.78 (n=3) and 
punicalagin β eluting at 17.58 min with an AUC 1503.8 ± 7.21 (n=3).  
 
Figure 4-10 Typical HPLC chromatogram of punicalagin 0.03 mg mL
-1
 
However, on addition of 0.1 M FeSO4 to 0.03 mg mL
-1
 punicalagin a new peak 
appeared at 5.3 min. This was accompanied with depletion of both punicalagin peaks 
(Figure 4-11). 
 
Figure 4-11 A typical HPLC chromatogram of punicalagin 0.03 mg mL
-1
 with FeSO4 (0.1 mM). 
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The relationship between the formation of the new peak and the depletion of both 
punicalagin α and β anomers over time is shown in Figure 4-12. The appearance of the 
new compound was clearly based on the consumption and was therefore a derivative of 
punicalagin (no peak was seen with FeSO4 alone). 
  
Figure 4-12 The decrease in absorbance of punicalagin anomer peaks and increase in the area of new 
unidentified peak (Figure 4-14) (red) following the addition of varying concentrations of FeSO4 (n=3 
±SD). 
Figure 4-13 shows a linear response to the decrease of punicalagin by the addition of 
increasing FeSO4, and a strong correlation is shown by the R
2
 value of 0.99. 
   
Figure 4-13 Unbound punicalagin concentration versus FeSO4 concentration (n = 3 ± SD). 
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In contrast to FeSO4, the addition of ZnSO4 to punicalagin exhibited no significant 
change (p > 0.05) in either peak area for punicalagin α and β or the concentration of 
punicalagin shown in Figure 4-14; a sample chromatogram of punicalagin                
0.03 mg mL
-1
 + ZnSO4 5mM is provided in Figure 4-15 showing the two punicalagin 
peaks and the absence of new peaks. 
  
Figure 4-14 Absence of depletion in the concentration of punicalagin following the addition of different 
concentrations of ZnSO4 (n = 3 ± SD).  
 
 Figure 4-15: Typical HPLC chromatogram at 258 nm of 0.03 mg mL
-1 
punicalagin with ZnSO4 (5 mM). 
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4.3.3. Isothermal calorimetry (ITC) 
ITC can determine binding constants, stoichiometry and enthalpy change. Results can 
either be obtained directly from Figure 4-16 or derived from the data using 
computational fit. Enthalpy change was determined by integrating the peaks formed by 
each injection. ∆H can then be determined directly from the experimental data by 
taking the sum of the integrals of the enthalpy change as shown in the bottom portion of 
Figure 4-16, ∆Ha1 = 1019.25 kcal M
-1
, which is considered a fairly small enthalpy 
change. 
 
 
Figure 4-16 The plot of enthalpy change measured via ITC of the injection of FeSO4 into PRE given as 
ucla s
-1
 against time (min) and kcal M
-1 
of injectant against the molar ratio. 
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Other thermodynamic parameters can be calculated from this data such as the binding 
constants (KA1, KB1) and the stoichiometry of binding by considering how they would 
thermodynamically react. 
 
                                                                              
 
Therefore KA1 can be derived in the following equation where Na1 = the stoichiometry 
of the binding site. 
      
       
              
 
Similarly then a secondary binding constant can be determined 
      
          
                 
 
From the data obtained two K values for Fe have been calculated, which have indicated 
that two binding events were occurring as the graph Figure 4-16 was not sigmoidal. It 
has been assumed that as the majority of the extract is punicalagin the major Ka value 
(Ka1) is related to punicalagin and the secondary enthalpy change is as a result of the 
other components within the solution. To be confident in the true value, a pure sample 
of punicalagin would need to be run. However, due to time and cost limitations this was 
not possible. 
For the addition of Fe it was determined that Ka1 was 3.97x10
5
 M
-1
. The stoichiometry 
(NA1) of this reaction was however shown to be specific with a value of (0.811); for 
practical reasons this is assumed to be 1. This is approximately 50 x less in comparison 
to the binding constant with Fe (II) with punicalagin determined by (Kulkarni, et al. 
2007), which is quoted as 1.8 x 10
7
 M
-1
. However, this binding constant was 
determined using a different technique and done with pure punicalagin therefore no 
interaction of other polyphenols present in PRE was accounted for. No other binding 
constant between iron and extracts of pomegranate are quoted in the literature. 
KA1, 
NA1 
∆Ha
1 
∆Hb
1 
KB1, 
NB1 
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The secondary binding event was determined to have a weaker Ka again with 1.56 x 10
4
 
M
-1
. This event was much less specific with an Nb1 of 5.42. 
Another test was run at a lower pH using an acetate buffer.  
 
Figure 4-17: graph to show two titrations of PRE 0.6 mg mL
-1
 with FeSO4 at pH 4.5 (blue) in acetate 
buffer (red). 
It was determined from the data (Figure 4-17) that the Ka of this reaction was weaker 
again compared with Figure 4-16 (3.90 x 10
3
 ± 566 dm
3
 mol
-1
) and the enthalpy change 
was similar ∆H (1.15 x 103  kcal mol-1 ±) (n = 2 ± 67.6 kcal S.D). 
4.4. Discussion 
It is a well-known phenomenon that the addition of FeSO4 to PRE leads to the 
formation of a dark black precipitate, and a black coloured solution; this has also been 
observed on addition to punicalagin, the main phytochemical within PRE. The addition 
of ZnSO4 to either solution does not result in any precipitate or colour change. It was 
theorised that the production of the black precipitate was due to the oxidation of Fe
2+
 to 
Fe
3+
 following a similar reaction between Fe
2+
 and tannic acid, and the formation of 
gall ink. From the results obtained it is apparent that the addition of FeSO4 to PRE 
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results in the formation of a new compound and this also occurs on addition to 
punicalagin. The UV-vis spectra showed no shift of λmax on the addition of FeSO4 to 
punicalagin, however a dose dependant increase in absorbance was observed, however 
a shift in the plateau of λmax on addition to PRE was shown. The binding constant 
obtained from this data was k=1.02 x10
-4 
M
-1
 for the addition to punicalagin and k = 
2.31 x 10
-4
 M
-1
 on addition to PRE, suggesting the FeSO4 is bound less strongly when 
added to PRE. The doubling of k could be due to the binding of Fe 
2+
 with various 
polyphenols within the PRE mixture, or that the binding to punicalagin within PRE is 
less stable due to molecular interactions within the PRE mixture. The shifts observed 
are indicative of electron transfer and thus a redox reaction, which is likely to be due to 
the chelation of the metal ion and the change in ionic state from Fe
2+
 to Fe
3+
. The lack 
of spectral change on the addition of ZnSO4 suggests that there was no formation of 
new molecules and no reaction was occurring.  
The analysis of FeSO4 and ZnSO4 reaction to punicalagin concurred with the UV-vis 
data by the depletion of the punicalagin peaks and the formation of a new peak. The 
correlation between the addition of FeSO4 and the decrease in punicalagin 
concentration and increase in the new peak formation shows that a new compound is 
formed supporting the theory that the metal ion is chelating with punicalagin. Once 
again there was no change to punicalagin on the addition of ZnSO4.  
Isothermal titration calorimetry alluded to a double binding reaction on the addition of 
FeSO4 to PRE, with a binding affinity of ka1 3.97 x 10
5
 M
-1
 and Ka2 1.56 x 10
4
 M
-1
. The 
double binding scenario is likely due to the interaction of FeSO4 and punicalagin, ka1, 
and to other phytochemicals ka2. This once again supports the previous data and the 
original theory that the addition of FeSO4 to PRE results in the formation of a new 
compound likely arising from the chelation of iron to punicalagin. 
If the oxidation of Fe
2+ 
to Fe
3+ 
and the concomitant loss of punicalagin in the formation 
of a new complex is detrimental to microbiological activity, then it can be hypothesised 
that substituting Fe
2+
 with more stable Zn
2+ 
will not result in the loss of punicalagin, 
and therefore maintain antimicrobial activity. 
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4.5. Conclusion 
The results demonstrated that the addition of FeSO4 to PRE resulted in a redox reaction 
of Fe
2+ 
+ punicalagin → Fe3+, with a new, as yet unidentified, compound being formed. 
The formation of this new compound and oxidation of the iron appears to coincide with 
the loss of virucidal activity (Chapter 3) and phagocidal activity (Jassim, Stewart and 
Denyer 1995) previously described. The results also proved that no such redox change 
occurred and no new compound was formed using ZnSO4. This is presumably due to 
the stability of the Zn
2+ 
ion, in terms of its resistance to further oxidation. 
Based on these results it was decided that ZnSO4 (and potentially other zinc salts) was 
deemed a good candidate for further microbiological examination, due to its longevity 
within the +2 state and thus hypothesised sustained antimicrobial activity.  
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Chapter 5 Microbiological Effects of 
PRE and Zn
2+
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5.1. Introduction 
In Chapter 2, plaque assays confirmed that the combination of PRE and FeSO4 
provided potentiated virucidal activity against HSV-1, ACR HSV-2. Chapter 3 found 
evidence for the mechanism behind the short-lived and unsightly black by-product of 
the PRE/FeSO4 combination, based upon redox chemistry. Chapter 3 also provided a 
candidate alternative potentiating agent, namely Zn
2+
, which is resistant to further 
oxidation in the presence of PRE. This, theoretically, should provide potentiated 
virucidal activity over an extended period of time, whilst not developing the black by-
product.  
The current chapter examines both the virucidal and anti-viral activities of PRE/Zn
2+
 
against HSV-1 infected Vero cells. The work concentrated on zinc sulphate (ZnSO4) for 
consistency with the previous work involving FeSO4. However, in order to probe the 
effects of alternative counterions, a variety of other zinc salts were also examined. 
Metal salts are combinations of the metal cation and non-metal anion that bind 
according their association/dissociation constants. Strongly bound salts tend to 
dissociate to a lesser degree and be less water soluble than weakly bound salts. This 
may affect the efficacy of a salt in anti-viral and virucidal tests. 
The distinction between virucidal (viral destruction) and anti-viral (viral inhibition) 
properties of a compound or product was outlined in Chapter 1. Currently available 
topically-applied medications that work against viruses are anti-viral; virucidal 
disinfection products would presumably be detrimental when applied to the skin. 
However, a product that possessed both virucidal and anti-viral properties would have a 
distinct advantage. Consequently, the activity of the PRE and ZnSO4 combination was 
studied in both modes.  
5.1.1. Objective and Aims 
To investigate the virucidal and anti-viral effects of ZnSO4, and other zinc salts, against 
HSV-1: 
 the virucidal activities of a range of zinc (II) salts in combination with PRE 
against HSV-1; 
 the optimal potentiation ratio between PRE and ZnSO4; 
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 the virucidal activity of the major phytochemicals within PRE (punicalagin and 
ellagic acid); 
 the potentiation in activity between ZnSO4 and punicalagin; 
 the anti-viral properties of PRE and its main polyphenols (punicalagin and 
ellagic acid) with and without the addition of ZnSO4 against HSV-1 and ACR-
HSV. 
5.2. Materials and Methods 
5.2.1. Materials 
Materials used in this section are detailed in Chapter 2 section 2.1. 
5.2.2. Methods 
The methodology for general cellular microbiology and the formulation of solutions 
extracts and buffers follows that described in Chapter 2 unless otherwise stated. 
5.2.2.1. Cytotoxicity 
The methodology for the cytotoxicity analyses followed that described in Chapter 2 
section 2.2.7.5., and further discussed in Chapter 3 section 3.2.2.4. 
PRE 0.1 mg mL
-1
, ZnSO4 0.1M and phthalate buffer alone and in combination were 
analysed using the Cell Titer 96
®
 AQueous assay method. All formulations were made 
using the phthalate buffer at pH 4.5.  
5.2.2.2. Virucidal Plaque Reduction Assay 
The virucidal analyses followed the method outlined in Chapter 2 section 2.2.5.9. and 
further discussed in Chapter 3 section 3.2.2.3. The concentrations and combinations of 
the materials which were investigated using the plaque reduction assay are shown in 
Table 5-1.  
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Compound Extract 
Zinc oxide 0.00001M ± PRE 0.05 mg mL-1 
Zinc nitrate 0.0005M ± PRE 0.05 mg mL-1 
Zinc citrate 0.0005M ± PRE 0.05 mg mL-1 
Zinc iodide 0.0005M ± PRE 0.05 mg mL-1 
Zinc stearate 0.0005M ± PRE 0.05 mg mL-1 
Zinc gluconate 0.0005M ± PRE 0.05 mg mL-1 
ZnSO4 0.5M (143.77 mg mL-1) 
0.1M (28.75 mg mL-1) 
0.05M (14.37 mg mL-1) 
0.01M (2.88 mg mL-1) 
0.005M (1.44 mg mL-1) 
0.001M (0.29 mg mL-1) 
0.0005M (0.14 mg mL-1) 
± PRE 0.05 mg mL-1 
± Punicalagin 0.01 mg mL-1 
No addition PRE 0.05 and 0.01 mg mL-1 
No addition Punicalagin 0.05 and 0.01 mg mL-1 
No addition Ellagic acid 1 mM 
Table 5-1 Mixtures employed in virucidal studies. 
5.2.2.3. Antiviral Plaque Assay 
Antiviral activity was determined by the application of test solution and then virus 
(after an incubation period) to confluent Vero cells in a 24 well plate (24wp). The 
methodology followed that stated in Chapter 2 section 2.2.5.10.  
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The test substances used with this method were PRE, ZnSO4, their combination, 
punicalagin, ellagic acid phthalate buffer and Aciclovir. The antiviral studies did not 
test above 100 µM of any compound. 
5.2.2.4. IC50 Calculation 
Antiviral results are typically presented as IC50 values, which refer to half the maximal 
inhibitory concentration, and are a measure of the effectiveness of a compound for 
inhibiting biological or biochemical function (Wilson and Walker 2010), following the 
methodology stated in Chapter 2 section 2.2.5.10.1. 
5.2.2.5. Avicel Overlay Media  
An overlay medium is added to the plaque assay in order to stop the virus becoming 
detached from the infected cells and spreading over the cell monolayer. The 
methodology for the use of this is stated in Chapter 2 section 2.2.5.11. 
5.3. Results 
5.3.1. Virucidal Activity of PRE and Various Zinc Salts 
Although the earlier work involved ferrous ions with a sulphate counterion, in this part 
of the work a range of different counterions for Zn
2+
 were examined. There were 2 
main objectives: 
1. to provide an indication of a mode of action, by probing whether it was 
the zinc cation (Zn
2+
), rather than the sulphate counterion (SO4
-
) that provided 
the potentiation effect with PRE 
2. to determine which counterion may facilitate maximal potentiation  
To achieve this, the range of zinc salts shown in Table 5-1 was evaluated for virucidal 
activity, at the same molar levels unless otherwise stated. Figure 5-1 shows the 
virucidal action of PRE ± Zn
2+
 with a range of anions. 
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Salt added to PRE 
(0.05 mg mL-1) 
Salt concentration 
(mM) 
Virucidal pfu log 
reduction 
Zinc sulphate 
(ZnSO4) 
0.5 3.18 ± 0.076 
Zinc oxide 
(ZnO) 0.01* 1.21 ± 0.21 
Zinc nitrate 
(Zn(NO3)2) 
0.5 1.59 ± 0.51 
Zinc citrate 
(Zn3(C6H5O7)2) 
0.5 3.19 ± 0.62 
Zinc iodide 
(ZnI2) 
0.5 1.65 ± 0.1 
Zinc stearate 
(Zn(C18H35O2)2) 
0.5 2.94 ± 0.35 
Zinc gluconate 
(C12H22O14Zn.xH2O) 0.5 3.26 ± 0.42 
Table 5-2 The range of zinc salts analysed for potentiated virucidal activity with respect to HSV-1 on 
addition to PRE (0.05 mg mL
-1
) (n=4 ± SD).  *lower concentration used due to low aqueous solubility. 
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Figure 5-1 Virucidal log reduction data for the addition of PRE (0.05 mg mL
-1
) and a range of Zn
2+ 
salts to HSV-1 (n = 3 ± SD).  Blue = salt alone, green = PRE alone, yellow 
= salt + PRE. 
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The results in Figure 5.1 show that the salts alone provided generally low activity. 
There were some small variations that could be related to the varying solubilities, 
and dissociation constants. However, across the range there was no statistically 
significant difference (p > 0.05).  
The salts zinc oxide, zinc nitrate and zinc iodide failed to demonstrate potentiation. 
In the case of zinc oxide, the solubility was very low and had to be evaluated at 10
-5
 
M, rather than 10
-4
 M as for the other zinc salts. Zinc nitrate and zinc iodide each in 
combination with PRE are represented as having low log reductions due to the high 
cytotoxicity of the mixture limiting the analysis at these concentrations. The iodide 
ion is a known biocide and it is believed application of zinc iodide was cytotoxic to 
the host Vero cells. This was apparent visually during the experiment by the full lysis 
of Vero cells and therefore lack of crystal violet staining. In a similar manner, it can 
be concluded that the nitrate ion was also cytotoxic to the Vero cells.  
However, the remaining salts were water soluble (≥ 0.0005 M) and did not result in 
cell cytotoxicity. Thus potentiated activity was successfully displayed by zinc 
sulphate, zinc citrate, zinc stearate and by zinc gluconate, with log reduction values 
of approximately 3.  Although there was some apparent variation, the differences 
were not statistically significant (p > 0.05). 
There were no colour changes with any of the zinc salts upon the addition of PRE, 
although zinc iodide was intrinsically a brown-coloured solution and remained so 
throughout the experiment. These observations supported the chemical analyses 
carried out in Chapter 4, in particular the absence of any evidence for a redox 
reaction involving Zn
2+
. 
It was decided to proceed further with the examination of the sulphate salt (ZnSO4). 
The reasons were: 
 high aqueous solubility 
 lack of colour change  
 the level of potentiated virucidal action  
 biocompatibility 
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5.3.2. Cytotoxicity of PRE, ZnSO4 and Phthalate Buffer 
Figure 5-2 shows the percentage of viable cells after application of PRE                 
0.1 mg mL
-1
, ZnSO4 0.1 M and phthalate buffer pH 4.5, alone and in combination. 
Each formulation was made in the phthalate buffer at pH 4.5. There was no 
significant difference (p >0.05) between the applied formulations at any time point 
over the 72 h period resulting in no decrease in the percentage of viable cells in 
comparison to the control. There was no cytotoxic effect observed on the application 
of PRE and ZnSO4 at any concentration analysed throughout this project. 
 
Figure 5-2 The percentage of viable cells after application of PRE 0.1 mg mL
-1
, ZnSO4 0.1 M and 
phthalate buffer pH 4.5, alone and in combination, after 6, 24, 48 and 72 h (n = 3 ± SD). 
5.3.3. Virucidal and Antiviral Analysis 
5.3.3.1. Virucidal Activity of PRE and Different Concentrations of ZnSO4 
Having selected ZnSO4 for further study, the next part of the work involved a study 
of the effects of ZnSO4 concentration on the potentiation of PRE virucidal activity. 
This would provide important information on the relative proportions of the two 
components that could usefully be combined in a potential product to achieve 
optimal virucidal activity. 
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Figure 5-3 shows the log reduction of HSV-1 pfus with increasing levels of ZnSO4. 
As the level of ZnSO4 increased so did the log reduction of HSV-1 pfu, with 
maximal log reduction of 4.47 ± 0.11 and 4.56 ± 0.11 after the addition of 1.44 and 
14.38 mg mL
-1
 of ZnSO4.  After this point a decrease in virucidal activity was 
observed. It is important to note that between the two maximal points a statistically 
significant decrease in the virucidal activity was observed, at a ZnSO4 concentration 
of 2.88 mg mL
-1
 the log reduction decreased to 3.11 ± 0.57.   
 
Figure 5-3 Effect of ZnSO4 concentration on the potentiated virucidal activity upon addition to PRE 
(0.05 mg mL
-1
) (n = 4 ± SD). 
5.3.3.2. Virucidal Activity of ZnSO4 and Different Concentrations of 
Punicalagin 
As outlined in the introduction, the major phytochemical present in PRE is the 
ellagitannin, punicalagin (Jingjing, Yun and Qipeng 2007), at approximately 20%, 
which has reported microbicidal activity  (Seeram, et al. 2005). It was therefore 
determined to examine the effect of this compound in isolation from the other 
components of PRE. A product based upon a single phytochemical such a 
punicalagin would be easier to standardise, with less liability to show batch-to-batch 
variation regarding the overall composition. Whether PRE or punicalagin was the 
more efficacious in terms of virucidal activity was not easy to determine, as a pure 
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compound (such as punicalagin) cannot be directly compared to a chemically diverse 
mixture (as is PRE). Notwithstanding, a comparison was made by evaluating both as 
equal mass mL
-1
. 
The virucidal log reduction of punicalagin in comparison to PRE (weight-to-weight) 
is represented in Figure 5-4. The results show that the log reduction of HSV-1 pfu 
due to the isolated punicalagin (0.05 mg mL
-1
) was 5.93 ± 0.35, significantly greater 
than the log reduction due to PRE (0.05 mg mL
-1
) of 0.76 ± 0.66 (p < 0.05). It is 
important to note that a log reduction of 5.93 is the maximal limit of the test due to 
viral titer, however the marked difference between the activities of PRE and 
punicalagin was again observed at the lower concentration of 0.01 mg ml
-1
.  
 
Figure 5-4 Comparison of the virucidal log reduction of HSV-1 by PRE and punicalagin on a mass-to-
mass basis at both 0.05 mg mL
-1
 and 0.01 mg mL
-1
 (n=4 ± SD). 
Punicalagin 0.01 mg mL
-1
 is representative of the concentration of punicalagin 
within 0.05 mg mL
-1
 PRE (i.e. punicalagin accounts for approximately 20% of the 
dry mass of PRE). The log reduction data of HSV-1 in Figure 5-4 shows that the 
virucidal log reduction due to PRE and punicalagin decreased from 0.76 ± 0.66 and 
5.93 to 0.05 and 2.4 ± 0.9 respectively. These results demonstrate the greatly 
enhanced virucidal activity of punicalagin on a mass-to-mass basis relative to PRE. 
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content with the extract, appears partially compromised by other components of the 
extract.  
5.3.3.3. Virucidal Activity of PRE and Ellagic Acid in Isolation 
Punicalagin, although in greatest proportion, is by no means the only phytochemical 
constituent of PRE. In this section, we examined the effect of another ellagitannin, 
ellagic acid (EA), a direct breakdown product of the esterification of punicalagin. 
However, obtaining a direct comparison with punicalagin proved problematic due to 
the extremely low aqueous solubility of EA. An alternative solvent was needed in 
which both species were soluble, and preliminary experiments to the use of 10% 
DMSO in DI H2O. Figure 5-5 shows that the virucidal activity of EA provided no 
statistical difference in comparison to DMSO solution (p > 0.05); however, 
punicalagin showed significantly greater virucidal action than either the control or 
ellagic acid (p < 0.05). 
 
Figure 5-5 Virucidal log reduction due to the main phytochemicals within PRE; ellagic acid and 
punicalagin solubilised in 10% aqueous DMSO (n = 4 ± SD). 
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5.3.3.4. Virucidal Activity of Punicalagin with Different Concentrations of 
ZnSO4 
Having demonstrated that punicalagin is active against HSV-1, the next part of the 
study examines the potentiation of activity by different concentrations of ZnSO4. 
Figure 5-6 shows the potentiation of different ZnSO4 concentrations on the virucidal 
activity of 0.01 mg mL
-1
 aqueous punicalagin. As previously shown in Figure 5-4 
punicalagin has a high innate virucidal effect resulting in a log reduction of 2.4 ± 0.9 
(note: 0.01 mg mL
-1
 used here rather than 0.05 mg mL
-1
).  
Addition of ZnSO4 (0.14 mg mL
-1
) caused a marked increase in potentiated virucidal 
action to 4.6 ± 0.16. However, in the PRE experiment (Figure 5-3), the addition of 
greater amounts of ZnSO4 caused a decrease in the virucidal activity below that of 
punicalagin alone. A biphasic trend was again observed, as at the higher 
concentrations of ZnSO4 (14.38, 28.75 and 143.77 mg mL
-1
) higher log reductions of 
3.01, 2.56 and 2.22 were observed.  
 
Figure 5-6 Effect of ZnSO4 concentration on the potentiated virucidal activity of punicalagin (0.01 mg 
mL
-1
) (n =4 ±SD). 
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5.3.3.5. Antiviral Activity of PRE, Punicalagin, Ellagic Acid and Aciclovir 
Against HSV-1 and Aciclovir-Resistant HSV-2  
As outlined in Chapter 1, most topical treatments for skin viral infections exploit an 
antiviral mechanism, where the active compound inhibits viral replication. In this 
section, the viral replication inhibitory activities of PRE, punicalagin and ellagic acid 
were determined alongside the established topical antiviral drug, Aciclovir. Two 
strains of Herpes simplex virus were used: HSV-1 and HSV-2 Aciclovir resistant 
(ACR). Table 5-3 shows that the IC50 of Aciclovir against HSV-1 was 0.81 µM 
(which is equivalent to 182 µg mL
-1
), agreeing with literature (Sarisky, et al. 2001) 
(Hobden, et al. 2011) and experimental findings of Dr JJ Bugert (personal 
communication). 
 Table 5-3 The antiviral IC50 against HSV-1 and HSV-ACR of PRE, punicalagin and ellagic acid in 
comparison to Aciclovir (n=3 ± SD) Note: concentration of PRE is in mass mL
-1
 rather than moles. 
Compound Virus IC50 
PRE HSV-1 0.560 ± 0.039 µg mL
-1 
HSV-ACR 0.016 ± 0.009 µg mL
-1 
PRE  + ZnSO4 (1:1) HSV-1 0.550 ± 0.062 (PRE=µg mL
-1
) 
(ZnSO4= µM) 
Punicalagin HSV-1 
HSV-ACR 
≥100µM 
≥100µM 
Ellagic Acid HSV-1 
HSV-ACR 
≥100µM 
≥100µM 
ZnSO4 HSV-1 ≥100µM 
 HSV-ACR ≥100µM 
Aciclovir HSV-1 0.809 ± 0.030 µM (182 µg mL
-1
) 
HSV-ACR ≥100 µM 
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The PRE extract exhibited strong antiviral properties against HSV-1 0.556 ± 0.39 µg 
mL
-1
.
 
On a mass-to-mass basis PRE is over 1000 times more potent than Aciclovir. 
PRE demonstrated an even greater antiviral response against HSV-ACR with an IC50 
of 0.016 ± 0.009 µg mL
-1
, whereas Aciclovir showed no effect (≥100 µM). 
Surprisingly neither punicalagin nor ellagic acid elicited any antiviral activity at the 
concentrations tested (IC50 ≥ 100 µM).  This result indicates that, unlike in the earlier 
tests where punicalagin was clearly involved in virucidal activity, the anti-viral 
activity of PRE cannot be attributed to this compound. Thus antiviral activity is due 
to another phytochemical constituent of PRE or, more likely, a combination of 
compounds.  
The addition of ZnSO4 was not found to increase the anti-replicative potential of the 
extracts. 
The concentration dependant antiviral profile from selected experiments is displayed 
in Figures 5-7 (PRE and HSV-1), 5-8 (PRE and HSV-2 ACR), 5-9 (PRE + ZnSO4 
and HSV-1) and 5-10 (Aciclovir and HSV-1). It is interesting to note the shape of 
these graphs, the sharp decline in viral activity over a small concentration gradient 
implies that PRE ± ZnSO4 requires a threshold concentration to have any antiviral 
effect. The shape of the IC50 curve for Aciclovir exhibits a gradual decline in 
antiviral activity over a wide concentration range (Figure 5-10); this, and the antiviral 
activity of against HSV-2 ACR which is resistant to Aciclovir suggests that the 
antiviral activity of PRE is exercised by a different mode of action to that of 
Aciclovir. 
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Figure 5-7 The IC50 curve arising from the antiviral activity of PRE against HSV-1 (n=3, ± SD). 
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Figure 5-8 The IC50 arising from the antiviral activity of PRE with against to HSV-2 ACR (n=3, ± 
SD). 
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Figure 5-9 The IC50 curve arising from the antiviral activity of PRE and ZnSO4 against HSV-1 (n=3, 
± SD). 
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Figure 5-10 The IC50 curve arising from the antiviral activity of Aciclovir against to HSV-1 (n=3, ± 
SD). 
 
 
 
 
112 
 
5.4.  Discussion 
Examination of a range of zinc salts showed that comparable potentiation was 
achieved to ZnSO4 when equal concentrations were employed and the counterion had 
no adverse effect on the host vero cells. This is strong evidence that the Zn
2+
 ion in 
solution is principally responsible for the potentiating effect. 
The biphasic concentration-dependant response to ZnSO4 of both PRE and 
punicalagin is surprising, although the experiments were performed four times. 
Potentiation increases up to 1.44 mg mL
-1
, after which it dips before again reaching a 
maximum, thereafter steadily diminishing. PRE is a complex mixture of 
phytochemicals and the addition of ZnSO4 adds to the complex interplay between 
constituents. 
To speculate, similarities between the virucidal effects of the higher concentrations 
of ZnSO4 combined with PRE and punicalagin can be observed and may indicate that 
a dual effect is occurring. Thus far the combination of ZnSO4 plus punicalagin at the 
lower concentrations of ZnSO4 (0.14 mg mL
-1
): the viral envelope is first 
compromised by the punicalagin and then bound by the free Zn
2+
 ions, however, at 
higher concentrations of ZnSO4, the Zn
2+
 ions may act first allowing for the 
punicalagin to then combine with the protein envelope thus destroying it. A similar 
level of viral destruction is observed within the PRE + ZnSO4 system, however, due 
to the protective nature of a natural product upon its constituent parts, the virucidal 
activity of punicalagin remains active and thus potentiation is maintained over a 
greater concentration range of ZnSO4 addition (0.14 and 28.75 mg mL
-1
). The 
decrease in virucidal activity at ZnSO4 concentrations 0.29, 0.144 and 0.288 mg mL
-1 
to punicalagin (shown in Figure 5-6) and 2.88 to PRE (shown in Figure 5-3) may 
indicate competitiveness for a specific protein and or binding site, hindering 
potentiation. Previous studies have not elucidated the virucidal mode of action of 
polyphenols found in pomegranate however a growing body of research has 
indicated the interaction between polyphenols, such as punicalagin and ellagic acid, 
with envelope viral glycol proteins in respect to varying strains of influenza (Nagai, 
et al. 1993); (Neurath, et al. 2004); (Song, Lee and Seong 2005).  
113 
 
It is interesting to note the apparent equivalence in antiviral activity between PRE 
and the established antiviral Aciclovir (Table 5-3). Even more interesting is the fact 
that PRE demonstrated an even greater activity against ACR-HSV – the implication 
is that PRE could have a role in future HSV strategies, when Aciclovir has become 
obsolete. The addition of ZnSO4 was found not to provide enhanced activity in any 
case, and therefore is not involved in a potentiating mechanism during the viral 
replication stage. 
In a practical context, the topical application of PRE and ZnSO4 might be expected to 
result in virucidal kill outside of the host cell post-budding and help eliminate the 
viral vesicles.  This would have important beneficial consequences for preventing 
viral transfer by a number of mechanisms, eg human mouth-to-mouth, mouth-to-
genital, mouth-to-drinking vessel, mouth-to-joint (shared smoking), vagina-to-
neonate (herpes infected mother). Additionally, PRE (alone) would inhibit viral 
replication within adjacent cells preventing formation of a viral cluster, which in turn 
would prevent a cold sore outbreak i.e., formation of a cold sore. 
5.5. Conclusion 
The activities of PRE and punicalagin with added ZnSO4 has been determined 
against HSV-1 and HSV-ACR in both virucidal and antiviral modes. Very 
encouraging data has been obtained in both cases that indicate therapeutic potential 
as anti-cold sore and herpes treatment, provided that the main chemical constituents 
are able to adequately penetrate skin. This is considered in Chapter 6. 
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Chapter 6 Penetration of Punicalagin 
and Zinc across Full Thickness and 
Heat Separated Epidermal 
Membranes from Solution  
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6.1. Introduction 
In Chapter 5 it was found that the combination of PRE and zinc salts provided 
significantly higher virucidal activity than either alone, thus providing the basis for a 
potential new product against HSV infections. HSV is a virus that generally affects 
perioral skin (cold sores) and the ano-genital area (herpes). The location of the viral 
load in each case is generally the stratum basale, particularly prior to eruption. 
Therefore, for a treatment based on PRE and zinc to be efficacious, it is necessary 
that the active compounds are able to penetrate across the skin to these areas. This is 
not straightforward given the barrier function of the skin, particularly in the early 
stages of an outbreak, where the stratum corneum is still intact. As outlined in 
Chapter 1 section 1.5.2., there are certain ground-rules that typically apply to the 
uptake and permeation of chemical compounds across skin. Most notably these relate 
to lipophilicity and molecular weight (Williams and Barry 1991). However, in the 
later stages of an outbreak, where the stratum corneum is breached, such parameters 
are of less importance. 
In this chapter the focus is on the penetration of punicalagin from PRE and Zn
2+
 from 
simple liquid solutions, separately and in combination, across excised skin 
membranes in vitro.  It was of great interest to establish that the main active 
compounds penetrate the skin at the same time and with the ratio of concentrations 
required to maintain virucidal potentiation. The in vitro examination of the 
permeation and penetration would suggest a similar result in vivo and, in particular, 
that antiviral and virucidal effects would be observed in lesion outbreak.  
Membrane permeation, referring to the transport of molecules across the skin, is 
depicted in permeation profiles (cumulative mass or moles per area vs time), from 
which skin permeability parameters may be taken, including steady state flux and lag 
time. However, in order to determine the amount of a compound resident within skin 
after a certain time, it is conventional to use the technique of tape stripping, where 
adhesive tape is used to sequentially remove layers of skin tissue from the diffused 
area when removed from an FDC. The compounds are then extracted from the strips 
and analysed to yield relative depth versus concentration information (Escobar-
Chávez, et al. 2008).  
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The membranes examined in the current work were porcine ear skin, which has been 
used extensively as a model for human skin in recent years. Porcine ear skin has been 
widely used for in vitro skin permeation studies and has shown to be the best 
alternative model for human skin (Meyera, et al. 2007) (Sekkat, Kalia and Guy 2004) 
(Simon and Maibach 2000). Full thickness skin is typically used in such experiments; 
although heat separated epidermal (HSE) membranes are also used, where the dermis 
is separated from the epidermis by heat action. Both were examined in this work, and 
were mounted in all-glass Franz diffusion cells, as described in Chapter 2 section 
2.2.3. 
 
 
 
Test solutions were prepared in pH 4.5 phthalate buffer for consistency with the 
microbiology work of Chapters 4 and 5. Furthermore, this is within the range of the 
natural pH of the PRE as stated in (Akbarpour, Hemmati and Sharifani 2009), and 
studies have shown that PRE stability is greatest under such conditions 
(Panichayupakaranant, Itsuriya and Sirikatitham 2010). In addition, the skin surface 
is acidic with a general pH of 5.5, so the use of this buffer was considered 
appropriate. Single finite doses (40 L) of the test solutions were applied to the 
membranes to approximate to in vivo use conditions. 
 
Figure 6-1 Glass Franz diffusion cell with Skin membrane in situ. 
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6.1.1. Objective and Aims 
To determine the potential for delivering punicalagin and Zn
2+
 into and across skin. 
1. Determination of the cumulative permeation of punicalagin and Zn
2+
 across skin 
membranes following the administration of a simple liquid dose. 
2. Determine the levels of punicalagin and Zn
2+ 
in the skin by depth profiling, 
following the administration of a simple liquid dose. 
6.2. Materials & Methods 
6.2.1. Materials 
The preparation of extracts and buffers used throughout this chapter are detailed in 
Chapter 2 section 2.2.1. unless otherwise stated 
6.2.2. Preparation of test solutions 
The procedures for the preparation of solutions of PRE, phthalate buffer at pH 4.5, 
ZnSO4 and their various combinations was outlined in Chapter 2 Section 2.2.1. Table 
6-1 outlines the test solutions used for each method of investigation. Prior to 
application all formulations were kept at 4°C and occluded from light.  
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Solution  Contents Test/membrane Volume 
Applied 
PRE Freeze dried PRE 1mg 
mL-1in pH 4.5 
phthalate buffer 
HSE penetration 
FT penetration 
FT permeation 
40 µL 
40 µL 
40 µL 
PRE + ZnSO4 Freeze dried PRE 1mg 
mL-1 and ZnSO4 1M in 
pH 4.5 phthalate buffer 
HSE penetration 
FT penetration 
FT permeation 
40 µL 
40 µL 
40 µL 
ZnSO4 ZnSO4 1M in pH 4.5 
phthalate buffer 
HSE penetration 
FT penetration 
FT permeation 
40 µL 
40 µL 
40 µL 
Blank pH 4.5 phthalate buffer  HSE penetration 
FT penetration 
FT permeation 
40 µL 
40 µL 
40 µL 
Table 6-1 Experimental conditions for the determination of penetration and permeation across heat 
separated membranes (HSE) and full thickness skin membranes (FT). 
6.2.3. Preparation of Porcine Ear Skin Membranes 
The preparation of both full thickness and HSE membranes from freshly excised 
porcine ears were detailed in Chapter 2 section 2.2.2. 
6.2.4. In-vitro Skin Permeation  
The general procedure for determination of in vitro skin permeation using Franz 
diffusion cells with DI water as donor phase was outlined in Chapter 2 section 2.2.3. 
Single finite doses of 40 µL were applied to mimic in use conditions as shown in 
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Table 6-1, with replication of n=3 and without massage. The entire receptor phase 
was removed using Pasteur pipettes at 3, 6, 12, 24 and 36 h and replaced with fresh 
receptor phase at 37C.  
6.2.5.  In-vitro Depth Profile Analysis by Tape Stripping  
The general method for tape stripping was detailed in Chapter 2 section 2.2.3.4. After 
24h post application, the membranes were recovered and 20 strips taken from the 
diffused areas, with constant pressure applied for each strips The first two strips were 
discarded to account for remaining test solution; each subsequent 2 strips were 
combined, dissolved in 2 mL MeOH, the strips were removed manually and the 
solvent was removed under vacuum. The residue was reconstituted in DI H2O and 
stored at - 20°C before analysis. 
6.2.6. Quantitative Analysis 
The punicalagin content of samples were analysed via reverse phase HPLC using an 
Agilent 1100 HPLC system following the method set out in Chapter 2 section 
2.2.4.1. Zinc analysis was conducted using Inductively Coupled Plasma Mass 
Spectrometry (ICP-MS) following the methods described in Chapter 2 section 
2.2.4.2.  Samples ranging between 0.1 and 10 µM of zinc were analysed using ICP-
MS following standard calibration of the machine. Cumulative moles per area are 
presented to allow numerical comparison between punicalagin and zinc quantities. 
6.3. Results 
6.3.1. Permeation across Heat Separated Epidermis 
Figure 6-2 shows the permeation profile of punicalagin that permeated porcine HSE 
following the application of a 40 L dose of test solution. The results show that 
punicalagin permeated rapidly, with pseudo steady state permeation during the first 6 
h of application. After this the trend was towards a plateau; there was no lag phase 
apparent. At 24h the permeation of punicalagin from the application of PRE and PRE 
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+ ZnSO4 was 3.64 ± 0.11 nM cm
-2
 and 4.13 ± 0.1 nM cm
-2
. This difference was 
statistically significant (p<0.05). 
No punicalagin peaks were observed when the HSE was dosed with either control 
sample or ZnSO4. 
 
 
Figure 6-2 Cumulative permeation of punicalagin across HSE over 24 h (n=3, ± SD). The plot 
correspond to: PRE 1mg mL
-1
 + ZnSO4 1 M (red), PRE 1 mg mL
-1
 (blue), ZnSO4 1 M (yellow)  and  
phthalate buffer control (green). 40 uL of each formulation was applied. 
Figure 6-3 shows the cumulative permeation of zinc across HSE. Firstly, it is clear 
that the same levels of zinc were detected in the control and PRE-dosed cells. This 
demonstrates that an amount of endogenous zinc leached from the skin; however, 
this level was the same as that from PRE, indicating no additional presence of zinc 
from the PRE. 
Similar to Figure 6-2, pseudo steady state permeation of zinc from skin dosed with 
ZnSO4 and PRE + ZnSO4 occurred within the first 6 h of application; after which 
point the permeation profile plateaued upon reaching equilibrium. 
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Figure 6-4 shows the permeation of the analytes, punicalagin and zinc, through the 
epidermal membrane after application of 40 µL of PRE (1 mg mL
-1
) + ZnSO4 (1M). 
This is the equivalent of applying 7.38 nM of punicalagin. It is apparent that after 3 h 
both punicalagin and zinc permeate at similar concentrations, 1.7 ± 0.46 nM cm
2
 and 
1.6 ± 0.16 nM cm
2
. After 6 h there is greater permeation of Zn (5.3 ± 0.49 nM cm
2
) 
in comparison to that of punicalagin (3.69 ± 0.09 nM cm
2
), after this time the 
permeation of both analytes reaches equilibrium. 
This data shows that the finite dosing of 40 µL of PRE (1 mg mL
-1
) + ZnSO4 (1M) to 
the epidermis resulted in the simultaneous permeation of zinc and punicalagin to the 
site specific area of HSV-1 vesicles at the epidermal dermal interface. The 
concentration of permeated zinc and punicalagin at both 3 h and 6 h were at a ratio 
for which potentiated virucidal activity was observed in Chapter 5.  
The results from the control and PRE treated epidermis were not statistically 
different (p>0.05) and in agreement with previous work that stated the penetration of 
zinc into the receptor phase from untreated epidermal membranes over 24 h was 0.09 
± 0.04 ug cm
-2
 (1.3 ± 0.6 nM cm
-2
) (Cross, et al. 2007). 
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Figure 6-3 The permeation of zinc across HSE over 24 h (n=3 ± SD). The plot colours correspond 
to: PRE 1mg mL
-1
 + ZnSO4 1 M (red), PRE 1 mg mL
-1
 (blue), ZnSO4 1 M (yellow)  and  phthalate 
buffer control (green). 40 µL of each formulation was applied at a pH of 4.5. 
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Figure 6-4 The permeation of punicalagin and zinc across HSE over 24 h after application of 40 uL of 
PRE (1 mg mL
-1
) + ZnSO4 (1M) (n=3 ± SD). The plot colours correspond to the analyte: red = Zn and 
green = punicalagin. 
A review of the literature has found no reports of ZnSO4 permeation through the 
epidermis. However, there has been a number of papers on the permeation and 
penetration of zinc in the form of ZnO. These generally concur that there was no 
permeation of zinc through the epidermis (Lansdown and Taylor 1997). Studies with 
microfine and nano sized particles have also drawn the same conclusion that no zinc 
penetrates the epidermis (Gamer, Leibold and Ravenzwaay 2006) (Cross, et al. 
2007).  
Figure 6-5 shows that the permeation of zinc occurred within the first six hours, the 
quantity of zinc detected after this is statistically similar to the values of the control 
and PRE alone. The quantity of zinc observed after 6 h and throughout the control 
and PRE treated epidermis is due to the leaching of zinc from the skin, which is 
relatively constant over the 24hr time period. 
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On the assumption that freely soluble zinc as ZnSO4 behaves differently to insoluble 
zinc as ZnO, it may be expected for the zinc to permeate in the first few hours as 
there was a limited amount applied. This is similar to the permeation of punicalagin 
and it is clear that zinc permeation was unaffected by the presence of PRE.  
The mixture of ZnSO4 and PRE as a topically applied drug was able to permeate the 
epidermis to an acceptable level (as indicated by virucidal data in Chapter 5.3.3.1.) 
so that it would still be effective in combination to target a skin virus under or in the 
epidermis. It is important to note that punicalagin permeation may have been affected 
due to ester hydrolysis; however, the concentration of porcine esterase within the 
epidermis is very low (Lau, White and Heard 2010). If ester hydrolysis occurred, 
there would be an expected increase of the breakdown products of punicalagin, but 
this was not observed in the HPLC chromatograms.  
6.3.2.  Tape Stripping 
Figure 6-6 shows the punicalagin amounts retrieved from each layer of the stratum 
corneum after 24h. The penetration of punicalagin is relatively constant throughout 
each layer of the epidermis, with higher amounts in the upper layers, as typically 
observed. However, by far the greatest recovery was from the dermis.  
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Figure 6-5 Permeation of Zn
2+
 through HSE at the specific time points 3, 6, 12, 18 and 24 h. 
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Figure 6-6 Depth profile of punicalagin in porcine skin after application of PRE (green), PRE + 
ZnSO4 (red) and control (blue) (n=3 ±SD). 
The amount of punicalagin recovered in each layer of the epidermis after application 
of PRE and application of PRE + ZnSO4 was in the region of 0.1- 0.2 nM cm
-2
 and 
0.05 - 0.1 nM cm
-2
 respectively. No peaks were identified at the specific time points 
for the control. 
The largest recovery of punicalagin after tape stripping was from the dermis. The 
level of punicalagin after the application of PRE was 2.39 ± 0.29 nM cm
-2
. After 
application of PRE and ZnSO4 the concentration of punicalagin was somewhat lower 
at 3.3 ± 0.47 nM cm
-2
 (p < 0.05). The total recovery of punicalagin after application 
of PRE and PRE + ZnSO4 from the tape strips and the dermis was not statistically 
different (p>0.05) at 3.58 ± 0.1 nM cm
-2
 and 3.91 ± 0.62 nM cm
-2
 respectively. 
These results are consistent with the permeation of punicalagin through the epidermis 
after application of 40 µL of PRE (1 mg mL
-1
) and PRE (1 mg mL
-1
) + ZnSO4 (1M). 
As shown in the previous permeation experiment, punicalagin permeation occurred 
rapidly, within the first three to six hours after application. Therefore it is reasonable 
to conclude that the punicalagin recovered in each of these layers after 24h 
application time has reached a point of equilibrium. The permeation profiles of 
punicalagin from both solutions shows that a greater concentration of punicalagin 
remains within the dermis when PRE is applied in combination with ZnS04 and that 
punicalagin has a more evenly distributed permeation through the stratum corneum 
-0.5 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
1
,2
 
3
,4
 
5
,6
 
7
,8
 
9
,1
0
 
1
1
,1
2
 
1
3
,1
4
 
1
5
,1
6
 
1
7
,1
8
 
1
9
,2
0
 
D
e
rm
is
 P
u
n
ic
a
la
g
in
 (
n
M
 c
m
-2
) 
Tape Strip 
Control 
PRE 
PRE + 
ZnSO₄ 
125 
 
and dermis after the application of PRE alone, the difference in the profiles is 
unknown. 
The maintenance of the ratio of punicalagin anomers after permeation and 
throughout the stratum corneum and dermis was expected, as the reversal or 
degradation of the concentration of the punicalagin anomers has only occurred in 
stability studies of pomegranate extracts at a basic pH10. The punicalagin anomers α 
and β are inverted or degraded at pH 10, at room temperature after reflux, or being 
microwaved (N. P. Seeram, Pomegranates Ancient Roots to Modern Medicine 2006).  
Figure 6-7 shows the cumulative concentration of zinc recovered from the tape 
stripping of full thickness porcine skin after the topical application of 40 µL PRE (1 
mg mL
-1
) + ZnSO4 (1 M), ZnSO4 (1 M) and control in vitro. The concentration of 
zinc recovered was greatest and not significantly different (p>0.05) after the 
application of ZnSO4 and PRE + ZnSO4, this remained true at all layers of the 
stratum corneum and dermis. As expected zinc was recovered from the porcine skin 
within each layer of the stratum corneum and within the dermis the total quantity 
recovered was 68.03 ± 5.6 nM cm
-2
 - this value is simlar to that stated previously 
(Gamer, Leibold and Ravenzwaay 2006).  
 
Figure 6-7 The cumulative concentration of Zn recovered from the tape stripping of full thickness 
porcine skin after 24h application of 40 µL PRE (1mg mL
-1
) + ZnSO4 (1M), ZnSO4 (1M) and control 
(n=3 ± SD). 
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6.4. Conclusion 
The finite dosing of PRE and ZnSO4 to porcine epidermal membranes shows that 
punicalagin, the virucidally active compound within PRE, and ZnSO4 all penetrate 
the epidermis at levels within the concentration ratio required so that a potentiated 
virucidal action will occur. The tape stripping of full thickness skin confirmed that 
both agents permeated all levels of the stratum corneum. However, it is apparent that 
Zn
2+
 permeates through the epidermis but does not permeate the dermis, as the zinc 
concentration found in this region was not statistically significantly different to the 
control. 
The results show that from a finite liquid dosing, both punicalagin and ZnSO4 are 
able to permeate in combination at the potentiated virucidal ratio to the epidermal 
dermal interface where HSV-1 and HSV-2 vesicular clusters form, this therefore 
shows that a therapeutic system based upon PRE and ZnSO4 has the potential to 
effectively kill virion at the site of reproduction.  
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Chapter 7 Probing the Anti-
Inflammatory Effects of Topically 
Applied PRE and Zinc Sulphate 
Combination on Epidermal COX-2 
Enzyme Activity  
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7.1. Introduction  
Herpes simplex virus type 1 and 2 lesion eruptions cause a significant level of 
inflammation to the localised area, resulting in erythema, swelling and pain 
particularly in the later stages. Although challenging the viral load is of primary 
importance when treating such lesions, there would be distinct advantages if a 
medication could also address this discomfort and discolouration. By the same token, 
it is clear that a topical treatment must not be pro-inflammatory as this would 
exacerbate discomfort. It is therefore pertinent to investigate the inflammatory effects 
of topically applied PRE and ZnSO4.  
Extracts from various parts of Punica granatum have been used for centuries to abate 
inflammation due to a wide range of diseases and afflictions (Aggarwal, et al. 2006). 
Dietary supplements containing various pomegranate extracts are currently popular 
in Western society for the treatment and prevention of arthritis and other 
inflammatory diseases. Anti-atherosclerotic and anti-inflammatory studies have 
shown the positive effect of consumption of pomegranate extracts and juice in vivo 
(Aviram and Dornfeld 2001)(Larrosa, et al. 2010). Anti-inflammatory effects using 
Punica granatum extracts have been shown in vitro by cellular biology, and excised 
porcine rat and human skin to decrease the inflammatory markers COX-2, LOX-5 
and iNOS (Lee, et al. 2010). The evidence of this research has led to the 
development of a commercial anti-inflammatory, antioxidant and vasodilating 
product containing pomegranate extract, IGNITE
®
, produced by ZANAGEN.   
The use of topically applied preparations containing zinc in order to accelerate the 
healing of wounds is well documented within the literature, and the use of gauze 
impregnated with zinc is known to decrease inflammation. However, much of the 
work on the anti-inflammatory properties of zinc has focussed on zinc oxide; indeed 
it has been reported that ZnSO4 has no positive or negative effect on wound healing 
in vivo involving porcine, rat and human subjects. It has also been stated that 
topically applied ZnSO4 to full thickness intact skin had no effect on the level of 
inflammation in vitro via analysis of the inflammatory markers cyclooxygenase-2 
(COX-2) and lipoxygenase (LOX) (Roselli, et al. 2003), and in vivo(Agren, Chvapil 
and Franzen 1991).  
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The processes involved in skin inflammation occur in the viable epidermis, which is 
composed of living cells (keratinocytes). During inflammatory challenge to the skin 
the keratinocytes respond by cytokine release and activation of arachidonic acid 
metabolism along the COX-2 and LOX pathways. Upon chemical or mechanical 
tissue injury COX-2 is rapidly upregulated, channelling the arachidonic pathway to 
produce the inflammatory mediators, prostaglandins. The upregulation of COX-2 and 
LOX is transient with a short half life and therefore can be analysed as a marker for 
the level of inflammation within the skin at particular time points. Analysis of the 
level of COX-2 expression in skin can provide a comparative model for the 
dermatological activity of topically-applied formulations on inflammation, the 
probing of COX-2 modulation in ex vivo porcine ear skin and determination of the 
pro- or anti-inflammatory effects of topically applied N-3 fatty acids, betamethasone 
dipropionate and an extract of Harpagophytum procumbens showed this (Thomas, 
Davidson and Heard 2007) (Zulfakar, Abdelouahab and Heard 2010). 
7.1.1. Objective and Aims 
The objective of this study was to probe the effect on the inflammatory marker COX-
2 expression following the application of individual or combined PRE and ZnSO4 on 
porcine skin, ex vivo. The molecular biology techniques of immunocytochemistry 
(ICC) and Western blotting were used to determine relative protein (COX-2) levels.  
Aims 
1. to confirm or otherwise the previously reported downregulation of COX-2 
expression within excised porcine epidermis following the topical application 
of PRE 
2. to determine the modulation of COX-2 after topical application of PRE, 
ZnSO4 and their combination by ICC and Western blotting. 
3. to assess the potential of PRE and ZnSO4 in combination as a topical anti-
inflammatory system 
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7.2. Materials and Methods 
7.2.1. Materials 
The materials used in this work are detailed in Chapter 2 section 2.1. 
7.2.2. Methods 
The methodology for the formulation of solutions, extracts and buffers follows that 
described in Chapter 2 section 2.2. unless otherwise stated. 
7.2.2.1. Formulation Preparation 
The preparation of phthalate buffer, PRE, ZnSO4 and their combinations followed 
the protocols outlined in section 2.2.1. Table 7-1 shows the concentration and 
volume of the formulations applied to ex vivo porcine epidermis and the method of 
molecular biological analysis used to probe protein levels. 
Test solution Formulation Volume 
applied to skin 
Molecular biology 
technique 
PRE 0.1 mg mL-1 in 
Phthalate buffer 
pH 4.5 
1 mL 
1 mL 
ICC 
Western Blotting 
ZnSO4 0.1 M in Phthalate 
buffer pH 4.5 
1 mL 
1 mL 
ICC 
Western Blotting 
PRE + ZnSO4 PRE 0.1 mg mL-1, 
ZnSO4 0.1 M, 
Phthalate buffer 
pH 4.5 
1 mL 
1 mL 
ICC 
Western Blotting 
Control Phthalate buffer 
pH 4.5 
1 mL 
1 mL 
ICC 
Western blotting 
Table 7-1 Test solutions, applied volume and molecular biology (MB) techniques employed. 
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7.2.2.2. Ex vivo Porcine Skin Preparation 
Ex vivo porcine skin membranes used for western blotting and ICC were prepared 
and used in a Franz diffusion cell following the approach outlined in Chapter 2 
sections 2.2.2. and 2.2.3. respectively. However, in this case the Franz diffusion cells 
were not occluded and Hanks buffer was used as the receptor phase. 
7.2.2.3. Immunocytochemistry (IHC) 
Table 7-1 describes the concentrations and volumes of PRE, ZNSO4 and their 
combination applied to the ex vivo skin. The full methodology for (IHC) is described 
in Chapter 2 section 2.2.4.5. 
7.2.2.4. PAGE and Western Blot Analysis 
The methodology for sample preparation of skin lysates, protein estimation and 
denaturation, PAGE and western blot analysis is given in Chapter 2 section 2.2.4.4. 
7.2.2.5. Data Analysis 
The Western blot bands were scanned and analysed using a densitometer (GS-690 
Imaging Densitometer, Bio-Rad Laboratories Ltd, Herts, UK) equipped with Alpha 
DigiDoc software. The data obtained was recorded and analysed using Excel 2007 
(Microsoft office, Microsoft Corp, Redmond, WA). Each experiment was performed 
in triplicate for each sample and the result expressed as the mean ± S.D. Statistical 
analysis was carried out with InStat for Macintosh, version 3.0 (GraphPad Software 
Inc, San Diego, CA). 
7.3. Results 
7.3.1. IHC Staining COX-2 
At time zero, within the control and all evaluated skin sections COX-2 was clearly 
observed, as shown by the dark brown staining (Figures 7-1 and 7-2). As expected, 
the initiation of the inflammatory metabolic pathway for COX-2 suggests substantial 
inflammation caused by the trauma inflicted during removal and dissection of the 
porcine ears. 
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At 6 h it is apparent that the degree of staining and thus the inflammation within the 
control is sustained, and after 24 h an increase of COX-2 expression is supported by 
the increase in the level (area) and darkness of the brown stain suggesting a sustained 
and increasing inflammatory response over the 24 h test period. Previous work has 
shown that after 24 h necrosis is initiated in such skin samples, making the 
determination of further time points impossible (Thomas, Davidson and Heard 
2007). 
In Chapter 6 it was shown that after 6 h of treatment with PRE and ZnSO4, 
punicalagin and zinc were both able to permeate the epidermis and dermis. Figure 7-
1 shows that after 6 h the permeation of PRE resulted in the obvious reduction of 
COX-2 expression. A similar reduction was observed after the application of PRE + 
ZnSO4 (Figure 7-2). The level of COX-2 expression, after application of PRE alone 
and in combination with ZnSO4, was further reduced over 24 h as shown by the 
lighter staining observed in Figures 6-1 and 6-2 at this time point.  
Application of ZnSO4 was found to have no effect on the level of COX-2 expression, 
as shown by Figure 7-2. The slight increase in the degree of staining after 24 h 
reflects that observed in the control. 
Overall, ICC analysis has demonstrated qualitatively that the topical application of 
PRE (with and without ZnSO4) reduced COX-2 expression, which implies a 
reduction in the inflammatory response of the ex vivo skin. The application of ZnSO4 
appeared to have no effect on the expression of COX-2. In summary, these data 
represent a qualitative examination of COX-2 mediation after the topical application 
of ZnSO4 and PRE alone and in combination. 
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Control 0h Control 6h Control 24h 
   
PRE 0h PRE 6h PRE 24h 
   
Figure 7-1 COX-2 IHC staining at 0h, 6h, and 24h after the topical application of Control (phthalate buffer pH 4.5) and PRE (1 mg mL
-1
) (40x 
magnification). 
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PRE + ZnSO4  0h PRE + ZnSO4  6h PRE + ZnSO4  24h 
   
ZnSO4 0h ZnSO4 6h ZnSO4 24h 
 
 
 
Figure 7-2 COX-2 IHC staining at 0h, 6h, and 24h after the topical application of PRE (1 mg mL
-1
) + ZnSO4 (1 M) and ZnSO4 (1 M) (40x 
magnification).
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7.3.2. Western Blotting 
To further verify and to quantify the qualitative results observed from the IHC COX-
2 expression shown above, Western blot analysis was performed. The test materials, 
formulation and volume stated in Table 7-1 of PRE, PRE + ZNSO4, ZnSO4 and 
control were applied to ex vivo full thickness porcine skin within a Franz diffusion 
cell for 6 h. After this time SDS PAGE and western blotting was carried out for 
COX-2, as an inflammatory marker, and β-Actin, as the protein loading control.  The 
variation of COX-2 expression shown by ICC led to a 6 h time point being chosen 
for experimental comparisons.   
Figure 7-3 shows the bands produced by Western blot analysis for COX-2 expression 
at ~ 72 kDa and the protein loading control of β-actin at ~42 kDa. Densitometric 
measurements of the bands for COX-2 were normalised using β-actin; levels of 
COX-2 expression in the control were arbitrarily assigned a value of 100% and test 
solutions were shown as a percentage of the control and graphically displayed as a 
histogram in Figure 7-3. The application of PRE and PRE + ZnSO4 led to the 
statistically significant (p>0.01) reduction of COX-2 expression by 66.5 ± 3.6 % and 
64.5 ± 5.1 % respectively. Application of ZnSO4 had no statistically significant 
(p>0.05) effect on the level of COX-2 expression. Both results were in agreement 
with those obtained using ICC. The reduction of COX-2 by PRE was similar to that 
reported by (Adams, et al. 2006) who showed a COX-2 reduction of 79%, and the 
lack of COX-2 reduction by the application of ZnSO4 at this concentration has also 
been previously shown (Roselli, et al. 2003). 
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Figure 7-3 Analysis of COX-2 protein expression by Western blot. Full thickness porcine skin was 
treated with topical ZnSO4 (1 M), PRE (1mg mL
-1
), PRE (1mg mL
-1
) + ZnSO4 (1 M) and phthalate 
buffer as a control for 6 hr, protein was extracted and 30 µg was loaded and separated through SDS-
PAGE. The histogram represents COX-2 levels normalised against β-Actin. Levels in control were 
arbitrarily assigned a value of 100%. (n=3 ± S.D). 
7.4. Conclusion 
It is apparent that the topical application of PRE to full thickness ex vivo skin 
downregulates the expression of COX-2, which was highly significant after just 6 h 
and which is maintained up to 24 h. There appeared to be no effect following the 
application of ZnSO4 on the regulation of COX-2 over this time period. When PRE 
and ZnSO4 were applied in combination a statistically similar downregulation of 
COX-2 was observed when compared to the application of PRE alone.  
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As the level of COX-2 present within the skin is a recognised marker for 
inflammation, the overall conclusion was that the topical application of PRE alone or 
in combination with ZnSO4 had a substantial anti-inflammatory effect in ex vivo skin 
and that this may be beneficial in ameliorating the inflammation and pain associated 
with lesions caused by Herpes simplex virus.  
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Chapter 8 Separation and Analysis of 
Pomegranate Rind Extract Fractions 
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8.1. Introduction 
In Chapters 3 and 5 the virucidal activity of PRE against HSV-1 was established and 
attributed to punicalagin, and these results were comparable to findings described for 
virucidal activity of PRE with respect to HSV-2 (Zhang, et al. 1995). The virucidal 
activity of punicalagin has further been demonstrated against the Influenza virus 
(Haidari, et al. 2009). Fractionation and analysis of PRE could elucidate other 
virucidal fractions or confirm the hypothesis that the virucidal activity is solely due 
to that of punicalagin. 
Conversely, results in Chapter 5 showed that PRE possessed antiviral activity against 
HSV-1 and HSV-2 ACR, whereas punicalagin and ellagic acid possessed no 
observable activity. From this it was hypothesized that a complex interplay between 
the phytochemical constituents was responsible for the antiviral activity. An 
alternative is that a previously untested fraction of the PRE may have been 
responsible and if this hypothesis is correct then the fractionation of PRE could lead 
to the isolation of a new antiviral compound. 
Further, the COX-2 modulation results obtained by Western blotting and IHC in 
Chapter 7 indicated that the total extract reduced the inflammatory response in ex 
vivo skin. This may be related to the total polyphenolic content as stated previously 
(Adams, et al. 2006) (Aggarwal, et al. 2006) (Larrosa, et al. 2010).  Extracts found 
within PRE were shown to exhibit anti-inflammatory responses (Lee, et al. 2010).  
More than 120 phytochemicals have been identified in the juice, seed, peel and rind 
of Punica granatum (Seeram, Schulman and Herber 2006). Pomegranate rind 
contains a large proportion of polyphenols e.g. ellagic acid, gallotannins, 
anthocyanidins such as delphinidin, cyanidin and pelargonidin, proanthocyanadins 
and various flavonoids. Of specific interest are the hydrolysable tannins punicalin, 
pedunicalin, punicalagin as well as gallic and ellagic acid, esters of glucose 
(Slusarczyk, et al. 2009), of which punicalagin is the most abundant-constituting 80-
85% w/w of total Punica granatum tannins (Seeram, et al. 2005). For the PRE used 
in this study, punicalagin is approximately one fifth of the total dry weight (Chapter 
2 section 2.2.4.1.).  
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Bioactivities described for PRE and punicalagin, include antiproliferative, apoptotic, 
antiviral, anti-inflammatory and antibacterial (Seeram, Schulman and Herber 2006). 
The antibacterial activity of various pomegranate rind extracts has been attributed 
mainly to fractions extracted with acetone and methanol which contained high 
concentrations of punicalagin. The antibacterial effect was observed against both 
Gram-positive and Gram-negative bacteria, with complete growth inhibition of B. 
cereus, B. subtilis, B. coagulens, S. aureus, E. coli and P. aeruginosa shown at 300 
ppm (Negi and Jayaprakasha 2003). The reduction in COX-2 expression due to PRE 
has been shown by the inhibition of the TPA-mediated increase in COX-2 expression 
in a time dependant manner in vivo (Afaq, et al. 2005). The downregulation of COX-
2 has been attributed to the phenolic content, and some of the activity observed was 
assigned to punicalagin, however PRE as a whole entity (i.e. without fractionation) 
resulted in the greatest anti-inflammatory activity (Adams, et al. 2006). Fractionation 
has also revealed some phytochemicals present in PRE that have HSV, HIV or 
influenza antiviral effects, these include casuarinin, gallic acid, methyl gallate, and 
punicalin (Satomi, et al. 1993) (Wang, et al. 2010). It has also been shown that 
pomegranate extracts which remain as a whole entity are antiviral against a range of 
enveloped virus; HIV, H5N1, HBV, HCV and HSV (Kotwal 2008)  (Sundararajan, et 
al. 2010). 
A greater understanding of the occasionally contradictory data relating to the activity 
of PRE and components in general may be obtained by isolating individual fractions 
of PRE and subjecting them to virucidal, antiviral and COX-2 modulation testing. 
8.2. Objective and Aims 
To gain further insight into the phytochemical basis of the virucidal, antiviral and 
COX-2 modulation activities observed in Chapters 5 and 7, through examination of a 
range of chromatographically-isolated PRE fractions. 
i. To obtain chromatographically separated fractions of PRE 
ii. To determine the cytotoxicity of fractions, in comparison to data obtained in 5.3.2. 
iii. To determine differences in virucidal activity of each fraction against HSV-1 in 
comparison to data obtained in 5.3.3.1. and 5.3.3.4. 
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iv. To determine differences in antiviral activity of each fraction against HSV-1 in 
comparison to data obtained in 5.3.3.5. 
v. To determine differences in COX-2 expression in ex vivo skin dosed with each 
fraction in comparison with the results obtained in Chapter 7 
8.3. Materials and Methods 
8.3.1. Materials 
The materials used are given in Chapter 2 section 2.1. 
8.3.2. Methods 
The general methodology for the preparation of solutions, buffers and extracts are 
given in Chapter 2 section 2.2.1. unless otherwise stated. 
8.3.2.1. Fractionation of PRE 
The chromatographic separation of compounds within PRE must follow a logical and 
structured method. The methodology used to fraction PRE into bands separating total 
pomegranate tannins (TPT) from the remainder of the extract, a tannin devoid 
fraction (TDF), used an Amberlite XAD16 stationary phase and followed the method 
summarised in Chapter 2 section 2.2.6. 
8.3.2.2. Fractionation of Total Pomegranate Tannins (TPT) 
Further fractionation of the TPT collected via Amberlite XAD 16 stationary phase 
was achieved using the method reported by Seeram, et al. (2005) involving a 
Sephadex LH-20 stationary phase, and is detailed in Chapter 2 section 2.2.6.; 
biological activity was assessed on three of the 9 fractions: 
 Fraction 1 containing a small number of tannins including delphinidin 3-
glucoside, cyanidin 3-glucoside  
 Fraction 2 containing the tannins found in fraction one with the inclusion of 
ellagic acid and a number of unidentified tannins 
 Fraction 9 predominantly comprising of the anomers punicalagin α and β  
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8.3.3. Cytotoxicity 
Followed the Cell Titre 96® AQueous method described in Chapter 2 section 
2.2.5.7. With the application of Fraction 1, 2, 9, TPT and TDF as described in Table 
8-1. 
8.3.4. Virucidal Plaque Reduction Assay 
HSV-1was incubated, according to the methods in Chapter 2 section 2.2.5.9., with 
test solutions of TPT, TDF and Fractions 1, 2, and 9 as shown in Table 8-1 prior to 
application on vero cells. 
8.3.5. Antiviral Plaque Assay 
The methodology was the same as that described in Chapter 2 section 2.2.5.10. Vero 
cells were incubated with the test solutions listed in Table 8-1 being TPT, TDF and 
Fractions 1, 2, and 9 before application of the HSV-1 virus. 
8.3.6. PAGE and Western Blot Analysis. 
The analysis of COX-2 expression after the application of TPT, TDF and Fractions 1, 
2 and 9 to full thickness porcine skin followed that outlined in Chapter 2 section 
2.2.4.4. The data shown in Chapter 7 for PRE was used as a comparison. 
8.3.6.1. Test materials 
Table 8-1 shows the test fractions, its composition, application volume and analysis 
method used within this chapter. 
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Test 
Material 
Composition Analysis method 
TDF TDF 0.01 mg mL-1, phthalate buffer 
pH 4.5 
Virucidal Plaque 
reduction assay 
TDF 100 µg mL-1, phthalate buffer 
pH4.5 (first dilution) 
Antiviral plaque assay 
TDF 1mg mL-1, phthalate buffer pH 
4.5 
PAGE Western Blot 
TPT (Total 
Pomegrana
te Tannin) 
TPT 1mg mL-1, phthalate buffer pH 4.5 Cytotoxicity 
TPT 0.01 mg mL-1, phthalate buffer pH 
4.5 
Virucidal Plaque 
reduction assay 
TPT 100 µg mL-1, phthalate buffer pH 
4.5 (first dilution) 
Antiviral plaque assay 
TPT 1mg mL-1, phthalate buffer pH 4.5 PAGE Western Blot 
Fraction 1 Fraction 1, 1mg mL-1, phthalate buffer 
pH 4.5 
Cytotoxicity 
Fraction 1, 0.01 mg mL-1, phthalate 
buffer pH 4.5 
Virucidal Plaque 
reduction assay 
Fraction 1, 100 µg mL-1, phthalate 
buffer pH 4.5 (first dilution) 
Antiviral plaque assay 
Fraction 1, 1mg mL-1, phthalate buffer 
pH 4.5 
PAGE Western Blot 
Fraction 2 Fraction 2, 1mg mL-1, phthalate buffer 
pH 4.5 
Cytotoxicity 
Fraction 2, 0.01 mg mL-1, phthalate 
buffer pH 4.5 
Virucidal Plaque 
reduction assay 
Fraction 2, 100 µg mL-1, phthalate 
buffer pH4.5 (first dilution) 
Antiviral plaque assay 
Fraction 2, 1mg mL-1, phthalate buffer 
pH 4.5 
PAGE Western Blot 
Fraction 9 Fraction 9, 1mg mL-1, phthalate buffer 
pH 4.5 
Cytotoxicity 
Fraction 9, 0.01 mg mL-1, phthalate 
buffer pH 4.5 
Virucidal Plaque 
reduction assay 
Fraction 9, 100 µg mL-1, phthalate 
buffer pH4.5 (first dilution) 
Antiviral plaque assay 
Fraction 9, 1mg mL-1, phthalate buffer 
pH 4.5 
PAGE Western Blot 
Table 8-1 Test solutions and biological analyses carried out: a tannin devoid fraction, TPT, Fraction 1, 
Fraction 2 and Fraction 9. 
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8.4.  Results 
8.4.1. PRE Fractionation 
8.4.1.1. Separating the Total Pomegranate Tannins (TPT) and a Tannin 
Devoid Fraction (TDF)  
The fractionation of 5 g PRE (dry weight) via an Amberlite XAD 16 packed column 
to refine the extract into TPT (freeze dried yield 1.3 g, 26%) and TDF (freeze dried 
yield 3.4 g, 68%).  The product red crystals of TPT are shown in Figure 8-3 and 
HPLC analysis of the TPT fraction provided the chromatogram in Figure 8-1.  It can 
be determined that this fraction contained 1.09 g of punicalagin (84% of the TPT 
fraction), and 0.009 g of ellagic acid (0.69%). These findings are in accordance with 
the literature which states that punicalagin was equivalent to 80-85% and ellagic acid 
1.3% of the total pomegranate tannin content (Seeram, et al. 2005). There was no 
presence of tannins within the TDF fraction as shown by the lack of any peaks within 
chromatogram (Figure 8-2).   
 
 
 
Figure 8-1HPLC chromatogram of the tannin devoid fraction (TDF) collected after XAD 16 column 
fractionation of PRE. Note: absence of ellagitannins. 
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Figure 8-3 Crystals of TPT isolated and collected after column fractionation. 
8.4.1.2. Separating the TPT Fraction 
A mass of 500 mg TPT was fractionated using MeOH:H20 elution through a 
Sephadex LH-20 packed column, resulting in a total yield of 492 mg separated into 9 
fractions. The HPLC chromatographic analysis of each fraction is shown in Figures 
8-4 and 8-5. The fractions were dried under vacuum and the total mass of 
punicalagin, ellagic acid and the remaining unidentified tannins in each sample 
determined and shown in Table 8-2. The fractions, 1-8, were collected sequentially 
after each hour of elution, fraction 9 was created by the pooling of the final 3 h of 
elution, ensuring the full recovery of tannins. The solvent gradient timetable, the 
collection of fractions and the removal of eluting solvents is given in more detail in 
Chapter 2 sections 2.2.6.2. and 2.2.6.2.1.  
Figure 8-2HPLC chromatogram of the total pomegranate tannin (TPT) fraction collected after 
XAD 16 column fractionation of PRE. 
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Figure 8-4 HPLC chromatograms of fractionated TPT from PRE through a Sephadex LH-20 column. Fractions taken at 1 h time points following the methods in 
2.2.6.2.: Fraction 1-6. 
Punicalagin α 
Punicalagin β 
Punicalagin β 
Punicalagin α 
Fraction 1 Fraction 2 
Fraction 6 
Fraction 5 
Fraction 4 Fraction 3 
Punicalagin β 
Punicalagin α 
Fraction 5 
Punicalagin α 
Punicalagin β 
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Figure 8-5 HPLC chromatograms of fractionated total pomegranate tannin from PRE through a sephedex LH-20 column. Fractions 7 and 8 taken at 1 h time points and 
fraction 9 the combination of 3, 1h, time points following the methods in 2.2.6.2.: Fractions 7-9. 
 
 
Fraction Punicalagin 
(mg) 
Ellagic 
acid 
(mg) 
Unidentified 
Tannins 
(mg) 
Total 
mass 
(mg) 
1 0 0 13.47 13.47 
2 0 0.97 21.61 22.58 
3 1.76 0.02 17.08 18.86 
4 79.86 0 12.06 91.92 
5 17.86 2.01 5.42 25.29 
6 80.72 0 0.90 81.62 
7 109.58 0 0.72 110.30 
8 62.12 0 0.36 62.48 
9 65.30 0 0.18 65.48 
Total 417.2 3 74.5 492 
 
Table 8-2 The specific levels of punicalagin, ellagic acid and unidentified 
tannins within each fraction (1-9) of TPT within PRE after sephedex LH-20 
fractionation. 
 
Punicalagin α 
Punicalagin β 
Punicalagin β 
Punicalagin β 
Punicalagin α 
Punicalagin α 
Fraction 9 
Fraction 8 
Fraction 7 
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The fractionation of PRE into the TPT and TDF fractions via an Amberlite XAD 16 
column was successful, as was the further separation of TPT into three fractions, one 
containing a high concentration of punicalagin using the Sephadex LH-20 column. 
The results can be summarised as follows: 
Fraction 1 contained no punicalagin and comprised solely of other ellagitannins, 
which remain unidentified in this project; however, comparison to HPLC 
chromatograms within the literature suggest this fraction probably contained 
delphinidin 3-glucoside, cyanidin 3-glucoside (Gil, et al. 2000) (Seeram, Schulman 
and Herber 2006).  
Fraction 2 contained a similar mixture of unknown compounds as that of fraction 1, 
with the inclusion of ellagic acid at 4.2% of the fraction. From the literature, 
galloylglucose and gallic acid were also likely to be present (Gil, et al. 2000); 
(Reddy, et al. 2007); (Seeram, et al. 2005).  
Fraction 3 contained a very small amount of ellagic acid 0.1% and punicalagin (9%) 
with a similar mixture of tannins found in fraction 2 at a lower concentration.  
Fraction 4 was comprised of all the tannins present within PRE as was fraction 5 this 
was however at much lower concentration.  
Fractions 6, 7, 8, and 9 were comprised almost entirely of punicalagin, with fraction 
9 containing the purest sample.  
Fractions 1, 2, and 9 were chosen as test fractions to assess the biological activity as 
they contained between them all of the tannins within PRE at different 
concentrations, with fractions 1 and 2 not containing punicalagin and fraction 9 
comprised almost entirely of punicalagin. 
8.4.2. Cytotoxicity  
The results of the Cell Titer 96 AQueous assay cytotoxicity tests for TPT, fractions 
1, 2 and 9 at 0.1 mg mL
-1
 are shown in Figure 8-6. All fractions were prepared in 
phthalate buffer at pH 4.5 and demonstrated no cytotoxicity over the 72 h period (p > 
0.05). This accorded with the lack of cytotoxicity exhibited by PRE, punicalagin and 
phthalate buffer at 0.01 mg mL
-1 
previously discussed in Chapter 5.  
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The data also suggests another important outcome. By isolating various compounds 
from the overall mix, it is conceivable that one fraction might have demonstrated 
greater cytotoxicity relative to another and the whole extract. Clearly this is not the 
case and suggests that variations in phytochemical levels, as in batch-to-batch 
variability, may not result in variable cytotoxicity. 
 
Figure 8-6 Cell Titre 96® AQueous assay cytotoxic evaluation of TPT and fractions 1, 2, and 9 at 0.1 
mg mL
-1
, in phthalate buffer at pH4.5, and expressed as the viable cell percentage of the control (n=3 
± SD). 
8.4.3. HSV-1 Virucidal Activity 
The log reduction of HSV-1 arising from the incubation with fractionated portions of 
PRE: (TPT, TDF and Fractions 1, 2 and 9) is shown in figure 8-7. The TDF fraction 
and fractions 1 and 2 exhibited a virucidal action that was not statistically different 
from the phthalate buffer in which they were dissolved (p>0.05). The TPT fraction 
and fraction 9 caused a logarithmic reduction of HSV-1 at 1.89 ± 0.12 pfu and 2.23 ± 
0.22 pfu respectively. The observed log reduction can be attributed to the punicalagin 
content found within the fractions as it is of a similar order to that of punicalagin 
shown in Chapter 5 of 2.4 ± 0.96 pfu.  
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Figure 8-7 The log reduction of HSV-1 after incubation with the pomegranate fractions: TDF, TPT, 
Fraction 1, Fraction 2 and Fraction 9 at 0.01mg mL
-1
, pH 4.5 (n=3 ± s.d.). 
 
The two fractions containing punicalagin, TPT (as a component) and Fraction 9 
(pure), were the only fractions that exhibited virucidal activity. This provides further 
evidence that the virucidal activity of PRE is determined by the punicalagin content. 
8.4.4. HSV-1 Antiviral activity 
The antiviral analyses of TPT, TDF and fractions 1, 2 and 9 are shown in Table 8-3. 
 
 
 
 
 
 
   
151 
 
Table 8-3 Antiviral IC50 against HSV for the fractions of PRE: TPT, TDF, Fraction 1, Fraction 2 and 
Fraction 3 (n=3 ± s.d.). 
The only fraction that showed antiviral activity was TPT, with an IC50 of 5.48 ± 0.34 
µg mL
-1
. In Chapter 5 it was found that PRE produced an IC50 of 0.556 ± 0.039 µg 
mL
-1
. Therefore, although TPT activity was considerable the IC50 was significantly 
higher than that of PRE (p < 0.05): i.e. TPT has significantly less antiviral activity 
than PRE.  
It is therefore reasonable to attribute the antiviral activity to the combined tannins 
within PRE; the removal of the TDF and further fractionation resulted in a 
significant loss of antiviral activity. This result is similar to that shown by Li et al. 
(2004), who stated that a pomegranate extract devoid of polyphenols did not exhibit 
antiviral activity and that fractionation led to a decrease in overall antiviral activity.  
8.4.5. COX-2 Modulation and Anti-inflammatory Activity  
As observed in Chapter 7, COX-2 is significantly downregulated following the 
application of PRE to full thickness porcine skin ex vivo by approximately 66%. In 
this part of the work, TPT, TDF, fractions 1, 2, and 9 were applied to skin in a 
similar manner and Figure 8-8 is representative of the bands produced by Western 
blot analysis for COX-2 expression at ~ 72 kDa with the protein loading control of β-
actin at ~42 kDa. Densitometric results of the bands for COX-2 were normalised 
using β-actin, levels of COX-2 expression in the control were arbitrarily assigned a 
value of 100%, test solutions were shown as a percentage of the control and 
graphically displayed as a histogram in Figure 8-8  
Compound Virus IC50 
TPT HSV-1 5.48 ± 0.34 µg mL
-1 
TDF HSV-1 >100 µg mL
-1
 
Fraction 1 HSV-1 >100 µg mL
-1
 
Fraction 2 HSV-1 >100 µg mL
-1
 
Fraction 9 HSV-1 >100 µg mL
-1
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Figure 8-8 Analysis of COX-2 protein expression by Western blot. Full thickness porcine skin was 
treated with topical TPT 1mg mL
-1
, TDF 1mg mL
-1
, Fraction 1 1mg mL-
-1
, Fraction 2 1 mg mL
-1
and 
Fraction 9 1 mg mL
-1 
and phthalate buffer as a control for 6 h. Protein was extracted and 30 µg was 
loaded and separated through SDS-PAGE. The histogram represents numerical data of COX-2 
normalised against β-actin. Levels in the control were arbitrarily assigned a value of 100%. (n=3 ± 
SD) 
COX-2 expression was only modulated after the application of TPT and fraction 9 
with a decrease of 40.5 ± 4.6% and 22.7 ± 1.4%  respectively (p<0.05). The 
application of the TDF and fractions 1 and 2 did not significantly alter the level of 
COX-2 within the samples in comparison to the control (p>0.05). These results are 
similar to those stated by Adams et al (2006), who showed COX-2 reduction of 55% 
and 48% after incubation of HT-29 Human colon cancer cells with TPT and 
punicalagin. The reduction in COX-2 expression is greatest when PRE remained as a 
whole extract, with TPT and punicalagin exhibiting anti-inflammatory activity, 
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although to a lesser extent - this is again similar to the findings by Adams et al 
(2006).  
8.5. Conclusion 
None of the fractions analysed exhibited toxic effects on Vero cells at 0.1mg mL
-1
. 
The HSV-1 virucidal activity was due to the polyphenolic content within PRE, and 
can be attributed to punicalagin, as the presence of punicalagin is directly associated 
with virucidal activity. The antiviral activity of PRE can be attributed to the phenolic 
content as antiviral activity was observed for the TPT fraction but not for TDF. 
However, the antiviral activity of PRE is much greater than that of TPT and none of 
the TPT fractions exhibited any antiviral activity at concentrations less than 100 µg 
mL
-1
.  
Modulation of the inflammatory marker COX-2 showed that the downregulation of 
COX-2 by PRE was due to the tannins present within PRE, and a portion of this 
activity can be attributed to punicalagin. In agreement with the findings of Adams et 
al (2006) the downregulation of COX-2 is greatest when PRE remains as a whole 
entity with a reduction in downregulation due to fractionation. 
Overall, biological activity was undoubtedly compromised or lost as a result of 
fractionation. This data supports the notion that separation of individual constituents 
from the PRE extract may decrease overall activity due to unanticipated and 
unidentified interplay between components. 
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Chapter 9 Formulation and 
Characterisation of a Prototype 
Hydrogel Product Containing PRE 
and Zinc Sulphate 
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9.1. Introduction  
Chapter 6 demonstrated that a simple solution of PRE and ZnSO4 enabled the 
penetration of both punicalagin and Zn
2+
 across freshly excised skin at levels that 
fulfilled 2 major criteria in the development of a medicinal product: 
1. to give high antiviral and virucidal activity against HSV;  
2.  to confer an anti-inflammatory effect.  
In order to facilitate the development of a viable product to treat HSV-induced 
lesions, PRE and ZnSO4 must be formulated into a form appropriate for topical 
delivery. A number of different dosage forms are commercially available for treating 
lesions, for example: the well established Zovirax (Aciclovir) and its generics, are 
creams; Cymex (Urea, cetrimide) is a cream; Dynamiclear is a liquid containing 
plant extracts; and Compeed Cold Sore Patch is a hydrocolloid adhesive disc.  
Creams are generally well accepted, but may leave an unsightly white residue; liquid 
formulations lack the viscosity that is often needed to retain the actives at the site of 
application. Although transparent, a hydrocolloid patch applied to a curved moist 
surface can cause adhesion problems, and users will be conscious of the attachment 
of a device.  
 
 
Figure 9-1 Four commercial products currently available for treating cold sores. 
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In this project it was considered desirable to concentrate on the development of a 
hydrogel formulation. Not only would this make any product dissimilar to current 
products, but there are sound reasons based upon biocompatibility (Hoffman 
2001)(Li, et al. 2011) that would make preferable a PRE and ZnSO4 formulation 
within a hydrogel matrix. Hydrogels are colourless and commonly used throughout 
the pharmaceutical industry for application of drugs and products to various 
membranes, including epidermal, vaginal, anogenital, oral and ophthalmic (Gulsen 
and Chauhan 2004); they are also digestible and used readily in the food industry 
(Guo, Zhank and Yang 2012). No complications would be expected to arise from the 
use of the hydrogel to treat herpetic lesions within the oral cavity. For comparison 
purposes, two emulsion formulations were also examined in this work. 
Formulation science is a very broad area of research (Osborne and Amann 1990) and 
a comprehensive study was beyond the scope of this thesis. However, in this chapter 
we investigated some commonly used excipients to derive a simple prototype 
formulation, suitable for further study. In the design of a topically-applied 
formulation the ability to deliver both zinc and punicalagin within the enhanced 
virucidal ratio (Chapter 3) is of key importance. Furthermore, the formulation must 
also be stable and of appropriate rheological properties. Other important 
considerations include aesthetical and tactile acceptability. The formulation should 
therefore be of a neutral colour, have a smooth feeling whilst being applied to the 
skin, and should leave minimal residue after application. Given these parameters it 
was considered that a hydrogel was the most appropriate type of formulation.  
9.1.1. Formulations 
9.1.1.1. Colloidal Hydrogels 
Hydrogels are a type of colloid, where one substance is microscopically dispersed 
evenly throughout another. A colloid system consists of two phases: an internal 
phase (the gel matrix) and the continuous phase (water).  The use of cross-linked 
polymers as hydrogels for the topical delivery of drugs was hypothesised in the 
1960s (Wichterle and Lim 1960). Hydrogels are generally defined as three-
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dimensional polymeric networks containing a high proportion of water when the gel 
is in the swollen state (Rosiak, et al. 2002) (Hamidi, Azadi and Rafiei 2008). They 
are often classified into two groups based upon bonding: reversible gels consist of 
networks that have transient junctions consisting of molecular entanglements, 
including ionic, H-bonding or hydrophobic forces; permanent gels form covalently 
cross-linked networks with permanent junctions (Murray and Snowden 1995) 
(Hoffman 2001).  
Hydrogels have many non-biological uses within agriculture and the oil industry. 
The biological compatibility of hydrogels used in medical and pharmaceutical 
research and commercial application has satisfied the properties needed in soft 
contact lenses, wound dressings and drug-delivery systems. Gels can present several 
advantages over other vaginal drug delivery systems, as in anogenital herpes 
infections, such as higher bioavailability, safety, versatility, and economic savings 
(Justin-Temu, et al. 2004).  
9.1.2. Emulsions 
Emulsions are mixtures of two or more immiscible liquids; for the purpose of this 
research only simple oil in water (O/W) systems were investigated, however more 
complex O/W/O, W/O/W and gel emulsions exist. Emulsions have a long history as 
topical drug delivery vehicles, however, they tend to leave an oily residue after 
application and do not have the same range of oral and vaginal application which 
hydrogels possess.  
9.1.2.1. Formulation Considerations 
While good biocompatibility is a justification for a hydrogel formulation it is 
important to note, however, that there are several hydrogel polymers which cannot 
form a colloid gel in the presence of zinc salts. For example, carrageenan a typical 
hydrogel internal phase is unsuitable for the topical delivery of ZnSO4 (Zn
2+
 ions), 
because this material naturally binds with Zn
2+
, the ion establishing a cross-link 
between the carrageenan polymer chains (Brown and Setloff 1982). Zinc 
concentration will have a specific effect on the rheology of the gel, since the 
concentration of Zn
2+
 is proportional to the viscosity of carrageenan in solution 
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(Keegan, et al. 2007). The formulation of a hydrogel as the carrier for the topical 
application of PRE and zinc was preferred; however the investigation also assessed a 
selection of possible emulsion formulations. 
Once a prototype formulation had been identified, it was important to characterize it 
and, in topical products, this typically involves four major considerations:  
1. Aesthetic properties.  
2. Spontaneous diffusional active release. 
3. Rheological properties.  
4. Stability. 
9.1.3. Aesthetic Properties 
The aesthetic properties of a pharmaceutical product are of vital importance in 
formulation science. Typical properties include an assessment of: 
 Appearance – homogeneity, colour, lustre, clarity 
 Feel – smoothness, grittiness, lumpiness, oiliness 
 Smell – odour, strength of odour, use of odourants/deodourants 
Failure in any one of the above may be sufficient to deter a patient from purchasing 
or using the product (Chadwar and Shaji 2007). Appearance can be determined from 
examination by eye, or spectrophotometrically. The feel of a formulation can be 
assessed (e.g. for lumpiness or grittiness) by rubbing between thumb and fingers, 
although a more scientific approach would involve instruments such as a texture 
analyser. The smell or taste of a product may appear simple to determine, although 
an expert panel may be required to discern subtle differences (Buhler 2001). 
9.1.4. Rheological Properties 
Rheology can be used to study the flow characteristics of topical formulations. Drug 
delivery from formulations is determined in part by its viscosity and ability to bind to 
drug molecules (Gallagher and Heard 2005) . The viscosity of a fluid may be 
described simply as its resistance to flow or movement. Semisolid, eg. gel, 
formulations can be difficult to characterize and compare rheologically, as they tend 
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to demonstrate non-Newtonian flow. Figure 6.2 shows typical rheograms or flow 
curves produced by materials that exhibit Newtonian, and non-Newtonian behaviour. 
 
 
Figure 9-2 Flow curves illustrating typical Newtonian, plastic, pseudoplastic and dilatant flow (Barry 
1983). 
9.1.4.1. Newtonian Flow 
A Newtonian material is one where the relationship between shear rate () and shear 
stress () is linear, and where the gradient is the viscosity (). Simple liquids such as 
water and propylene glycol exhibit Newtonian flow. 
9.1.4.2. Non-Newtonian Flow 
Non-Newtonian flow can be of several different categories: 
Plastic (Bingham flow) 
The material flows readily, provided that shear stress is high enough, although below 
a critical value - the yield stress (y) - the material will not flow. At lower stresses 
the substance behaves as a solid or elastic material. The rheogram plot is generally 
linear, but extrapolation of the linear portion intersects the shear stress axis at the 
yield value instead of passing through zero.   
Pseudoplastic Flow (shear thinning)  
The rheogram for a pseudoplastic material begins at the origin and has no yield 
value, unlike the case with plastic materials. When a shear stress is applied to the 
material the gradient of the curve gradually decreases with an increasing rate of 
shear, with no single characteristic value of viscosity observed. Typically, apparent 
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viscosity data are quoted, in conjunction with the specific shear rate at which the 
determination was made. Dermatological preparations that typically exhibit 
pseudoplastic behaviour include natural and synthetic gums. 
Dilatant Flow (shear-thickening) 
Materials exhibiting dilatant flow properties, produce flow curves opposite to 
pseudoplastic flow, thus as the rate of shear increases the resistance to flow also 
increases. There is a corresponding increase in viscosity with increased rate of shear. 
Suspensions that contain greater than 50% v/v of deflocculated particles typically 
exhibit dilatant flow, however this type of behaviour is less common than 
pseudoplastic and plastic flow.  
Time Dependent Effects – Continuous Shear 
Once the shear stress has been removed, the material may not return to its original 
rheological ground state instantly. A common feature of these materials, in response 
to increased shear rate followed by decreased shear rate to zero, is the formation of a 
hysteresis loop consisting of an up-curve and a down-curve see Figure 9-3. The 
hysteresis loop is an indication that a breakdown in the structure has occurred, with 
the area of the loop generally indicative of the extent of this breakdown.  This effect 
is an isothermal and comparatively slow recovery, on standing of a material, of a 
consistency lost through shearing. Such thixotropy is temperature dependent and can 
be exhibited by plastic, pseudoplastic and dilatant materials. 
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Figure 9-3 Hysteresis loops and different types of thixotropic behaviour  (Barnes, Hutton and Walters 
1989). 
9.1.5. Cone and Plate Rheometer  
Rheological measurement of materials generally falls into four main categories: 
Capillary, Rolling or Falling Sphere, Coaxial and Cone & Plate. The work in this 
chapter involved using a Bohlin Cone and Plate Rheometer, which operates by 
shearing the test material between a small angled cone and a flat circular plate 
(Figure 9-4). Provided the angle is small (< 4 degrees) the shear rate is essentially 
uniform throughout the sample. 
 
.  
Figure 9-4 Cone and Plate Rheometer (Staniforth 2002). 
r (m) 
 (rad/s) 
α (radians) 
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Where  is the angular velocity of the plate, r is the radius of the cone and α is the 
angle between the cone and plate. 
 
A sample of the test material is placed onto the centre of the temperature controlled 
plate and the cone is lowered so the tip just touches the plate. Typically, the lower 
plate remains stationary and the upper cone is rotated at a constant speed, with a 
torque sensor measuring the developed shear stress. Alternatively the cone can be 
rotated at a constant stress with the shear rate being measured.  
 
Provided the angle is small, viscosity is calculated by: 
 
 = 3 T / 2 r3 α  (Units of Pa s) Equation 5.1 
 
where  is the angular velocity of the plate, T is the torque, r is the radius of the cone 
and α is the angle between the cone and plate (Barnes, Hutton and Walters 1989) 
(Figure 5.3). 
 
The shear rate is calculated by: 
 
 = /α    (Units of 1s-1) Equation 5.2 
 
And shear stress calculated by:  
 
α = 3 M / 2  r3   (Units of Pa)  Equation 5.3 
 
Where M = Spindle torque. 
      
9.1.6. Spontaneous Diffusional Release 
Spontaneous diffusional release can be defined as the tendency of a molecule to 
dissociate from the bulk of the other excipients within the applied formulation (Wu 
and Zhou 1999). However, whether release is independent of the solvent is unclear 
(Aggarwal 2009). It is governed by affinity of attraction for other compounds, for 
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example Cabosil M5 has been shown to retard release due to binding events between 
a drug and the silica particles (Gallagher and Heard 2005). The most common way to 
determine release is to apply the formulation to a minimal resistance barrier 
membrane mounted in a Franz diffusion cell (Jeans and Heard 1999)(Kros, et al. 
2001). The active or active/solvent complex spontaneously exits the formulation 
passing through the minimal resistance membrane to arrive in the receptor phase, 
which is then analysed. The information gained can be considered as the maximal 
amount of active that can be delivered from a given formulation. It is thus highly 
important that the release membrane used offers minimal resistance to diffusion. 
9.1.7.  Stability 
Stability determinations are an indispensable element in the pre-clinical evaluation of 
a product. Before a drug product is submitted for regulatory approval, ICH stability 
testing helps demonstrate it will continue to be safe and efficacious for its stated 
shelf life. Real-time ICH stability testing is conducted at room temperatures to 
reproduce actual storage conditions. Launched in 1990, ICH is a unique undertaking 
that brings together the drug regulatory authorities and the pharmaceutical industry 
of Europe, Japan and the United States. Harmonisation is achieved through the 
development of ICH Tripartite Guidelines. Document Q1A (R2) Stability Testing of 
New Drug Substances and Products (Food and Drug Administration 2009) sets out 
requirements including temperature, humidity and trial duration. 
Over a pre-determined time frame simple laboratory determination can indicate 
whether: 1. The levels of active remain essentially unchanged and 2. Whether the 
pharmacological or microbiological activity remains essentially unchanged. 
9.1.8.  Objective and Aims 
To identify and characterise a simple prototype formulation, suitable for further 
study. 
1. Evaluate a range of commonly used excipients in order to derive a suitable 
prototype 
2. Characterise the prototype gel in terms of spontaneous diffusional release 
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3. Characterise the prototype gel in terms of its macroscopic properties 
4. Characterise the prototype gel in terms of its rheological properties 
5. Determine the chemical and microbiological stability of the prototype formulation 
9.2. Materials and Methods 
9.2.1.  Materials 
The materials used within this chapter are listed in Chapter 2 section 2.1. 
9.2.2. Formulation of PRE and ZnSO4 Solutions. 
The formulation of PRE and ZnSO4 solutions follows the methods described in 
Chapter 2. The stock solutions of 2 M ZnSO4 and PRE 2 mg mL
-1
 were diluted in DI 
H2O to the concentrations required. 
9.2.2.1. Emulsion 1  
Oleaginous phase and aqueous phases shown in Table 9-1 were heated to 65°C 
separately in a water bath. Once dissolved, the oleaginous phase was slowly added to 
the aqueous phase with constant agitation. When the formulation reached 50°C it 
was homogenised using the homogeniser RW 20 DZM (IKA Works, Asia) for 60s 
and cooled with continuous stirring until the emulsion turns viscous and reaches 
room temperature. The emulsion is then cooled to 4°C and stored occluded from 
light until further use (maximum 24 h).  
An example preparation of Emulsion 1 with the final concentration of PRE               
5 mg mL
-1
 and ZnSO4 0.5 M follows the procedure described above. PRE 500 mg 
and ZnSO4 28.75 g were diluted in 100 mL of DI H2O before the addition of the 
other aqueous phase constituents. The aqueous phase including PRE and ZnSO4 was 
heated to 65°C, after which the addition of the oleaginous phase was slowly added 
with constant agitation. 
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Oleaginous phase Percentage composition 
Stearic acid 13 
Stearyl alcohol 1 
Cetyl alcohol 1 
Aqueous phase 
Glycerine 10 
Methylparaben 0.1 
Propylparaben 0.05 
Potassium hydroxide 0.9 
DI H2O 100 
Table 9-1 The formulation concentration for Emulsion 1. 
9.2.2.2. Emulsion 2  
The formulation of Emulsion 2 followed that described in Brown and Setloff (1982) 
a topical emulsion containing zinc. Lauric acid 11 mg, paraffin wax 3.0 mg, 
polyethylene glycol (100) stearate 6 mg, polyethylene glycol sorbitan beeswax 4mg 
was heated to 65°C.  Separately water 77 ml was also heated to 65°C. The aqueous 
phase was slowly added to the oleaginous phase with constant agitation until a thick 
emulsion was formed. This was left to cool over night to 4°C. ZnSO4 0.01M and 
PRE 0.1 mg ml
-1 
were added to the aqueous phase before heating. 
9.2.2.3. Preparation of Aqueous Polymer Dispersions and PRE, Zinc Ion 
Solutions  
9.2.2.4.    
Hydrogel 1: Carbopol 971 P (C971P) 
-Carbopol 971 PNF stock solution 
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The method used for the preparation of Hydrogel 1 was: 1g of carbopol 971 P was 
dispersed in 50 ml DI H2O under magnetic stirring for 4 h. The pH of the solution 
was adjusted by addition of 0.1M sodium hydroxide or 0.1M HCl and this was then 
cooled overnight to 4°C.  
-Zinc Carbopol 971 PNF 
10ml of ZnSO4 solution were slowly added to 10 ml of the C971P stock solution with 
constant magnetic stirring and continuously stirred for 4 h.  This was then cooled to 
4°C overnight.  
-PRE Carbopol 971PNF. 
10ml of PRE solution were added slowly to 10 ml of the C971P stock solution with 
constant magnetic stirring and continuously stirred for 4 h.  This was then cooled to 
4°C overnight.  
-PRE and Zinc Carbopol 971 P. 
10ml of PRE and zinc solution were added slowly to 10 ml of the C971P stock 
solution with constant magnetic stirring and continuously stirred for 4 h.  This was 
then cooled to 4°C overnight.  
 
-Hydrogel 2: Carbopol 942 P (C942P) 
  -Carbopol 942 P stock solution 
1g of Carbopol was dispersed in 50 ml DI H2O under magnetic stirring at 350 g for  
4 h. The pH of the solution was adjusted by addition of 0.1M sodium hydroxide or 
0.1M HCl: this was then cooled overnight to 4°C.  
-Zinc Carbopol 942 P complexes 
10ml of known concentration (0 M, 0.01 M, 0.1 M and 1 M) ZnSO4 phthalate buffer 
solution was slowly added to 10 ml of the C971P stock solutions with constant 
magnetic stirring and continuously stirred for 4h: this was then cooled to 4°C 
overnight. 
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-Hydrogel 3: Hydroxymethyl cellulose 
-Zinc hydroxyl methyl cellulose 
Using the cold method described in Chapter 2 section 2.2.7. Hydroxymethyl 
cellulose (5g) was added to 100 ml of known concentration ZnSO4 solution (0, 0.01, 
0.1 and 1M) with constant stirring at 300 g for 50 min, pH adjusted via addition of 
NaOH: this was then cooled to 4°C overnight. 
-Hydrogel 4: Cab-o-sil M5 
Cab-o-sil M5 10 g was added to a known concentration of ZnSO4 solution (0, 0.01, 
0.1 and 1M) with constant agitation, pH adjusted by the addition of NaOH: and 
cooled to 4°C overnight. 
-Hydrogel 5: Pluronic F 127 
A control formulation used the cold method following a revised version of that stated 
in Valenta and Schultz (2004). 20 mg of PF127 was slowly added to 100ml of a 
known concentration ZnSO4 solution (0, 0.01, 0.1 and 1M) at 5–10°C with gentle 
mixing until complete dissolution of the polymer, then stored overnight at 4°C .  
-Hydrogel 6: Methocel 856 N Hydroxypropyl Methylcellulose 
Using the hot/cold method stated in Chapter 2 section 2.2.7.  2.5g Methocel 856N 
was added to 40 mL DI H2O at 80 °C with constant stirring until all particles are 
thoroughly wetted. 60 mL cold or iced DI H2O was then added to the solution with 
constant agitation for 30 min. This enables the hydration of the powder and the 
increase in the hydrogels viscosity. The resulting hydrogel was cooled to 4°C. The 
addition of PRE 0.01 and a series of ZnSO4 concentrations 0.01, 0.1, 1, 10 g mL
-1
 
and ZnSO4 0.01, 0.1 and 1 M and their combinations were added to 60 ml of cold or 
iced DI H2O. 
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9.2.3. Aesthetic properties 
The aesthetic tests outlined in Chapter 2 section 2.2.7.1 (aesthetic tests) were 
conducted on the formulations following the methodology for appearance, odour and 
tactile properties. 
9.2.4. Rheology 
Rheological properties were examined according to the methodology stated in 
Chapter 2 section 2.2.4.6 out on a Bohlin CS10 Rheometer (Figure 9-5), which uses 
the ‗cone and plate‘ technique where a metal cone spins above a plate covered with 
test material. The hydrogels analysed via this method are shown in the table below 
Named Formulation Methocel 856N  (w/w) PRE (mg ml-1) ZnSO4 (M) 
Un-named 
1% 0 0 
2% 0 0 
2.5% 0 0 
2.5% 0 0.1 
2.5% 0 0.125 
2.5% 0 0.2 
2.5% 0 0.25 
2.5% 1.25 0 
2.5% 50 0 
Hydrogel A 2.5% 0.05 0.01 
Hydrogel B 2.5% 0.1 0.02 
Hydrogel C 2.5% 0.5 0.1 
Hydrogel D 2.5% 1 0.2 
Hydrogel E 2.5% 1.25 0.25 
Hydrogel F 2.5% 0 0 
Table 9-2 The formulation of hydrogels used for rheological analysis. 
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Figure 9-5 Bohlin CS10 Rheometer used in this study. 
9.2.5. Spontaneous Diffusional Release 
The methodology used to examine the spontaneous diffusional release follows that 
stated in Chapter 2 section 2.2.3.2.  
9.2.6. Stability 
The stability of PRE and ZnSO4 within the Methocel 856 N hydrogel matrix was 
analysed by the spontaneous release of punicalagin and Zn
2+
 from Hydrogel 6 C and 
Hydrogel 6 E through CTEM following the methodology stated in Chapter 2 section 
2.2.3.3. after 0, 3, 6, and 12 months of storage at room temperature with occlusion 
from light and air. 
9.3.  Results 
9.3.1. PRE and ZnSO4 formulations 
9.3.1.1. Emulsion 1 and 2 
PRE 5 mg mL
-1
 and ZnSO4 0.5 M resulted in similar thick emulsions in comparison 
to the control, however the emulsion was orange in colour. The emulsion had a 
smooth texture and left no residue after application. This is in contrast to emulsion 2, 
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which formed a thick white emulsion as a control and on the addition of ZnSO4; 
however the addition of PRE even at all concentrations resulted in separation of the 
phases, with no emulsion forming. 
9.3.1.2. Hydrogel 1; Carbopol C971P 
C971P formed a thick clear hydrogel with the addition of ZnSO4 this is in accordance 
with Justin-Temu et al. (2004) following their assessment of a C971PNF ZnSO4 
hydrogel. However on the addition of PRE (± ZnSO4) to the C971PNF it is appears 
that a reaction between one or two components of PRE and the C971PNF occurred, 
causing the separation of the gel and liquid forming a very thick hydrophobic 
substance.  
 
Formulation Zinc Concentration 
(M) 
PRE 
concentration  
(mg mL
-1
) 
Appearance 
Hydrogel 1 
C971PNF 
0 0 Thick gel 
 0.01 0 Thick gel 
 0.1 0 Thick gel 
 1 0 Thick gel 
 0 0.1 Separation of gel/liquid 
 0 1 Separation of gel/liquid 
 0 10 Separation of gel/liquid 
 0.01 0.05 Separation of gel/liquid 
Table 9-3 The formulation and analysis (visual, macroscopic) of a Carbopol 971 Hydrogel 1 
containing ZnSO4 and PRE. 
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9.3.1.3. Hydrogel 2; C942P 
The addition of C942P to DI H2O produced a thick gel at the pH range formulated. 
On addition of ZnSO4 solutions a similar gel was formed, however if the formulation 
exceeded a pH of 3.5 then the C942P precipitated out of solution. 
 
Formulation Zinc Concentration (M) pH Appearance 
Hydrogel 2 C942P 0 2 
3.5 
5.5 
Thick gel 
Thick gel 
Thick gel 
 0.01 2 
3.5 
5.5 
Thick gel 
Thick gel 
No gel  
 0.1 2 
3.5 
5.5 
Thick gel 
Thick gel 
No gel  
 1 2 
3.5 
5.5 
Thick gel 
Thick gel 
No gel  
Table 9-4 The formulation and analysis (visual, macroscopic) of a Carbopol 942 Hydrogel 2 
containing ZnSO4. 
9.3.1.4. Hydrogel 3; hydroxymethyl cellulose 
The appearance of Hydrogel 3 containing 5% (w/v) methylcellulose is detailed in 
Table 9-5. The formation of thick clear gel was attained with the addition of 
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hydroxymethyl cellulose to DI H2O however, upon the addition of ZnSO4 the 
formation of a white precipitate and clear liquid solution was observed.  
 
Formulation Zinc Concentration 
(M) 
Appearance 
Hydrogel 3  
0 Thick gel 
 
 0.01 White ppt , clear 
liquid 
 
 0.1 White ppt , clear 
liquid 
 
 1 White ppt , clear 
liquid 
 
Table 9-5 The formulation and analysis (visual, macroscopic) of a hydroxymethyl cellulose Hydrogel 
3 containing zinc. 
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9.3.1.5. Hydrogel 4 Cab-o-sil M5 
Table 9-6 describes the visual and macroscopic analysis of hydrogel 4 containing 
10% (w/v) Cab-o-sil M5. A thick non-translucent white gel was formed on the 
formulation of Cab-o-sil M5 alone and with the addition of ZnSO4, however the 
addition of ZnSO4 gel left a white powder residue after application and after 
macroscopic evaluation had an unwanted grainy tactile property. 
Formulation Zinc Concentration 
(M) 
Appearance 
Hydrogel 4 Cab-o-sil 
M5 
0 Thick gel 
 0.01 Thick gel 
 0.1 Thick gel 
 1 Thick gel 
Table 9-6 the formulation and analysis (visual, macroscopic) of a Carbosil M5 Hydrogel 4 containing 
zinc 
9.3.1.6. Hydrogel 5: Pluronic F127 
The visual and macroscopic properties of hydrogel 5 containing 20% (w/v) Pluronic 
F127 is shown in table 9-7. As stated previously (Valenta and Schultz 2004), 
pluronic F127 formed a thick clear hydrogel; on the addition of ZnSO4 a hydrophobic 
film formed on top of a clear liquid which contained a thick white precipitate. 
Formulation Zinc Concentration (M) Appearance 
Hydrogel 5 Pluronic 
F127 
0 Thick gel 
 0.01 Thick gel 
 0.1 Thick gel 
 1 Thick gel 
Table 9-7 The formulation and analysis (visual, macroscopic) of a Pluronic F127 Hydrogel 5 
containing zinc. 
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9.3.1.7. Methocel 856N 
2.5% w/w Methocel 856N formed a thick, clear hydrogel on the addition of ZnSO4  
up to the concentration of 0.1 M.  As the ZnSO4 concentration increased, the gel 
became thinner until the concentration exceeded 0.3M whereupon the gel phase 
separated forming a clear liquid and solid hydrophobic film. There was no observed 
difference to the control gel on the addition of PRE >50 mg ml
-1
 apart from a slight 
discoloration of the gel. A Methocel 856N hydrogel was formulated containing 1.25 
mg ml
-1
 PRE and 0.25M ZnSO4, the gel was translucent with a slight orange tinge. 
The gel felt smooth and left no residue after application. 
 
Formulation Zinc Concentration 
(M) 
PRE concentration 
(mg mL
-1
) 
Appearance 
Hydrogel 6 
Methocel 856N 
0 0 Thick gel 
 0.01 0 Thick gel 
 0.1 0 Thick gel 
 0.3 0 Thin gel 
 1 0 Separation of gel 
liquid 
 0 0.1 Thick gel 
 0 1 Thick gel 
 0 10 Thick gel 
 0.01 0.05 Thick gel 
 0.25 1.25 Thick gel 
Table 9-8 The formulation and analysis (visual, macroscopic) of a Methocel 865N Hydrogel 6 
containing ZnSO4 and PRE. 
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The overriding factors of emulsion and hydrogel formulation appear to be the 
interaction between polymers and zinc ions or compounds within PRE. Of the two 
emulsions tested, the addition of PRE and or zinc to emulsion formulation 1 appears 
to have no effect on the formation of a formulation that has acceptable aesthetics and 
tactility, however the addition of PRE to emulsion 2 separated the oil and water 
phases, rendering it useless - the reason for this is not known. 
Methocel 856N was selected for further study. 
9.3.2. Rheological properties of Methocel gels 
Figure 9-6 shows shear rate vs shear stress profiles for aqueous Methocel 856N, at 1, 
2 and 2.5% and demonstrates the significant effect of the level of Methocel 856N on 
the shear stress observed. 
 
Figure 9-6  Shear stress vs shear rate of Methocel 856N at 1%, 2% and 2.5% 
As the concentration progressed from 1% to 2% to 2.5% the relevant shear stress 
increased: at a shear rate of 300 s
-1
 the shear stress increased from 48.63 Pa to 207.5 
Pa and 382.3 Pa respectively, ergo the higher the concentration of Methocel the 
greater the viscosity. 
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Figure 9-7 Shear rate vs viscosity of Methocel 856N at 1%, 2% and 2.5%. 
Figure 9-7 shows the viscosity trend vs shear rate of the hydrogels in a steady state 
flow test. The plots concur with Figure 9-6 and demonstrate the increased viscosity 
with respect to concentration of Methocel 856N. The two curves (forward and 
reverse) overlap, meaning that the material morphology had not changed following 
the stress induced by the rheometer. This indicated the pseudoplastic nature of the 
hydrogels at all the concentrations analysed. Due to the acceptable macroscopic 
analysis of the hydrogel at 2.5% with the resulting level of viscosity stated above, 
this concentration was maintained for further analysis with the addition of PRE and 
ZnSO4 alone, and in combination. 
Figure 9-8 shows shear rate versus shear stress for the 2.5% Methocel gel with the 
addition of different amounts (0, 0.1, 0.125, 0.2 and 0.25 M) of zinc sulphate. 
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Figure 9-8 Shear rate vs shear stress for Methocel 2.5% following the addition of ZnSO4. 
The formulation containing 0.1 M ZnSO4 slightly increased the shear stress observed 
for that of the blank gel from 382.3 Pa to 434.9 Pa at a shear rate of 300 s
-1
, 
indicating a rise in the viscosity of the gel. However as the concentration of ZnSO4 
increased to 0.125 M and 0.2 M the shear stress decreased to 376.2 and 292.6 Pa. 
The shear stress was greatly altered when the hydrogel contained 0.25M ZnSO4 
resulting in a shear stress of 15.37 Pa at a shear rate of 300 s
-1
. 
 
Figure 9-9 Viscosity vs shear rate of 2.5% Methocel 856N following the addition of ZnSO4 at 0.1, 
0.125, 0.2 and 0.25 M. 
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Figure 9-9 demonstrates that the viscosity of the Methocel 856N is similar on the 
addition of ZnSO4 up to the concentration of 0.2 M at either the beginning or end of 
both the forward and backwards curves of the steady state flow test. The curves 
overlap for the blank hydrogel and for the formulations containing 0.1, 0.125, and 
0.2 M ZnSO4, showing that the pseudoplastic nature of the hydrogel is not altered.  
However at a concentration of 0.25 M ZnSO4 the viscosity has decreased and the two 
curves (forward and backward) did not overlap, meaning that the material 
morphology had changed after the rheometer stress. The area within the two curves 
(the hysteresis loop) is representative of the energy loss required to obtain the 
solution gel transition. The presence of the hysteresis-loop demonstrates that the 
addition of 0.25 M ZnSO4 changes the gel from pseudoplastic to thixotropic in 
nature. 
 
Figure 9-10 Shear rate vs shear stress of 2.5% Methocel 856N loaded with 0, 1.25 and 50 mg mL
-1
 
PRE. 
Figure 9-10 shows that the shear stress of the Methocel hydrogel was not 
significantly affected at any given shear rate. At a shear rate of 300 s
-1
 the control 
hydrogel had a shear stress of 382.3 Pa, the 1.25 mg mL
-1
 PRE loaded gel had a 
shear stress of 381.8 Pa. When the hydrogel was loaded with PRE 50 mg mL
-1
 the 
shear stress decreased to 151.9 Pa. 
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Figure 9-11Viscosity vs shear rate in the steady state flow test for 2.5% Methocel 856N loaded with 0, 
1.25 and 50 mg mL
-1
 PRE. 
The pseudoplastic nature of the hydrogel remained unaffected with the addition of 
PRE at 1.25 mg mL
-1
 or 50 mg mL
-1
 as shown by the overlapping forward and 
backward curves in Figure 9-11. 
 
Figure 9-12 The change in shear stress with respect to shear rate on the addition of PRE + ZnSO4 to 
Methocel 856N 2.5% Hydrogel 6 A-E (Table 9-2). 
Figure 9-12 illustrates that the shear stress was unaffected upon addition of PRE and 
ZnSO4 at the lower concentrations in Hydrogel 6 A, B and C with a shear stress ~370 
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Pa at a shear rate of 300 s
-1
. However, on the addition of the more concentrated 
mixture the shear stress was greatly reduced to 51.54 Pa and 4.98 Pa for Hydrogel 6 
D and E respectively. 
 
Figure 9-13 Viscosity vs shear rate in the steady state flow test for 2.5% Methocel 856N loaded with 
PRE and ZnSO4. Hydrogel A-E (Table 9-2) 
It is apparent from Figure 9-13 that low concentrations of PRE and ZnSO4 loaded 
into the 2.5% Methocel did not alter the pseudoplastic nature of the matrix, as shown 
by the overlapping of the forward and reverse curve of Hydrogel 6 A, B, and C in 
comparison to the control gel. However, as the PRE and ZnSO4 combination 
increased in concentration, the hydrogel became thixotropic, as shown by the 
prominent hysteresis loop for both Hydrogel 6 D and E. Also, the viscosity of both 
these gels was greatly reduced. The cause of the change of gel from pseudoplastic to 
thixotropic is unknown, it is expected that a greater release of constituents over a 
longer time after applied stress will be seen from the Hydrogel 6 D and E, however 
the stability of the gel and its matrix due to the change in nature could affect the 
chemical stability and/or the permeation of the analytes from the formulation.   
9.3.3. Spontaneous Release of Punicalagin and Zinc  
Figure 9-14 shows that after 30 min the spontaneous release of punicalagin from all 
the formulations was statistically similar (p >0.05) at roughly 2 nM cm
-2
. The highest 
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average mass of punicalagin permeation at 24 h was from Emulsion 1 and Hydrogel 
6 E when compared with each other (p >0.05). Emulsion 1 has a statistically greater 
release in comparison to Hydrogels A, B, C, D and E. However, Hydrogel E was not 
significantly different from Hydrogel D (p >0.05) but was significantly different 
from Hydrogel C (p <0.05).  The spontaneous release data at 24 h was expected with 
a graduated rise in punicalagin release from hydrogels proportional to the 
concentration within the formula. Emulsion 1, containing 4 times the concentration 
of PRE in comparison to Hydrogel 6 E, did not, however, release a substantially 
greater amount of punicalagin. 
 
 
Figure 9-14 Spontaneous release of punicalagin from 6 test Hydrogels and Emulsion 1 at 0.5 and 24 h. 
(n = 3 ± SD) 
Figure 9-15 graphically illustrates the analysis for the spontaneous release of zinc 
from the different formulations, which were analysed via ICP MS.  To minimise 
analytical costs it was decided that the three samples at each time point of Hydrogel 
6 C, 6 E, 6 F and Emulsion 1 would be pooled together and analysed. Figure 9-15 
shows that the release of zinc from the formulations was greatest at both 0.5 and 24 h 
from Emulsion 1 releasing 2.04 x 10
-5
 M cm
-2
 and 4 x 10
-5
 M cm
-2
 (6 x 10
-5 
M cm
-2
 
cumulative) respectively. After 0.5 h, Hydrogel 6 C released 1.4 x 10
-5
 M cm
-2
 and E 
released 1.24 x 10
-5
 M cm
-2 
- these are similar levels of zinc release; however due to 
the necessity for pooling of samples no statistical analysis could be undertaken. It is 
apparent that Hydrogel 6 E released greater concentrations of zinc after 24 h in 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0.5 24 C
u
m
m
u
la
ti
v
e
 r
e
le
a
s
e
 o
f 
p
u
n
ic
a
la
g
in
 (
n
M
 c
m
-2
) 
Time (h) 
Hydrogel 6 A 
Hydrogel 6 B 
Hydrogel 6 C 
Hydrogel 6 D 
Hydrogel 6 E 
Emulsion 1 
182 
 
comparison to Hydrogel 6 C, this result is expected as the continued release offered 
by the thixotropic nature of Hydrogel 6 E and the increase in loading will result in 
longer and greater release time. However, it would be expected that a greater 
concentration was released after 0.5 h. The increased release from Emulsion 1 was 
expected due to the increase in loading. As expected no zinc was released from the 
control Hydrogel F. 
 
Figure 9-15 Spontaneous release of zinc from hydrogel 6 C, E and F and Emulsion 1 at 0, 0.5 and 24 h 
(n=3 ± SD). 
The ratio required between punicalagin and Zn
2+
 to potentiate the virucidal activity 
of PRE and Zn
2+ 
shown in Chapter 5 is that 1M punicalagin and between 50-10000M 
Zn
2+
 were released simultaneously – a very important feature in this type of 
formulation. As shown by the release data of Hydrogel 6 C, E and Emulsion 1 after 
30 min ~ 2 x 10
-9
 M cm
-2
 of punicalagin was released and 1 x 10
-5
 M of Zn
2+
 was 
released, giving a ratio of 1:5000 which lies well within the required level for 
activity between Zn
2+
 and punicalagin; the release of punicalagin and zinc observed 
in Figures 9-14 and 9-15 show that the three formulations, Hydrogel 6 C, 6 E, and 
Emulsion 1 released zinc and punicalagin at concentrations that were within the 
synergistic virucidal ratio. 
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9.3.4. Stability of Prototype Methocel 846N Hydrogel 
The stability data acquired for Hydrogel 6 C and 6 E was based upon the release of 
punicalagin and zinc from Methocel 846N hydrogel matrix at 0, 3 6 and 12 months 
through CTEM, and follows the methodology previously described (9.2.6.) and 
guidelines set out by the US Food and Drug Administration (Food and Drug 
Administration 2009). 
Figures 9-16 and 9-17 show the punicalagin and zinc release data from Hydrogel 6 C 
at 0.5 and 24 h. At 0.5 and 24 h the release of the virucidally active agents, 
punicalagin and zinc, over the 12 month analysis period from the hydrogel matrix 
was not significantly different (p >0.05) from that released upon the date of 
formulation. At 0.5 h the release of punicalagin was 1.95 ± 0.3 nM cm
-2
 and the 
release of Zn
2+
 was 1.37 x 10
-5
 ± 5.76 x 10
-7 
M cm
-2
. The cumulative release of 
punicalagin after 24 h of application at time of formulation was 4.1 ± 0.5 nM cm
-2
, 
and after a period of 3 months 4.3 ± 0.8 nM cm
-2
, 6 months 4.45 ± 1.03 nM cm
-2
 and 
12 months 4.62 ± 1.28 nM cm
-2
, with an average release of 4.74 ± 0.92 nM cm
-2
. It is 
important to note that at 24 h the release of punicalagin had a larger standard 
deviation, the reason for this is not entirely clear. The release of Zn
2+ 
after 24 h over 
the 12 month period of stability analysis was 2.75 x 10
-5
 ± 5.01 x 10
-7
 M cm
-2
.  
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Figure 9-16 The spontaneous release of punicalagin from Hydrogel 6 C at 0.5 and 24 h after storage at 
room temperature and occlusion from light at 0, 3 6 and 12 months after formulation (n=3), and the 
average release over the 12 month time points (n=12 ± SD). 
 
 
 
Figure 9-17 The spontaneous release of zinc from Hydrogel 6 C at 0.5 and 24 h after storage at room 
temperature and occlusion from light at 0, 3 6 and 12 months after formulation, and the average 
release over the 12 month time points (n = 4 ± SD). 
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Figures 9-18 and 9-19 show the release data of punicalagin and zinc from Hydrogel 6 
E over a 12-month stability analysis. At 0.5 and 24 h the release of both punicalagin 
and zinc was maintained and not significantly different (p >0.05). Over the 12-month 
period the average release of punicalagin and zinc from Hydrogel 6 E was 2.3 ± 0.07 
nM cm
-2
 and 1.42 x 10
-5
 ± 1.71 x 10
-6
 M respectively. The average 24 h release of 
punicalagin was 6.94 ± 1.29 nM cm
-2
, the high standard deviation of the average 
release value resulted from the large variation of released punicalagin at the point of 
formulation. The average release of zinc was 4.18 x 10
-5
 ± 2 x10
-6
 M.  
 
Figure 9-18 The spontaneous release of punicalagin from Hydrogel 6 E at 0.5 and 24 h after storage at 
room temperature and occlusion from light at 0, 3 6 and 12 months after formulation (n=3), and the 
average release over the 12 month timepoints (n = 12 ± SD). 
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Figure 9-19 The spontaneous release of zinc from Hydrogel 6 E at 0.5 and 24 h after storage at room 
temperature and occlusion from light at 0, 3 6 and 12 months after formulation, and the average 
release over the 12 month time points (n = 4 ± SD). 
The stability of the Hydrogels C and E from the above release data shows that both 
formulations are unaffected over a 12-month storage time. There is no decrease in 
the level of punicalagin released enabling the deduction that over 12 months the 
punicalagin content within the PRE + ZnSO4 hydrogel matrix stored at room 
temperature was maintained and that no breakdown has occurred.  Due to the 
instability of the punicalagin anomers as a pure extract and the readiness for its 
breakdown due to ester hydrolysis within the PRE mixture it is safe to assume that 
concentration of the majority of phytochemicals present in PRE remains constant 
over 12 months within the formulation of PRE, ZnSO4 and Methocel 856N when 
stored at room temperature and occluded from light and oxygen. 
9.4. Discussion 
All of the hydrogel and emulsion formulations without the addition of PRE or zinc 
resulted in thick gels which are appropriate for topical administration, having both 
positive aesthetic and tactile properties. However, the addition of either zinc 
(ZnSO4), PRE or a combination of the two appeared to affect the gelling properties 
of the polymers in varying ways. The addition of PRE to Hydrogel 1 prevented the 
0 
0.000005 
0.00001 
0.000015 
0.00002 
0.000025 
0.00003 
0.000035 
0.00004 
0.000045 
0.00005 
0.5 24 
C
u
m
u
la
ti
ve
 r
e
le
as
e
 o
f 
zi
n
c 
(M
 c
m
-2
) 
Time (h) 
Gel E 
Gel E 3 months 
Gel E 6 months 
Gel E 12 months 
Average Release Gel E 
187 
 
formation of a gel with a thick white semisolid at the base of the container and an 
orange liquid above. Hydrogel 2 with the inclusion of ZnSO4 did not form a gel 
above a pH of 3. On the addition of ZnSO4 to Hydrogels 3 and 5 a white precipitate 
formed with a clear liquid, and with respect to Hydrogel 5 a hydrophobic solid film 
formed on the top of the liquid after cooling.  Although Hydrogel 5 did form a thick 
and clear hydrogel, a white residue was left on the skin after application, and on 
palpable examination the addition of ZnSO4 led to a grainy feel. Hydrogel 6 formed a 
very promising gel on the addition of PRE to high concentrations (50 mg ml
-1
) 
however the gel would not form above a concentration of 0.3 M ZnSO4. A greater 
concentration of ZnSO4 resulted in the formation of a white precipitate and clear 
hydrophobic layer similar to Hydrogels 3 and 5. Emulsion 1 was unaffected by the 
addition of both PRE and ZnSO4, apart from slight discolouration and Emulsion 2 
was unable to form after the addition of PRE.  
From the literature, it is a recognised phenomenon that the addition of zinc and or 
PRE to many common formulations results in a chemical interaction between the 
polymer matrix of gels and emulsions. It is common for ionic polymers to lose 
viscosity in the presence of metal ions and other ionic species (Kawakami, et al. 
2006); however the complete dissolution and formation of hydrophobic compounds 
on addition to common gel forming polymers is not widely disclosed. Common 
water soluble polymers such as carbopol, hydroxyethyl cellulose and hydroxypropyl 
cellulose have been reported to have little or no influence on the addition of salts 
(Keegan, et al. 2007) (Abzaeva, et al. 2009).  
Emulsion 1 and Hydrogel 6, with the addition of both PRE and ZnSO4, appeared to 
have acceptable aesthetic and tactile properties. The investigation into formulation 
was by no means exhaustive and there is a possibility that other simple or more 
complex emulsions or hydrogels may be formulated with higher concentrations of 
active ingredients that are both aesthetically acceptable and with a satisfactory 
tactility. However, it was deemed acceptable to proceed with release and permeation 
experiments with both a hydrogel and an emulsion to investigate. 
The preference of a hydrogel formulation over an emulsion formulation, which led to 
the research for a wider range possible hydrogels, was due to the range of possible 
applications of hydrogels and the very high biocompatibility that hydrogels possess. 
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It should also be noted that due to the possible application of any formulation to the 
buccal cavity, the formulation must be harmless upon consumption due to the 
possibility of ingestion (Methocel 856N has been used as a thickening agent within 
the food industry).   
The rheological properties of the Methocel 856N hydrogel as expected showed that 
as the Methocel content increased, the viscosity of the gel increased; an unloaded 
2.5% Methocel 856N hydrogel (Hydrogel 6 F) acted as a typical non-Newtonian 
pseudoplastic hydrogel throughout rheological examination and was chosen for 
further analysis due to palpable and viscosity analysis. On the addition of ZnSO4 to 
the formulation at 0.125 and 0.2 M to the hydrogel a decrease in viscosity was 
observed and pseudo-plastic behaviour maintained, however upon the addition of 
0.25 M of ZnSO4 the formulation showed a large decrease in viscosity with a shear 
stress change from 382.3 Pa for Hydrogel 6 F to 15.37 Pa at a shear rate of 300 s
-1
; 
the gel also changed from pseudo-plastic to thixotropic, showing an hysteresis loop 
(Figure 9-9) upon the analysis of viscosity vs shear rate. The addition of PRE at 1.25 
mg ml
-1
 to the Methocel 856 N hydrogel showed no change in the viscosity or 
pseudo-plastic nature of the gel. 
The formulations Hydrogel 6 A-E with a Methocel content of 2.5% were analysed 
for any rheological changes occurring on the addition of both PRE and ZnSO4 at a 
range of concentrations, in accordance with the potentiated virucidal data and 
concentration of punicalagin within PRE, the ratio 5:1 PRE mg ml
-1
: ZnSO4 M 
(concentrations in Table 9-2) was maintained. Hydrogel 6 A (PRE 0.05 mg mL
-1
, 
ZnSO4 0.01 M), B (PRE 0.1 mg mL
-1
, ZnSO4 0.02 M) and C (PRE 0.5 mg mL
-1
, 
ZnSO4 0.1 M) were shown not to affect the pseudo-plastic nature or viscosity of the 
blank hydrogel, however Hydrogel 6 D (PRE 1 mg mL
-1
, ZnSO4 0.2 M) and E (PRE 
1.25 mg mL
-1
, ZnSO4 0.25 M) both decreased the viscosity in comparison to the 
blank gel and changed the nature of the blank gel from pseudo-plastic to thixotropic 
with Hydrogel 6 E having the greater effect. It is apparent that the introduction of 
PRE and zinc in combination has a greater effect on the viscosity and properties of 
the gel than when introduced separately.  
The spontaneous release data of punicalagin from Hydrogels 6 A-E and Emulsion 1 
show that after 0.5 h there is no significant difference in the release from any of the 
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formulations, after 24 h it is apparent that Emulsion 1 and Hydrogel E release more. 
The release of permeant from a formulation usually dictates the maximum amount 
available to be taken up by the skin and permeate. The stability data showed that the 
formulation performed equitably across the 12-month test period, and thus it can be 
assumed no detrimental changes (eg phase separation) took place over this period – 
i.e. the formulation is stable under the conditions used. 
9.5. Conclusion 
A simple hydrogel has been developed which has acceptable properties, in terms of 
aesthetics, spontaneous release and rheology. This will be used as a prototype gel 
formulation in further investigation into the topical delivery of PRE and Zn
2+.
. 
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Chapter 10 Permeation Of Punicalagin 
And Zinc (II) Across Epithelial 
Membranes Prone To HSV Infection 
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10.1. Introduction 
In Chapter 9, a simple prototype formulation was produced that was stable and which 
allowed the spontaneous release of the two major components in the system: 
punicalagin and zinc. In the current chapter, the performance of the formulation was 
determined in terms of its ability to deliver both punicalagin and zinc (II), following 
dosing onto a number of anatomical membranes that are prone to infection by HSV. 
Cold sores mainly affect the perioral region in which case normal skin can be used as 
a model for determining penetration. HSV lesions also occur on the lips and in the 
mucous membranes of the buccal cavity, where the inner cheeks and gums can be the 
site of lesions, as shown in Figure 10-1. Ano-genital infections of HSV, commonly 
referred to as ‗herpes‘, can involve the areas of normal skin or mucous membranes.   
  
Figure 10-1 Manifestations of HSV-1 and 2 as lesions on perioral and normal skin, within the buccal 
cavity and the mucus membrane of the vagina (X Herpes 2011). 
Depending on the progression of the lesion, the precise location of the viral load can 
vary from deep within the skin to near or on the surface. By using native or normal 
membranes, the levels of permeation would represent minimal deliverable amounts. 
Advanced lesions would have compromised barriers and so the amounts deliverable 
would be expected to be greater, particularly given the hydrophilic nature of the 
actives and the hydrated state of the buccal and vaginal mucosal membranes. 
10.1.1. Objective and Aims 
The objective of this chapter was to determine the extent of in vitro delivery of 
punicalagin and zinc (II) to models for HSV-1 and -2 vesicular specific sites, from 
topically applied hydrogel formulations loaded with PRE and ZnSO4. The aims were: 
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- to determine delivery across heat separated porcine epidermis (HSE) 
- to determine delivery across heat separated porcine buccal membrane (HSBM) 
- to determine delivery across scalpel dissected porcine vaginal membrane (SDVM) 
10.2. Materials & Methods 
10.2.1. Materials 
The materials used within this chapter are given in Chapter 2 section 2.1. 
10.2.2. Formulation Preparation. 
10.2.2.1. Emulsion 1 
The formulation of Emulsion 1 to be analysed for permeation through the epidermal 
membrane followed that described in Chapter 9 section 9.2.2.1., with a PRE content 
of 5 mg mL
-1
 and ZnSO4 concentration of 0.5 M. 
10.2.2.2. Hydrogel 6 C, 6 E and 6 F Formulation 
Hydrogel 6 C, E and F were prepared following the hot cold method stated in 
Chapter 9 section 9.2.2.3.6., using 2.5 % Methocel 856N. The use of Hydrogels 6 C 
and E was due to the comparative spontaneous release data after 0.5 h and the 
difference in the rheological properties, i.e. Hydrogel 6 C is pseudo-plastic in nature 
maintaining its viscoelastic properties whereas Hydrogel 6 E is thixotropic, resulting 
in a decreased viscosity after shear thinning. Hydrogel 6 C containing 0.5 mg mL
-1 
PRE and 0.1 M ZnSO4 and Hydrogel 6 E with 1.25 mg mL
-1 
PRE and 0.25 M 
ZnSO4. Hydrogel 6 F was used as a control and contained no PRE or ZnSO4.  
10.2.3. Preparation of Isolated Membranes 
10.2.3.1. Heat separated epidermis 
This membrane was used to model drug delivery to HSV-1 and -2 vesicular clusters 
which form in the early stages of a HSV or ―cold sore‖ lesion formation, where the 
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skin and barrier function are still essentially intact. This could represent surrounding 
non-labial regions either of the mouth or vagina. The methodology for heat separated 
epidermal membrane followed that described in Chapter 2 section 2.2.2.2. 
10.2.3.2. Heat Separated Buccal Membrane (HSBM) 
Due to the fact that HSV-1 and -2 most commonly transverse the trigeminal nerve 
which enables the virus to present not only on the prolabium (lip) but also within the 
buccal cavity, it was important to determine the delivery of both punicalagin and zinc 
through the buccal mucosa. The preparation of this membrane follows the 
methodology in Chapter 2 section 2.2.2.3. 
10.2.3.3. Scalpel Dissected Vaginal Membrane (SDVM) 
Scalpel dissected vaginal membrane was used to model the presentation of HSV-1 
and -2 vesicular clusters within and around the vaginal cavity soft tissue in female 
Herpes simplex infection. Porcine vaginal mucosal membrane (Figure 10-2) was 
excised via blunt dissection of the vagina and the slow removal of overlying fat and 
muscle until a thin semi transparent membrane remained, following the method 
stated in Chapter 2 section 2.2.2.4. 
 
Figure 10-2 Dissected porcine vagina; a - urogenital opening, b - vaginal mucosal membrane, c - fat 
and muscle surrounding tube, d – uterus. 
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10.2.4. Membrane Permeation, In Vitro 
Within the literature, methodology for the dosing of formulations onto membranes 
within a Franz diffusion cell (FDC) varies greatly but generally falls into 2 
categories:  
finite, representing in-use conditions  
infinite, representing maximal effect (Corbo, et al. 1993).  
For assessment of permeation in the current work it was decided that an infinite dose 
of 300 mg aliquot of formulation would be applied, and thus allow determination of 
maximal levels of delivery. The methodology for FDC experiments with each 
membrane followed that stated in Chapter 2 section 2.2.3.    
Following the formulation and spontaneous release of punicalagin and zinc data 
obtained in Chapter 9, Emulsion 1 and Hydrogels 6 C, and E were analysed for the 
permeation of punicalagin and zinc through the epidermal membrane using Hydrogel 
F as a control. The 2.5 % Methocel 856N formulations Hydrogel 6 C (PRE 0.5 mg 
mL
-1
 and ZnSO4 0.1 M), E (PRE 1.25 mg mL
-1
 and ZnSO4 0.25 M) and F (control) 
were used to analyse the delivery of both punicalagin and zinc through the vaginal 
and buccal mucosal membranes.  The use of these formulations was because 
Hydrogel 6 E contained the highest concentration of PRE and zinc, and release and 
delivery data showed that Hydrogel 6 E was the most effective. The unaffected 
pseudo-plastic nature and the benefit for the comparison of a loaded formulation led 
to the use of Hydrogel 6 C.  Emulsion 1 was not analysed for permeation delivery of 
zinc through the epidermal membrane or the analysis of punicalagin or zinc through 
either the buccal or vaginal membrane due to the non-permeation of punicalagin 
from Emulsion 1 through the epidermal membrane. 
After 0.5, 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24 h the receptor fluids were removed via a 
sterile pipette and stored in 10 mL glass vials until further use. The receptor chamber 
was then refilled with DI H2O using another sterile pipette. 
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10.2.5. Reverse Tape Stripping 
To allow a comparative determination of the levels of actives in the basal layer areas 
of the 3 test membranes, reverse tape stripping was conducted after 24 h (Searby 
2011). The membrane was removed from the FDC and carefully dabbed clean of 
excess formulation detailed in Chapter 2 section 2.2.3.5.  
10.2.6. Recovery of Penetrants in FDC Receptor Phases 
The methodology for the collection of the penetrants after the application of 
Hydrogel 6 E for Western blot and virucidal testing followed that stated in Chapter 2 
section 2.2.5.12. 
10.2.7. Virucidal Analysis 
The virucidal analysis of reconstituted freeze dried receptor phase followed the 
methodology stated in Chapter 2 section 2.2.5.9. of the plaque reduction assay. 
Whereby HSV-1 was incubated with the test material for 30 min before serial 
dilution and plating onto 24 WP of confluent Vero cells for a 3 day incubation, at 
which point the plaques were counted.  
10.2.8. Western Blot Analysis 
The analysis of the test material, Hydrogel 6 E, on COX-2 levels after application to 
porcine skin for 6 h was done by SDS-PAGE and Western blotting following that 
stated in Chapter 2 section 2.2.4.4. using β-actin as the loading control.  
10.2.9. Data Processing 
Samples were analysed by HPLC or ICPMS as described in Chapter 2 sections 
2.2.4.1. and 2.2.4.2., and plotted as cumulative permeation  ±  standard deviation. 
Where appropriate, flux was determined by linear fit to the linear part of permeation 
profile. 
Statistical tests were performed using Instat 3 for Macintosh. A one way analysis of 
variance test was applied with a confidence interval of 95%, and a p value of <0.05 
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was considered significant.  If values were found to be of significance a Turkey-
Kramer multiple comparison test was applied. 
10.3. Results and Discussion 
10.3.1. Permeation of Punicalagin and Zinc (II) across HSE  
10.3.1.1. Punicalagin 
Figure 10-3 shows the levels of punicalagin permeated across heat separated 
epidermis from Hydrogel 6 C, E and Emulsion 1. Hydrogel 6 F was run as a control, 
no punicalagin penetration was observed. Although previous release data (Chapter 9 
section 9.3.3.) showed that punicalagin was released at a high rate from Emulsion 1, 
it is apparent from the results that no recordable permeation has occurred. This may 
be due to the oleaginous nature of the emulsion preventing permeation of punicalagin 
through the epidermis. The graphical analysis obtained a Jmax for Hydrogel 6 C and E 
giving fluxes of 0.3900 ± 0.0048 nM cm
-2
 hr
-1
 and 2.01 ± 0.25 nM cm
-2
 hr
-1
 
respectively. The spontaneous release data of punicalagin from both Hydrogel 6 C 
and E is very similar to the penetration of punicalagin through the epidermal 
membrane. This is due to the pressure applied during application to the epidermal 
membrane, which in both cases will decrease the viscosity of the hydrogel resulting 
in a greater release of punicalagin. The data shows that the permeation of punicalagin 
from Hydrogel 6 E was the greatest. This is likely to be due to the increased 
concentration within Hydrogel 6 E and the fact that after application, and shear 
thinning, the thixotropic nature of Hydrogel 6 E will result in a gel of decreased 
viscosity during and after the shear thinning caused by application. Therefore a 
greater release and permeation of punicalagin from the hydrogel matrix is expected, 
and observed, at the time of application and afterwards. 
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Figure 10-3 Cumulative permeation of punicalagin across HSE after infinite topical delivery of PRE 
and ZnSO4 loaded Hydrogels 6 C, E, F (blank control) and Emulsion 1. (n= 4, ± SD). 
10.3.1.2. Zinc (II) 
Zinc analysis was conducted via ICP MS. Due to reasons previously described, it 
was necessary to pool the repeat samples. It was also deemed unnecessary to 
evaluate the permeation of zinc from Emulsion 1 due to the lack of punicalagin 
permeation.  
 
Figure 10-4 Cumulative permeated zinc through HSE After infinite dosing of Hydrogel 6 C, E and F 
(n=4, ± SD). 
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The zinc permeation analysis illustrated in Figure 10-4 reveals that a low level of 
zinc is present after application of the control Hydrogel 6 F. This is due to a leaching 
of zinc which is naturally found in porcine epidermis and observed in the analyses 
conducted within Chapter 6. Flux calculations subtracted this concentration from the 
results. 
It is observed that permeation across HSE is similar to that across CTEM Hydrogel 6 
C and E: both permeate with high concentrations of zinc over the first hour, 
Hydrogel 6 C plateauing after this period and Hydrogel 6 E continuing to deliver 
zinc over the 24h period.  
The graphical analysis of the first three data points allowed for the flux calculation of 
zinc delivery from Hydrogel 6 C and E after subtraction of the control, the flux was 
0.23 µM cm
-1
 hr
-
 and 0.21 µM cm
-1 
hr
-1
 respectively.  
The penetration of zinc through the epidermal membrane from both Hydrogel 6 C 
and E show that the applied force during application has led to similar penetration 
concentration in comparison to release concentration. The thixotropic nature of 
Hydrogel 6 E has shown to be beneficial as a greater concentration of Zn
2+
 
penetrated over a greater time.  
The Figures 10-3 and 10-4 above show that after application of Hydrogel 6 C and E 
to HSE both biologically active compounds, punicalagin and zinc, permeate through 
the membrane. Hydrogel 6 E allows for a greater permeation of both compounds, in 
comparison to Hydrogel 6 C, with over 5 times the flux value of punicalagin and 3 
times the flux obtained for zinc. This supports the hypothesis in Chapter 9 that the 
thixotropic nature of Hydrogel 6 E would allow for a greater permeation over a 
longer time. 
10.3.1.3. Localisation of Punicalagin in HSE Basal Layer Region 
Figure 10-5 represents the punicalagin which remained at the basal layer, i.e. the site 
of vesicular clusters in the interior region of the epidermis. All epidermal membranes 
were reverse tape stripped, three strips were used each time. 
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Figure 10-5 The mass of punicalagin recovered after reverse tape stripping epidermal membrane that 
had been dosed with Hydrogel 6 C and E (n=4, ± SD). 
Reverse tape strip analysis shown in Figure 10-5 of HSE after a 24h application 
period of Hydrogel 6 C and E revealed that delivery of punicalagin was greatest to 
the lowest area of the epidermis. The second and third tape strip revealed only a very 
low level of punicalagin delivery by both gels. The results demonstrate that 
punicalagin was successfully delivered to the site of HSV-1 and -2 vesicular clusters. 
10.3.2. Virucidal Testing on the Penetrants in FDC Receptor Phases 
The HSV-1 virucidal analysis of the penetrants after a 24 h application of Hydrogel 6 
E and Hydrogel 6 F to the epidermis is shown in Figure 10-6. The penetrants from 
Hydrogel 6 E caused a 2.57 ± 0.36 log reduction of HSV-1 pfus. The penetrants from 
Hydrogel 6 F, the control, show a negligible log reduction. 
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Figure 10-6 The log reduction of HSV-1 after the incubation with the reconstituted penetrants after 
the 24 h application of Hydrogel 6 E and 6 F to the epidermis (n=4, ± SD). 
10.3.3. Western Blotting 
To verify if the release of PRE from Hydrogel 6 E maintained similar anti-
inflammatory levels as that stated for the application of the liquid formulation in 
Chapter 7, Western blot analysis was carried out. Hydrogel 6 E and control were 
applied to ex vivo full thickness porcine skin within a Franz diffusion cell for 6 h. 
After this time SDS PAGE and Western blotting was carried out for COX-2, as an 
inflammatory marker, and β-Actin, as the protein loading control.  
 Figure 10-7 shows the shows the bands produced by Western blot analysis for COX-
2 expression at ~ 72 kDa and the protein loading control of β-actin at ~42 kDa. 
Densitometric results of the bands for COX-2 were normalised using β-actin, levels 
of COX-2 expression in the control were arbitrarily assigned a value of 100%. Test 
solutions were shown as a percentage of the control and graphically displayed as a 
histogram in Figure 10-7.  
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Figure 10-7 Analysis of COX-2 protein expression by Western blot. Full thickness porcine skin was 
treated with topical Hydrogel 6 E (H) and phthalate buffer as a control (C) for 6 h, protein was 
extracted and 30 µg was loaded and separated through SDS-PAGE. The histogram represents 
numerical data of COX-2 normalised using β-actin. Levels in control were arbitrarily assigned a value 
of 100%. (n=4, ± SD). 
 
The application of Hydrogel 6 E caused the statistically significant reduction of 
COX-2 expression by 67.69 ± 3.93% (p<0.01). 
There was not a significant difference (p>0.05) of the reduction of COX-2 after the 
application of the hydrogel in comparison to that of either the application of PRE (1 
mg mL
-1
) alone or in combination with ZnSO4 ( 1M) (data given in Chapter7 section 
7.3.2.). 
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10.3.4. Permeation of Punicalagin and Zinc (II) Across Heat Separated 
Buccal Membrane (HSBM) from Three Formulations 
10.3.4.1. Punicalagin 
Hydrogel 6 E and F were applied to HSBM following the same method used for HSE 
application and analysis. HSBM was used as a model for the presentation of HSV-1 
and -2 lesions within the buccal cavity.  
 
Figure 10-8 Permeation profile of punicalagin from Hydrogel 6 E and F (control) across the buccal 
membrane (n=4, ± SD).
 
Figure 10-8 demonstrates that the permeation of punicalagin within the first 0.5 h 
was comparable to epidermal permeation at 1.09 ± 0.18 nM cm
-2
 and 0.83 ± 0.3 nM 
cm
-2
 respectively, resulting in a statistically similar flux of 2.17± 0.16 nM cm
-2
 hr
-1
 
for the buccal membrane and 2.01 ± 0.25 nM cm
-2
 hr
-1
for the epidermal membrane. 
However, the level of permeation through the buccal membrane plateaued after 0.5 
h. After 16 h of application it appears that the normal barrier function of the buccal 
membrane is inconsistent resulting in large error. It is hypothesized that receptor 
fluid which will be absorbed has greatly altered the membrane by this time point. 
10.3.4.2. Zinc (II) 
The samples collected after application of Hydrogel 6 E and F were pooled and 
analysed via ICP MS.  
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Figure 10-9 Permeation profile of zinc across HSBM after Application of Hydrogels 6 E and F (n=4, 
± SD).
 
Figure 10-9 shows the permeation of zinc through the buccal membrane from 
Hydrogel 6 E and F, it is noted that a low level of zinc has leached from the buccal 
membrane after application of Hydrogel 6 F. This is at a much lower concentration 
in comparison to epidermal membrane.  
The permeation of zinc from Hydrogel 6 E through the buccal membrane results in a 
flux 0.055 x 10
-6 
M cm
-2
 h
-1
, which is much lower in comparison to the flux of zinc 
through the epidermal membrane at 0.21 x 10
-6 
M cm
-2
 h
-1
. The large decrease could 
be due to an increase of zinc absorption by the buccal membrane cells. The 
permeation of profile of zinc over the 24 h period is similar to that through HSE; a 
plateau is observed after 1 h, maintained up to 12 h. and tailing off.  
10.3.4.3. Localisation of Punicalagin in HSBM Basal Layer Region 
The fragility of the buccal membrane after 24 h allowed for only one tape strip 
sample to be conducted. The average punicalagin concentration of the reverse tape 
strip was 0.52 ± 0.052 nM cm
-2
 (n=3), demonstrating the delivery of punicalagin to 
the site of buccal membrane vesicular clusters. 
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10.3.5. Permeation across Porcine Vaginal Membrane 
10.3.5.1. Punicalagin  
Hydrogels 6 E and F were applied to the vaginal membrane following similar 
methods of application to both other membranes to allow for comparable results. 
 
Figure 10-10 Permeation profile of punicalagin through the vaginal mucous membrane after 
application of Hydrogel 6 E and F (control) (n=4, ± SD). 
The permeation of punicalagin through the vaginal membrane is illustrated in Figure 
10-10. Within 30 min of application a large percentage of the total permeation of 
punicalagin is reached. After 1 h the permeation plateaus. The permeation of 
punicalagin across the vaginal mucosal membrane quickly reaches equilibrium after 
the topical application of Hydrogel 6 E, the resultant flux of which is 1.08 ± 0.26 nM 
cm
-2
 h
-1
. The flux of punicalagin through the vaginal membrane is about half of that 
through the buccal and epidermal membranes. 
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10.3.5.2. Zinc (II) 
The samples collected after application of Hydrogel 6 E and F to SDVM were pooled 
and analysed via ICP MS. 
 
Figure 10-11 Cumulative permeation of zinc though the vaginal mucosal membrane after application 
of Hydrogel 6 E and F (control) (n=4, ± SD). 
Figure 10-11 graphically illustrates the permeation of zinc through the vaginal 
mucosal membrane from Hydrogels 6 E and F.  The leaching of zinc from the 
vaginal membranes after application of Hydrogel F was not significantly different 
(p>0.05) to that leached from the buccal membrane but was a lot less than that from 
the epidermis. The permeation profile reveals that zinc continues to permeate at high 
concentration for 12 h, reaching a plateau after this time point. This is very different 
to the permeation through the epidermal and buccal membranes which both 
plateaued after 1 or 2 h.  
The permeation through this membrane was also much greater at 4
 M cm-2 h-1 than 
through the other tested membranes, suggesting that there is a much greater 
permeation of Zn through the vaginal mucosal in comparison to the epidermal and 
buccal membranes; however, the greatest permeation of punicalagin was through the 
epidermal membrane. 
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10.3.5.3. Localisation of Punicalagin in SDVM basal layer region 
The fragility of the membrane once again prevented repeat stripping, as with the 
buccal membrane only one tape strip was performed on each membrane. The average 
punicalagin concentration of the reverse tape strip was 0.46 ± 0.048
 
µM cm
-2
 (n=3). 
This was directly comparable to the first tape strip removed from buccal membrane, 
demonstrating the delivery of punicalagin to the site of all membrane vesicular 
clusters. 
10.3.6. The Comparison of Tape Stripping 3 Porcine Membranes after 24 
h Application of Hydrogel 6 E. 
 
Figure 10-12 Comparison of punicalagin recovered from lowest reverse tape strip after 24 h 
application of hydrogel 6 E to three porcine membranes (n=4, ± SD).  
The concentration of punicalagin recovered after 1 tape strip is shown in Figure 10-
12. The concentration recovered from the basal layer of each membrane tested are 
shown to be directly comparable (P>0.05). The results indicate that punicalagin is 
being delivered to the intended site of vesicular clusters through all three 
membranes. 
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10.4. Discussion 
The decrease in permeation through HSE in comparison to the release data obtained 
using CTEM was expected to be due to the greater barrier provided by the epidermis 
(Davidson, et al. 2010). The permeation of punicalagin from the PRE ZnSO4 
formulations analysed, Hydrogel 6 C and E and Emulsion 1, was best achieved after 
application of Hydrogel 6 E. This result was expected due to the increased loading 
and release of Hydrogel 6 E. Emulsion 1 proved not to overcome the epidermal 
barrier and no punicalagin permeated from this formulation. 
The permeation of Zn from both Hydrogel 6 C and E was observed through the 
epidermal membrane with a greater permeation from Hydrogel 6 E. 
Both Hydrogel 6 C and E facilitated the permeation of punicalagin and Zn through 
HSBM with a greater delivery from Hydrogel 6 E. The permeation profiles of both 
punicalagin and Zn were similar over the 24h period, however a much greater 
concentration of both analytes permeated the epidermal membrane. 
The delivery of punicalagin from Hydrogel 6 E through the SDVM was comparable 
to that through HSBM however a greater permeation of Zn was achieved through 
this membrane. The comparison of the permeation data through the 3 membranes 
allows for the conclusion that with respect to punicalagin the permeability of the 
membranes follows HSE>SDVM>HSBM and with respect to Zn
2+
 the permeability 
of the membranes follows SDVM>HSE>HSBM. The delivery of the bioactive 
analytes through each susceptible membrane and to the site specific areas as shown 
by the reverse tape stripping of each membrane results in the conclusion that both 
punicalagin and zinc were sufficiently delivered to the site of vesicular cluster 
formation on recurrence of herpetic lesions in the epidermis, buccal mucosa, and 
vaginal cavity. Hydrogel E therefore has the potential as a viable treatment for HSV-
1 and -2 herpetic lesions resulting in cold sores throughout all common areas in 
which they present. 
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10.5. Conclusion 
Punicalagin and Zn
2+
 from the formulation Hydrogel 6 E are able to penetrate 
through epidermal, vaginal mucosal and buccal membranes at concentration ratios 
for which potentiated virucidal activity has been observed. Application of Hydrogel 
6 E to ex vivo full thickness skin also showed that the punicalagin released from the 
gel penetrated the epidermis maintaining a statistically similar reduction in COX-2 
expression to that of PRE in a liquid formulation. 
Overall, Hydrogel 6 E containing 2.5% Methocel, 1.25 mg mL
-1
 PRE and 0.25 M 
ZnSO4 is able to topically deliver, from a stable formulation, the bioactive 
compounds within PRE and Zn
2+
 to the site specific region of Herpes simplex 
vesicular clusters, maintaining antiviral, anti-inflammatory and potentiated virucidal 
properties. A possible, novel therapeutic system for the treatment of HSV-1 and 
HSV-1 lesions has been identified. 
It is important to note: the experimental data have been collected under ex vivo 
conditions, and while the epidermal membrane of the porcine is a well recognised 
and accepted model for the epidermal penetration in humans, the use of the porcine 
scalpel dissected vaginal membrane and porcine heat separated buccal membrane has 
not been previously reported, and therefore its validity as a model for human 
extrapolation should not be assumed. 
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Chapter 11 General Discussion 
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11.1. General Discussion 
The medicinal use of the extracts taken from various parts of the plant Punica 
granatum L, has been of interest for many centuries and remains so to the present 
day. Aligned with a greater understanding of the chemical nature of these extracts in 
recent times, has been heightened appreciation of the breadth of potential 
pharmacological activities. In particular, interest has focussed upon the high 
concentration of polyphenolic tannins, most notably punicalagin, contained within 
such extracts. The impetus for the current research was the finding by Stephen 
Denyer and colleagues at the University of Nottingham a decade or so ago. They 
noted that the phagicidal activity of PRE was markedly enhanced or potentiated by 
the co-administration of ferrous sulphate. Intriguingly, such potentiated activity was 
short-lived (approximately 3 minutes) and resulted in the development of a black 
byproduct. However, there seemed to be the basis of a therapeutic antimicrobial 
system, given further development. This view was supported by the Welsh Office of 
Research and Development who funded the current work following a competitive 
call for proposals. 
The object of this thesis was therefore to probe the virucidal activity of PRE in 
respect to HSV-1 and to investigate any potentiation with the addition of metal salts, 
including FeSO4. A key aim was working towards the development of a therapeutic 
system, particularly for the treatment of orofacial and ano genital HSV-1 and HSV-2 
lesions. 
The work commenced by revisiting the PRE + FeSO4 combination, only the focus 
was on HSV, as this is a major infective agent involved in skin infections. Chapter 3 
concluded that the potentiated activity previously observed in bacteriophage was 
essentially reproduced in virucidal experiments involving HSV-1 and -2 where the 
combination of PRE and FeSO4 led to a 600 fold increase in activity. However, also 
reproduced was the transient timescale of the potentiation and the development of the 
black byproduct, post mixing. These factors were considered to be significantly 
detrimental in the context of a therapeutic product. 
In Chapter 4 I attempted to examine the kinetics of the PRE/FeSO4 reaction, and 
potentially identify an alternative to the metal salt with better properties. The results 
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indicated that the rapid oxidation of Fe II to Fe III as the basis for, not only the 
development of the black byproduct, but also the transient nature of the biological 
activity. This was a clue that a metal ion that remained in the +II oxidation state, 
resisting further oxidation, may provide a longer-lived system with no 
discolouration. Consequently, our attention turned to zinc, and in particular salts of 
Zn II. The addition of ZnSO4 to the PRE produced no colour change, no redox 
change and no new compound, due to the stability of the Zn
2+ 
ion, in terms of its 
resistance to further oxidation. This was therefore chosen for use in further 
potentiated virucidal experiments. 
In Chapter 5 the potentiated virucidal activity of PRE, when added to ZnSO4 was 
comparable to the initial addition of FeSO4. However, unlike with FeSO4, there was 
no evidence of any diminishing activity. There was a biphasic potentiated virucidal 
response to ZnSO4 added to PRE. The unknown complex interplay between the 
mixture of phytochemicals and the addition of ZnSO4 upon the virus and the precise 
mechanism of action has not been fully elucidated. The range of PRE : ZnSO4 ratios 
for which a greater than 1000 fold reduction in viral count is: 
PRE 1 : 2.8-575 ZnSO4 (mg mL
-1
). 
The ratios PRE 1 : 28.8 ZnSO4 (mg mL
-1
) and PRE 1 : 287.6 ZnSO4 (mg mL
-1
) had 
the greatest potentiated reduction of viral load: over a 9000 fold reduction in 
comparison to either agent alone. 
Examination of alternative Zn (II) salts established that it was indeed Zn
2+
 that 
provided the potentiation, rather than the sulphate counterion. Interestingly ZnO, a 
common ingredient in topical formulations, demonstrated minimal activity due 
(almost certainly) to low dissociation and solubility in water. Punicalagin, the most 
abundant polyphenol within PRE, was highly virucidally active and potentiation by 
ZnSO4 was observed. At lower concentrations this was only at a very specific ratio 
(punicalagin 1 : 14 ZnSO4 (mg mL
-1
)). At concentrations outside of this ratio (lower 
than and including punicalagin 1 : 288 ZnSO4 (mg mL
-1
))  the addition of ZnSO4 was 
deleterious to the virucidal activity of punicalagin. Similarities between the 
potentiated virucidal activity of the higher concentration ratios of: ZnSO4 to 
punicalagin (above and including, punicalagin 1 : 1438 ZnSO4 (mg mL
-1
)), and 
ZnSO4 to PRE (above and including, PRE 1 : 287.6)  are observed. 
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From this data a hypothesis was developed that a dual effect was occurring whereby 
upon the addition to PRE of ZnSO4 at: 
 Lower concentrations 
-An as yet unidentified viral envelope glycoprotein(s) is/are first 
compromised by the punicalagin enabling the absorbtion of and or interaction 
of free Zn
2+
 molecules to the viral tegument resulting in the combined 
destruction of the virus. 
Higher concentrations  
-The Zn
2+
 ions may act first allowing the punicalagin to then combine with 
the protein envelope thus destroying it. 
There is evidence of some viral destruction for each of the chemicals separately and 
it is likely that a different mechanism of damage exists for each chemical. The 
combination of PRE and ZnSO4 is creating a system in which free Zn
2+
 ions, 
irrespective of the anion, are significantly potentiating the virucidal effect of 
punicalagin. Punicalagin alone appears to be inhibited by components of PRE. 
In terms of antiviral activity, the IC50 of PRE demonstrated impressive comparability 
to Aciclovir by weight with respect to HSV-1. Furthermore, an even lower IC50 was 
observed with respect to HSV-2 ACR. Overall the data suggested that PRE is 
comparable to the established cold sore treatment and that as Aciclovir resistant 
strains become ever more prevalent PRE may have a major role in future HSV 
therapeutic strategies. ZnSO4 appeared to have no antiviral effect (>100 µM) alone or 
in combination with PRE. 
Taken together, these in vitro results supported the development of an unprecedented 
product within the HSV treatment market that could not only inhibit virus 
intracellular replication at eruption outbreak, but could also kill any extracellular 
virus that was able to emerge from the host cell. Pivotal to this development is the 
finding that there was no cytotoxicity in the models used. However, these in vitro 
data did not take account of the location of the viral load, i.e. the viable epidermis. 
Therefore the next step was to determine whether the main actives could penetrate 
skin in order to deliver the required doses to the skin.  
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Initially the work concentrated on a simple aqueous solution, which was the subject 
of Chapter 6. Finite dosing of PRE and ZnSO4 to freshly excised porcine epidermis, 
modelling in situ conditions, showed that punicalagin from PRE and Zn
2+
 both 
penetrated to the site of HSV-1 vesicular clusters (the formation of a cold sore). Tape 
stripping of full thickness porcine epidermis showed that all levels of the stratum 
corneum contained the actives, indicating reservoir formation. 
Knowing that a simple solution of PRE and ZnSO4 possessed such remarkable 
activity against HSV and was deliverable across skin, the attention turned to probing 
the anti-inflammatory properties of the combination. Using modulation in the 
expression of COX-2 in ex vivo skin as a marker, Chapter 7 used the techniques of 
Western blotting and IHC to demonstrate that the topical application of PRE to full 
thickness ex vivo skin downregulates the expression of  COX-2 within 6 h and was 
maintained over at least 24 h. As COX-2 expression is an important mediator for 
inflammation in the arachidonic acid pathway, it was concluded that the topical 
application of PRE (with or without ZnSO4) has a substantial anti-inflammatory 
effect in ex vivo skin. The inference of this finding is that a product based on PRE 
would be expected to result in the amelioration of inflammation and pain associated 
with Herpes simplex lesions which would be highly advantageous within a 
therapeutic system, as no current treatment for cold sores utilises a system which 
incorporates the combined benefits of anti-inflammation and pain relief. 
Therefore it is clear that if ZnSO4 was used in combination with PRE to potentiate 
the virucidal activity, its inclusion would not jeopardise the antiviral or anti-
inflammatory activity of PRE 
The next step was to examine the biological activity of PRE in greater detail. 
Successful separation of PRE yielded fractions either devoid of tannins or containing 
only total pomegranate tannins (TPT). The further isolation of 3 distinct fractions 
from TPT was also achieved, one comprising almost entirely of punicalagin and two 
containing a mixture of other tannins present in PRE, although not containing 
punicalagin. Further COX-2 analysis showed that a degree of COX-2 modulation 
observed by PRE was within the TPT fraction and the punicalagin fraction. 
However, the level of COX-2 downregulation diminished with each fractionation. 
The diminished biological activity due to fractionation was also observed with 
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respect to antiviral activity, TPT the only antivirally active fraction with an IC50 
lower than 100 µg mL
-1
. The fractionation processes showed that the only virucidally 
active component of PRE was punicalagin. However, overall the data shows that 
biological activity is greatest when PRE remains as a whole entity. 
In the following Chapter, a semi-solid formulation was sought, suitable for further 
study. Chapter 9 consequently pinpointed a prototype hydrogel formulation 
comprised of 2.5 % Methocel 856 n,  1.25 mg  mL
-1
 PRE and ZnSO4 0.25 M, that 
spontaneously released both punicalagin and Zn
2+
, was aesthetically acceptable and 
which had suitable rheological properties for a topical application. It was further 
determined that the gel and the phytotchemicals within PRE remained stable over a 
12 month period, retaining statistically similar spontaneous release of punicalagin 
and ZnSO4 over this time period. The next step was to determine the delivery of 
punicalagin and Zn
2+
 from the gel across membranes that were representative of the 
tissues prone to the development of HSV-induced lesions. 
The penetration of punicalagin and Zn
2+
 through epidermal, vaginal mucosal and 
buccal membranes was established in Chapter 10. Both analytes penetrated at 
sufficient concentrations through the epidermal membrane to maintain virucidal 
activity; similar levels of penetration were observed through the vaginal mucosal and 
buccal membranes. The comparison of the permeation through: heat separated 
epidermis (HSE), heat separated buccal membrane (HSBM) and scalpel dissected 
vaginal mucosal membrane (SDVM) allows for the conclusion that permeability of 
the membranes 
-with respect to punicalagin HSE > SDVM > HSBM 
-with respect to Zn
2+
 SDVM > HSE > HSBM 
It must be stated that this order was not expected, as HSE with its stratum corneum 
barrier would be expected to give the lowest permeation.  
The application of the 2.5% Methocel Hydrogel 6 E (1.25 mg mL
-1
 PRE and 0.25 M 
ZnSO4) to ex vivo full thickness skin showed that PRE released from the gel 
penetrated the epidermis maintaining a statistically similar reduction in COX-2 
expression to that of PRE in a liquid formulation. 
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In conclusion, the main objective of this research has been realised, in that a 
potentially potent therapeutic system has been developed. Based on a hydrogel 
matrix containing PRE and ZnSO4 the prototype gel: 
1. is non-cytotoxic 
2. produces high potentiated virucidal activity against HSV-1   
3. has antiviral activity, comparable to the Gold Standard compound, 
Aciclovir, against HSV-1  
4. has even greater antiviral potency against Aciclovir-resistant HSV-2 
5. possesses potent innate anti-inflammatory activities  
6. maintains the activities above after the release, penetration, and 
permeation of the bioactive compounds, to the area of HSV vesicular 
clusters at the epidermal dermal interface, through all common 
epithelial membranes where the Herpes simplex virus presents.  
7. has good aesthetic and rheological properties 
8. demonstrates good stability 
11.2. Further work 
The therapeutic potential for this system are manifest. However, there are many ways 
in which the system could be further explored. 
Prior to any human trials, standardisation of PRE needs to account for the variation 
of content between batches by TPT concentration within predefined limits of each 
molecule i.e. punicalagin between 80-85%. We believe this not to be an issue given 
the large dilutions that occur in the preparation of PRE. 
The continuation of this work for the progression of the therapeutic system to be 
used within the community must analyse the observed in vitro effects in an in vivo 
situation. This would first be done by the HSV-1 virucidal, antiviral and anti-
inflammatory analysis within a mouse model. Followed by a human trial ―scratch 
test‖ testing the biological response to the topical application of the therapeutic 
system. Ideally this would be followed by a full human trial for the in situ use of the 
formulation as a therapeutic system for the treatment of HSV-1 and HSV-2 lesions. 
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The potentiated virucidal activity of the PRE + ZnSO4 combination with regards to 
HSV-1 must be further tested against a range of virion, with specific interest in 
enveloped virion which are transmitted sexually i.e. HIV followed by Hepatitus B, 
HPV and MCV. 
I propose that due to the similarities between the viral glycoproteins of the envelope 
of HSV and HIV it is conceivable that comparable virucidal activity could be 
observed, and that the formulation could be used as a lubricant on condoms, as a 
lubricating gel and or as a vaginal suppository for the prevention of the spread of 
HIV through sexual contact. The prevalence of HSV lesions within the mucous 
membrane of the vaginal cavity also greatly increases the level of infectious HIV 
virions within vaginal secretions (Baeten, et al. 2004). 
Lastly, we believe it is worth revisiting the bactericidal potential of this system. 
Although it had been specifically stated in a previous patent application that PRE and 
ZnSO4 were not active, there are grounds to believe that further work involving 
better in vitro models could prove otherwise. 
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